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ABSTRACT
Background
Huntington’s disease (HD) is a chronic neurodegenerative disorder characterised by a
progressive loss of cognitive function, motor control and psychiatric features. Individuals
also display a variety of systemic features. Progressive neuronal dysfunction and neuronal
cell death are thought to underlie the onset and progression of many clinical features of HD.
Despite scientific progress, there is still no cure or disease modifying therapy for HD, and
available pharmaceutical agents only provide partial relief of motor and psychiatric features.
An emerging body of evidence indicates that lifestyle enrichment may delay the onset and
progression of clinical features, and exert favourable effects on neuropathological aspects of
HD. Few studies have evaluated the effects of lifestyle enrichment strategies like
multidisciplinary rehabilitation on the clinical features of HD. Moreover, no study has
evaluated the effects of multidisciplinary rehabilitation on neuropathological aspects of HD.
Aims
The initial aim of this thesis was to determine factors that contribute to features of the disease
that negatively impact on activities of daily living such as mobility and balance (Chapter 2),
and to identify, using a literature review, a rehabilitation strategy that could positively impact
on these features of HD (Chapter 3). These studies informed our ultimate aim which was to
investigate the clinical utility of multidisciplinary rehabilitation on clinical and
neuropathological features of HD (Chapters 4, 5 and 6)
Methods
In study 1 (Chapter 2), 22 participants were assessed using a battery of balance, mobility,
cognitive tests, assessments of muscle strength and body composition measures. Data was
iii

then statistically examined using stepwise linear regression to identify factors that contribute
to balance and mobility impairments in individuals with manifest HD. In study 2 (Chapter 3),
a systematic search of journal databases was made from inception to July 2014 for studies
reporting on resistance exercise in patients with neurodegenerative disorders. Selected studies
were abstracted and critically appraised using a quality control checklist.
For the intervention studies, (3 and 4 Chapters 4 and 5), 20 participants with manifest HD
were randomly assigned to either a control or training group. Individuals randomised to the
intervention group were provided with a nine month multidisciplinary intervention
comprising once weekly supervised clinical exercise, thrice weekly home based exercise and
fortnightly occupational therapy, while those randomised to the control group were asked to
continue with their standard care and daily activities. Participants were assessed using motor,
cognitive, psychological, body composition and quality of life measures at baseline and at the
completion of the intervention. In study 5 (Chapter 6), 15 participants with manifest HD were
assessed using magnetic resonance imaging and a battery of cognitive assessments after nine
months of multidisciplinary rehabilitation to see whether such a therapy is capable of
inducing favourable changes in brain structure and cognitive function.
Results
The main factors that contribute to mobility and balance impairments in patients with
manifest HD were found to be lower limb muscle weakness and a loss of cognitive function
(Study 1). Systematic evaluation of the effects of resistance exercise for neurodegenerative
disorders showed that it is beneficial for multiple sclerosis and Parkinson’s disease. In
particular, improvements in muscle strength, mobility, balance, clinical disease progression,
fatigue, functional capacity, quality of life, disease biology, electromyography activity, mood,
skeletal muscle volume and architecture were reported in individuals with multiple sclerosis
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or Parkinson’s disease (PD) after resistance exercise. The most robust effects of resistance
exercise were found for muscle strength outcomes, and were more pronounced in individuals
with PD (Study 2).
The multidisciplinary rehabilitation intervention studies conducted as part of this thesis
significantly improved isometric and isokinetic muscle strength, self-perceived balance, body
mass, lean tissue mass and fat mass in patients with HD (Studies 3 and 4). Moreover,
multidisciplinary rehabilitation also increased grey matter (GM) volume in the caudate
nucleus and dorsolateral prefrontal cortex of patients. The significant increases in GM
volume were accompanied by, and correlated to, a significant improvement in performance in
verbal learning and memory.
Conclusions
The work presented here shows that lower extremity muscle weakness and a loss of cognitive
function significantly contribute to impairments in mobility and balance. This work also
shows that strength training has favourable effects on motor function, including strength,
mobility and balance, as well as other clinical features in similar neurodegenerative disorders,
and thus should be integrated into multidisciplinary rehabilitation interventions for HD. In
addition, this study provides evidence that multidisciplinary rehabilitation can significantly
improve aspects of motor control, cognitive function and body composition. Finally we show,
for the first time, that multidisciplinary rehabilitation can increase GM volume in structures
known to degenerate in HD, and that such increases are functionally related to changes in
verbal learning and memory. Future work is urgently required to confirm and expand on
these exciting findings, particularly with respect to the neurorestorative properties of
multidisciplinary rehabilitation.
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CHAPTER 1 - GENERAL INTRODUCTION
1.1 HISTORY OF HD
Huntington’s disease (HD), formerly known as ‘Huntington’s
chorea’, was first comprehensively described by George
Sumner Huntington in his self-titled publication ‘On Chorea’
in 1872 (Figure 1.1) (Huntington, 1872). This landmark
publication vividly described the autosomal dominant
inheritance, adult-onset and central features of HD.
Huntington’s description laid the foundation for future
genetic investigations, which over a century later mapped the

Figure 1.1 George Huntington
(1850-1916)

Huntington gene (HTT) to chromosome 4 (Gusella et al., 1983). The ensuing decade led to
the isolation of the HTT gene (4p16.3) and identification of the expanded cytosine-adenineguanine (CAG) sequence responsible for HD (MacDonald et al., 1993). In the years that
followed, many scientific advances were made, including the genetic engineering of
transgenic HD mice (Carter et al., 1999; Mangiarini et al., 1996). These mouse models have,
over the last two decades, enabled the investigation of pathological mechanisms involved in
HD, as well as genetic manipulation and pharmacological/molecular interventions.
1.2 EPIDEMIOLOGY OF HD
The exact worldwide prevalence of HD is unknown, however recent estimates suggest a
prevalence of 5-8 per 100,000 (Kumar et al., 2010). Countries of European ancestry display a
higher prevalence of HD (3-10 per 100,000) than countries of non-European ancestry (0.110.45 per 100,000) (Gatto et al., 2014). Recent figures indicate that the prevalence of HD is
12.3 per 100,000 in the United Kingdom (Evans et al., 2013) and 7 per 100,000 in Australia
(Harper, 1992; Pridmore, 1990). By contrast, the prevalence of HD within Asia is a mere 0.4
1

per 100,000 (Pringsheim et al., 2012). “Demographic hot spots”, have also been identified,
such as the Zulia region of Venezuela, where the prevalence of HD is extraordinarily high
(~50%), owing to a founder effect (Wexler, 2004).
1.3 CLINICAL VARIANTS OF HD
Individuals carrying the mutant HTT gene typically present during midlife (4th to 6th decades
of life) (Tabrizi et al., 2009; 2012; 2011a; 2013), however early and late age of onset variants
are also well documented (Foroud et al., 1999; James et al., 1994; Lipe and Bird, 2009;
Mahant et al., 2003; Robertson et al., 2012; Roos et al., 1993). Early onset HD, termed
Juvenile HD (JHD) accounts for 4.92% of all HD cases worldwide (Quarrell et al., 2012).
Often arising through paternal transmission (Merritt et al., 1969), JHD cases typically carry
60 or more CAG repeats and present before 21 years of age (Cloud et al., 2012; Douglas et
al., 2013; Quarrell et al., 2013). Typical features of JHD include a progressive rigid-ataxic
like phenotype, cerebellar signs, chorea, speech and language problems, oropharyngeal
problems, epilepsy, seizures (tonic-clonic and myoclonic), depression, aggression, weight
loss and cachexia (Barker and Squitieri, 2009; Cannella et al., 2004; Cloud et al., 2012;
Gonzalez-Alegre and Afifi, 2006; Nance and Myers, 2001; Quarrell et al., 2013; Ribaï et al.,
2007; Yoon et al., 2006). Late onset HD, in stark contrast to JHD, is characterised by mild
chorea and more globalised dementia (not too dissimilar to Alzheimer’s disease) (Aziz et al.,
2008; Foroud et al., 1999; James et al., 1994; Lipe and Bird, 2009; Mahant et al., 2003; Roos
et al., 1993). Interestingly, in late onset HD, individuals typically succumb to age-related
diseases like cancer, cardiovascular disease and Alzheimer’s disease rather than the diseaserelated processes of HD (Bürger et al., 2002; Lipe and Bird, 2009).
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1.4 HUNTINGTON GENE
The gene responsible for HD, IT15 (‘interesting transcript’) or HTT, was located on the short
arm (p) of chromosome 4 by Gusella and colleagues in 1983. Over the next ten years, a
dedicated group of scientists exhaustively investigated chromosome 4 using emerging genemapping and genomic technology, which in 1993 led to the isolation of HTT (4p16.3) and
discovery of the mutation responsible for HD. The causative mutation is an expanded
cytosine-adenine-guanine (CAG) repeat sequence in exon 1 of HTT. Under normal
circumstances healthy individuals possess between 6 and 35 CAG repeats. While individuals
with HD typically possess in excess of 39 CAG repeats. Although rare, individuals that
possess between 36 and 39 CAG repeats are said to have incomplete penetrance, and may
develop HD at some stage in their lifetime (MacDonald et al., 1993).
1.5 INTRICATE ROLE OF THE CAG REPEAT
Robust evidence shows that the length of the expanded CAG sequence is strongly correlated
with age at onset (Andrew et al., 1993; Claes et al., 1995; Duyao et al., 1993; MacDonald et
al., 1993; MacMillan et al., 1993; Nørremølle et al., 1993; Snell et al., 1993; Zühlke et al.,
1993). The length of the CAG expansion is estimated to account for 47% to 72% of the
variance in age at onset (Brinkman et al., 1997; Craufurd and Dodge, 1993; Ranen et al.,
1995; Rosenblatt et al., 2001; Squitieri et al., 2000). The remainder of the variance in age at
onset is influenced by environmental and additional genetic factors. In line with this, Wexler
et al (2004) found that environmental factors accounted for 62% of the remaining variance in
age at onset in four hundred and fifty eight individuals with HD. Interestingly, Kremer et al
(1993) has shown that the length of the CAG expansion only accounts for 7% of variation in
the age of onset of individuals beyond fifty years of age. This indicates that the effect of the
CAG repeat length on age of onset may diminish with increasing age.
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1.6 HUNTINGTIN PROTEIN STRUCTURE
Huntingtin (Htt) is an extremely large protein comprising 3114 amino acids (Johnson and
Davidson, 2010). The high molecular mass of Htt (348-kDa) has hampered the full
elucidation of its structure (Zuccato et al., 2010). Structural domains of Htt have nevertheless
been identified and described in detail. The most recognisable structure within Htt is the
polyglutamine stretch (PolyQ), which commences at the 18th amino acid (Perutz et al 1994;
Huntington’s Disease Collaborative Research Group). Immediately following the PolyQ is a
polyproline domain (PolyP), which is believed to stabilise the PolyQ (Darnell et al., 2007;
Kim et al., 2009; Steffan et al., 2004). Downstream of the PolyQ and PolyP regions, 16
Huntingtin, Elongation Factor 3, PR65/A subunit of protein phosphatase 2A and TOR1 the
target of rapamycin (HEAT) repeat sequences have been identified (Andrade and Bork, 1995;
Neuwald and Hirano, 2000; Takano and Gusella, 2002). The precise role of these HEAT
repeat sequences still remains unclear, however increasing evidence indicates an involvement
in protein-protein interactions (Medicine, 2013; Takano and Gusella, 2002). Htt also
possesses well-characterised cleavage sites, where proteolytic enzymes such as caspases,
calpains and aspartyl proteases cleave Htt into smaller fragments (Kim et al., 2001; Zuccato
et al., 2010). An active nuclear export signal and a less active nuclear localisation signal have
also been found on Htt, which indicates that Htt may also be involved in the transport of
molecules from the nucleus to the cytoplasm (Desmond et al., 2013; Xia et al., 2003). Many
post-translational modification sites are also present on the Htt protein, particularly in
polypeptide sequences enriched in proline, glutamate, serine and threonine (PEST domains)
(Warby et al., 2008), where ubiquitination (Bhat et al., 2014), phosphorylation (Aiken et al.,
2009; Humbert et al., 2002; Khoshnan et al., 2004; Rangone et al., 2004; Schilling et al.,
2006), SUMOylation (Steffan et al., 2004), palmitoylation (Yanai et al., 2006) and
acetylation (Jeong et al., 2009) of Htt can take place. The exact role of these post4

translational modifications is not yet clear, however they have been postulated to modulate
protein-protein interactions as well as influence the stability and localisation of Htt (Bates et
al., 2014).

Figure 1.2 Schematic diagram of the Huntingtin (Htt) amino acid sequence
(Q)n indicates the polyglutamine tract, which is followed by the polyproline sequence (P)n;
the red emptied rectangles indicate the three main HEAT repeats (HEAT group 1, 2, 3). The
small green rectangles indicate the caspase cleavage sites and their amino acid positions,
while the small pink triangles indicate the calpain cleavage sites and their amino acid
positions. Boxes in yellow: B, regions cleaved preferentially in the cerebral cortex; C, regions
of the protein cleaved mainly in the striatum; A, regions cleaved in both. Posttranslational
modifications: ubiquitination (UBI) and/or sumoylation (SUMO) sites (green); palmitoylation
site (orange); phosphorylation at serines 13, 16, 421 and 434 (blue); acetylation at lysine 444
(yellow). NES is the nuclear export signal while NLS is the nuclear localisation signal. The
nuclear pore protein translocated promoter region (TPR, azure) is necessary for nuclear
export. Htt huntingtin. ER, endoplasmic reticulum (Image from Zuccato et al 2010).
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1.7 HUNTINGTIN PROTEIN EXPRESSION
Htt is ubiquitously expressed throughout neuronal and non-neuronal tissues (Landwehrmeyer
et al., 1995; Vonsattel and DiFiglia, 1998), with the greatest enrichment in the central
nervous system and testes (Sapp et al., 1997; Sharp et al., 1995; Wood et al., 1996). Modest
expression of Htt is also evident in the lungs, heart, kidneys, liver and muscle (Sharp et al.,
1995; Wood et al., 1996). In the cell, Htt co-localises with most organelles, including the
nucleus, mitochondria, endoplasmic reticulum and golgi apparatus (Atwal and Truant, 2008;
Choo et al., 2004; DiFiglia et al., 1995; Gutekunst et al., 1998; Milakovic and Johnson, 2005;
Panov et al., 2002; Velier et al., 1998). Studies using immunolabeling and
immunoprecipitation have also shown that Htt associates with vesicle membranes and
microtubules (DiFiglia et al., 1995; Gutekunst et al., 1995; Sharp et al., 1995). Its ubiquitous
expression and numerous interactions with cellular organelles suggest that Htt is vital for
normal molecular and cellular function.
1.8 HUNTINGTIN PROTEIN FUNCTION
The biological role of Htt is not well understood. Studies in transgenic animal models and
cell lines have however provided insights into the molecular and cellular roles of Htt. Early
investigations in mice showed that constitutive inactivation of Htt causes embryonic lethality
between embryonic day 8.5 and 10.5 (Duyao et al., 1995; Nasir et al., 1995). Experimental
reduction of Htt below 50% of resting levels has been shown to cause epiblast defects as well
as profound cortical and striatal architectural anomalies (Auerbach et al., 2001; White et al.,
1997). These studies clearly implicate wild-type Htt involvement in the formation of the
central nervous system.
In vitro and in vivo studies indicate that Htt is also involved in antiapoptotic activities (Ho et
al., 2001; Leavitt et al., 2006; Sardo et al., 2012). Elegant work by Rigamonti et al (2001;
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2001) has shown that striatal cells overexpressing wild-type Htt are resistant to lethal
biological stresses, such as serum deprivation and 3-nitropropionic acid. However depleting
wild-type Htt using short inhibitory RNA compounds has been found to increase the
vulnerability of cells to apoptotic events (Zhang et al., 2006).
Studies in animal models and cell lines have also shown that wild-type Htt stimulates the
production of brain derived neurotrophic factor (BDNF) by activating BDNF promoter II
(Benn et al., 2008; Zuccato et al., 2001). BDNF has known roles in synaptogenesis and
neurogenesis, and is highly expressed in corticostriatal structures, which degenerate in HD.
These findings indicate that wild-type Htt may mediate the transcription of neuronal genes
involved in maintaining neuronal homeostasis (Zuccato and Cattaneo, 2007).
A number of studies also implicate wild-type Htt involvement in axonal and vesicle transport
(Gunawardena et al., 2003). Experimentally lowering wild-type Htt to 50% of resting levels
has been documented to impair fast axonal trafficking of mitochondria as well as BDNF
transport in mammalian neurons (Gauthier et al., 2004; Trushina et al., 2004).
Finally, wild-type Htt has been reported to interact with cytoskeletal and synaptic vesicle
proteins involved in exocytosis and endocytosis, implicating its involvement in synaptic
activity (Smith et al., 2005). Early investigations showed that wild-type Htt binds to the SH3
domains of postsynaptic density protein 95 (PSD95) (Sun et al., 2001). PSD95 is a
multivalent scaffolding protein that colocalises with N-methyl-D-aspartate (NMDA)
receptors at the postsynaptic density and controls synaptic transmission (Sun et al., 2001). A
decreased interaction between wild-type Htt and PSD95 leads to an increased interaction
between PSD95 and NMDA receptors causing an over activation and sensitisation of NMDA
receptors promoting excitotoxicity (Fan et al., 2009).
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These findings collectively indicate that a loss of wild-type Htt function at least in part
contributes to the molecular and cellular pathology witnessed in HD.
1.9 PATHOLOGICAL MECHANISMS INVOLVED IN HD
Studies investigating wild-type Htt have shown that it interacts with many proteins involved
in transcription, synaptic transmission, energy metabolism and protein degradation. Thus a
loss of wild-type Htt and toxic gain in mutant Htt results in wide scale molecular and cellular
dysfunction.
1.9.1 Transcriptional dysregulation in HD
Transcription anomalies maybe one of the earliest pathological events in HD (Cha, 2007). In
situ hybridisation experiments on the post-mortem human HD brain have documented
decreased expression of preproenkephalin, substance P, dopamine receptors D1 and D2,
glutamate transporter 1 (GLT-1) and NMDA subunits NR1 and NR2B messenger RNA
(mRNA) (Arzberger et al., 1997; Augood et al., 1997; Augood et al., 1996). Similar findings
have also been reported in the R6/2 mouse model (Cha et al., 1999; Cha et al., 1998). A
number of mechanisms have been proposed through which mutant Htt may disrupt
transcription regulation (Cha, 2007; Luthi-Carter and Cha, 2003). For instance, mutant Htt
may perturb the interaction between transcription factors (e.g. Sp1) (Schaffar et al., 2004),
their transcriptional coactivators (Zhai et al., 2005) and target DNA thereby reducing the
expression of many important target genes. Mutant Htt may also aberrantly interact with the
core transcription machinery, such as RNA polymerase II, Transcription Factor II F,
Transcription Factor II D, TATA-Associated Factor II130 and TATA binding protein, causing
transcriptional dysregulation (Dunah et al., 2002; Luthi-Carter et al., 2002b; Shimohata et al.,
2000; Zhai et al., 2005).
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1.9.2 Altered synaptic activity in HD
Alterations in synaptic activity are well documented and may be responsible for many of the
clinical features of HD (Gil and Rego, 2008; Milnerwood and Raymond, 2010; Raymond et
al., 2011; Sepers and Raymond, 2014; Smith et al., 2005). Mutant Htt interacts with a variety
of cytoskeletal and synaptic vesicle proteins involved in synaptic function (Caviston and
Holzbaur, 2009; Dominguez and Munoz-Sanjuan, 2014; Li et al., 2003; Qin et al., 2004).
leading to synaptopathology (Li et al., 2003; Smith et al., 2005).
Studies in mouse models and postmortem HD brain tissue have reported changes in
neurotransmitter release, uptake and postsynaptic signalling in corticostriatal pathways
(Sepers and Raymond, 2014). In particular, elevated glutamate release is evident in early HD,
followed by a decrease in glutamate release later in HD (Joshi et al., 2009; Miller and
Bezprozvanny, 2010).
1.9.3 Impaired energy metabolism in HD
Impairments in energy metabolism are considered central to the pathogenesis of HD (Aziz et
al., 2010b). Disruptions in cell metabolism have been reported in central and peripheral
tissues in human and rodent models of HD (Aziz et al., 2010b; Underwood et al., 2006).
Investigations using positron emission tomography (PET) have reported decreased glucose
metabolism in striatal structures in people with manifest HD (Antonini et al., 1996; Kuwert et
al., 1990; Underwood et al., 2006; Young et al., 1986). There is also evidence of increased
lactate levels in the cerebral cortex and an elevated lactate-to-pyruvate ratio in the
cerebrospinal fluid of both manifest and pre-manifest HD patients (Jenkins et al., 1998;
Jenkins et al., 1993; Koroshetz et al., 1997). Decreased adenosine triphosphate (ATP) levels
have additionally been observed in the brain and muscle (Ciarmiello et al., 2006; Cross et al.,
1986; Miller and Bezprozvanny, 2010).
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Accumulating evidence suggests that mitochondrial dysregulation mediates many of the
outlined deficits in energy metabolism. For example, impairments in electron transport chain
(ETC) complexes I, II and III have been reported in HD (Browne et al., 1997; Gu et al., 1996;
Parker et al., 1990; Stahl and Swanson, 1974). Impaired ETC activity has been found to
correlate with reduced ATP synthesis and an increase in reactive oxygen species (ROS) in
HD (Chakraborty et al., 2014; Tabrizi et al., 1999). Impeded axonal transport of mitochondria
to cellular sites with high energy demands, like neurons, synapses and muscles has also been
reported (Reddy and Shirendeb, 2012; Shirendeb et al., 2011). Mutant Htt has also been
found to decrease the expression of peroxisome proliferator-activated receptor-γ (PPAR- γ)
coactivator-1α (PGC-1α) through cAMP response element-binding protein-dependent
transcriptional inhibition (Cui et al., 2006). Down-regulation of PGC-1α decreases
mitochondrial energy metabolism by impairing oxidative phosphorylation (Lin et al., 2005).
1.9.4 Impaired protein degradation pathways in HD
Strong evidence indicates that protein degradation pathways are also impaired in HD (Gu et
al., 1996). Protein degradation pathways are essential for removing dysfunctional and
damaged proteins, ensuring cellular homeostasis (Labbadia and Morimoto, 2013). Two
pathways responsible for degrading mutant Htt include the ubiquitin-proteasome system
(UPS) and autophagy-lysosome pathway (Rubinsztein, 2006). Briefly, the UPS degrades
short-lived misfolded, oxidized and mutant proteins (Young et al., 1986). In contrast, the
autophagy-lysosome pathways degrade dysfunctional or damaged cytosolic proteins in
lysosomes (Jenkins et al., 1993).
In HD, an accumulation of ubiquitinated mutant Htt fragments is observed within cells,
particularly neurons, indicating an impairment in the UPS (Ciarmiello et al., 2006; Jenkins et
al., 1998). The inability of the UPS to degrade mutant Htt has been proposed to stem from its
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inability to unfold the stabile β–sheet structure formed by the poly-Q stretch. These
observations suggest that autophagy degradation pathways may be preferentially used to
degrade mutant Htt. Like the UPS, autophagy degradation pathways appear impaired in HD
(Koroshetz et al., 1997). Elegant work by Maria Cuervo’s group has shown that mutant Htt
impairs the recognition of cytosolic cargo not enabling the degradation of dysfunctional or
damaged proteins (Martinez-Vicente et al., 2010). Deficient autophagy degradation pathways
do not enable the recycling of important organelles, like mitochondria, which accumulate in
cells in HD, facilitating homeostatic distress and proteasome destabilisation (MartinezVicente et al., 2010).
1.10 NATURAL HISTORY AND DIAGNOSIS OF HD
The clinical course of HD is incredibly complex but can be simplistically divided into three
disease stages; asymptomatic, premanifest and manifest HD. Asymptomatic or ‘at risk’
terminology is used to describe individuals with an affected parent, who have not undergone
genetic testing and do not display clinical features of HD. Genetic testing is available to
individuals at risk of inheriting HD from eighteen years of age, however the uptake of genetic
testing services remains low worldwide. Individuals that undertake genetic testing and are
identified as gene positive, but do not possess clinical features by which to make a formal
diagnosis of HD, are typically termed premanifest. The premanifest disease stage typically
spans 15-20 years, during which time an individual transitions from completely
asymptomatic to displaying subtle motor, cognitive and psychological signs. The Unified
Huntington’s Disease Rating Scale (UHDRS) is currently the preferred clinical tool for
assessing the onset of HD (Hungtington, 1996). While the scale comprises cognitive,
behavioural, emotional and functional components, formal diagnosis rests on the presence of
unmistakable motor features. In particular, clinicians are required to provide a ‘diagnostic
confidence score’, indicating their level of certainty that any observed motor signs are
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representative of HD (0-4; where 0 indicates no motor abnormalities suggestive of HD and 4
indicates motor abnormalities likely to be due to HD with ≥ 99% certainty). Gene positive
individuals with a score of 4 are said to display manifest HD. This period is marked by the
presentation and gradual worsening of clinical features, which over time renders the affected
individual functionally impaired and eventually results in death (Bates et al., 2014; Tabrizi et
al., 2009; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013).
1.11 NEURODEGENERATION IN HD
1.11.1 Neurodegeneration in HD
Neuronal cell loss is a pathological hallmark of HD (Georgiou-Karistianis et al., 2013c; Kim
et al., 2014; Ross et al., 2014; Thu et al., 2010). Studies on the post-mortem HD brain and
more recent in vivo neuroimaging investigations reveal a striking degeneration of cortical and
subcortical structures over time in HD (Aylward et al., 2011; Georgiou-Karistianis et al.,
2013a; Guo et al., 2012; Hobbs et al., 2010; Kim et al., 2014; Majid et al., 2011; Nana et al.,
2014; Ross et al., 2014; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013; Thu et
al., 2010; Vonsattel et al., 1985). Morphometric investigations of the post-mortem HD human
brain (n=385) have documented significant whole brain atrophy (mean HD brain weight
1067g vs mean healthy brain weight 1350g) and regional atrophy within the striatum,
frontal, temporal, parietal and occipital lobes as well as an enlargement of the lateral ventricle
(Suzanne et al., 1988; Vonsattel et al., 1985; Vonsattel, 2008; Vonsattel and DiFiglia, 1998).
These macroscopic findings have now been robustly confirmed in vivo using a variety of
neuroimaging approaches (Aylward et al., 2000; Ginestroni et al., 2010; Harris et al., 1992;
Peinemann et al., 2005; Ruocco et al., 2006; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi
et al., 2013; Vandenberghe et al., 2009)
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1.11.2 Striatal degeneration in HD
Strikingly selective striatal atrophy is evident in HD (Aylward et al., 1997; Ross et al., 2014;
Suzanne et al., 1988; Tabrizi et al., 2009; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et
al., 2013; Vonsattel, 2008; Vonsattel and DiFiglia, 1998). Striatal degeneration typically
follows an ordered and topographic pattern over the natural course of the disease (Vonsattel,
2008; Vonsattel and DiFiglia, 1998). Degeneration typically begins in the tail and body of the
caudate nucleus and progresses over time in caudorostral, dorsoventral and mediolateral
directions encompassing the putamen and globus pallidus (Vonsattel, 2008; Vonsattel and
DiFiglia, 1998). Annual volume losses of 2.9 to 4.9% and 4.5% in the caudate nucleus and
putamen of individuals with manifest HD are observed in vivo (Aylward et al., 2011; Tabrizi
et al., 2011a). The most vulnerable neuronal populations within the striatum are GABAergic
medium spiny neurons, which constitute 90-95% of striatal neurons (Graveland et al., 1985).
Perplexingly, less common striatal interneurons (5-10%) appear to be relatively spared in HD
(Albin et al., 1992; Ferrante et al., 1985; 1991; 1987; Reiner et al., 1988; Richfield et al.,
1995). Differences in the neurochemical properties of each neuronal population are thought
to account for the discrepancy in neuronal vulnerability (Cicchetti et al., 2000).
The medium spiny neurons of the striatum are involved in direct and indirect striatal
pathways that modulate motor control through attenuating and facilitating movement
(Calabresi et al., 2014; Gerfen and Surmeier, 2011). The indirect striatal pathway comprises
medium spiny neurons that predominantly express dopamine receptor 2 and project to the
external segment of the globus pallidus (Gerfen and Surmeier, 2011; Gerfen and Wilson,
1996). In contrast, the direct striatal pathway comprises medium spiny neurons that express
dopamine receptor 1, dynorphin and substance P and project to the globus pallidus interna
and substantia nigra reticulata (Gerfen and Surmeier, 2011; Gerfen and Wilson, 1996).
Disruption of these pathways contributes to the onset and progression of hyperkinetic and
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dyskinetic movements in HD. Studies investigating the indirect striatal pathway have found
that a loss of medium spiny neurons coincides with the onset and progression of
choreoathetoid features (Bates et al., 2014). By contrast, a preferential loss of medium spiny
neurons in the direct striatal pathway has been shown to be associated with the onset and
progression of parkinsonism features (André et al., 2011; Galvan et al., 2012).
1.11.3 Extrastriatal degeneration in HD
It is becoming increasing clear that extra-striatal structures are also susceptible to the
neurodegenerative processes involved in HD (Douaud et al., 2006; Forno and Jose, 1973;
Heinsen et al., 1999; Kassubek et al., 2004; Kremer, 1992; Kremer et al., 1991; Kremer et al.,
1990; Lange et al., 1976; Mühlau et al., 2007; Roizin et al., 1979; Rüb et al., 2013; Suzanne
et al., 1988; Tellez-Nagel et al., 1974; van den Bogaard et al., 2011). Pathological studies
have reported significant cortical volume loss in frontal, temporal, parietal and occipital lobes
of the post-mortem HD human brain (Halliday et al., 1998). Widespread cortical volume loss
has also been documented in vivo using MRI (Jernigan et al., 1991; Nopoulos et al., 2011;
Rosas et al., 2005; Rosas et al., 2002; Rosas et al., 2008; Tabrizi et al., 2011a). For instance,
Rosas et al (2008) reported significant cortical thinning in primary motor, sensory and visual
cortical regions, with the most pronounced thinning being found in primary motor and visual
cortices.
Pathological and in vivo neuroimaging studies have also reported significant volume loss in
the globus pallidus (Lange et al., 1976), substantia nigra (Campbell et al., 1961;
Hallervorden, 1957; Kiferle et al., 2013; Lewy, 1923; Richardson, 1990; Schröder, 1931;
Spielmeyer, 1926), nucleus accumbens (Lange et al., 1976), subthalamic nucleus (Lange et
al., 1976; Spielmeyer, 1926), thalamus (Gavazzi et al., 2007; Heinsen et al., 1999; Heinsen et
al., 1996; Kassubek et al., 2005; Mühlau et al., 2007), hypothalamus (Douaud et al., 2006;
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Kassubek et al., 2004; Kremer, 1992; Kremer et al., 1991; Kremer et al., 1990; Politis et al.,
2008; Vogt, 1952), hippocampus (Rosas et al., 2003; Suzanne et al., 1988), cerebellum
(Fennema-Notestine et al., 2004; Rosas et al., 2003; Rüb et al., 2013) and cingulate gyrus
(Henley et al., 2009; Kim et al., 2014; Ruocco et al., 2008; Thu et al., 2010) in manifest HD.
Within the thalamus, significant neuronal loss has been reported in the dorsomedial nucleus
(23.8%) and centromedial parafascicular nucleus at post-mortem (Grade 3 & 4) (1999;
Heinsen et al., 1996). Significant neuronal loss has also been reported by Kramer et al (1992;
1991; 1990) in the lateral tuberal nucleus of the hypothalamus (90%). Lastly, Rosas et al
(2003) has documented significant volume loss in the hypothalamus (95%) and amygdale
(24%) in vivo, using MRI.
1.11.4 Neurodegeneration and clinical expression
Accumulating evidence suggests that neuronal dysfunction and cell loss mediate the clinical
expression of HD (Delmaire et al., 2013; Guo et al., 2012; Kim et al., 2014; Nana et al., 2014;
Scahill et al., 2013; Sprengelmeyer et al., 2014; Thu et al., 2010). In particular, cortical
interneuron loss in the primary motor cortex and anterior cingulate cortex has been found to
correlate with the expression of motor features and mood (Kim et al., 2014; Thu et al., 2010).
Moreover, neuronal cell loss in the striatum, subthalamic nuclei, primary motor, primary
sensory, secondary visual cortex as well as associational cortices in frontal, temporal and
parietal lobes has been found to be associated with the expression of motor symptoms (Guo
et al., 2012; Nana et al., 2014). Lastly, cortical thinning has been found to be associated with
cognitive and motor performance (Bechtel et al., 2010; Peinemann et al., 2005; Rosas et al.,
2005).
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1.12 COGNITIVE FUNCTION AND HD
Cognitive decline is an invariable trait of HD. Cognitive deficits markedly worsen throughout
the disease in a non-linear pattern (Paulsen, 2011), leading to a severely impaired cognitive
state, at which point facilitative support is often required (Wheelock et al., 2003). Consistent
with a frontal-subcortical profile, cognitive features often include cognitive slowing, impaired
verbal fluency (Eddy and Rickards, 2014), declines in working memory (Bonelli and
Cummings, 2008; Ho et al., 2003), perceptual and spatial difficulties, impaired construction
of higher intellectual thoughts and visuoconstructional difficulties (Beglinger et al., 2010).
Memory problems initially manifest as absent-mindedness, though later develop into more
debilitative problems including episodic, semantic and nondeclarative memory impairments
(Knowlton et al., 1996; Rohrer et al., 1999), which greatly impede the affected individual’s
everyday functioning (Eddy and Rickards, 2014; Hart et al., 2013). Though not consistent
with frontal-subcortical deficits, features of aphasia, agnosia and anosagnosia may also
develop in latter stages of the disease, owing to a more cortical profile, as is commonly
observed in AD (Bonelli and Cummings, 2008). Impairments in executive functioning also
feature prominently. In particular, deficits in planning, organisation, multi-tasking, attention
and concentration have been reported previously (Caine et al., 1977). Deficits in attention and
concentration often manifest early in the disease and likely underpin distractibility in HD
(Pillon et al., 1991).
1.13 AFFECTIVE FEATURES AND HD
Affective disorders vary considerably between affected individuals and progress in an
unpredictable manner. Typical manifestations include depression (Epping and Paulsen,
2011), irritability (Craufurd et al., 2001; Kingma et al., 2008), apathy (Baudic et al., 2006;
Reedeker et al., 2011) and obsessive-compulsive behaviours (Anderson et al., 2001;
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Beglinger et al., 2007), though features of aggression (Rosenblatt and Leroi, 2000),
impulsivity, mania (Mendez, 1994; Shiwach, 1994), psychosis-like states (Paulsen et al.,
2001) and schizophrenia-like delusional states (Folstein et al., 1983a; Folstein et al., 1983b;
Pflanz et al., 1991) may also present (Thompson et al., 2012). A depressive syndrome has
long been recognised in HD, even dating back to Huntington’s original

description

(Huntington, 1872). In fact, major depression is estimated to be present in 30-40% of patients
during their lifetime and subsyndromal depressive mood is estimated to be present in 35-60%
of HD patients (Craufurd et al., 2001; Paulsen et al., 2001). Depression is often accompanied
by suicidal ideation, which coupled with life stressors can lead to impulsive urges to commit
suicide. Suicide is estimated to be 5-10% higher in HD than in the general population
(Walker, 2007), and is greatest in individuals presenting with soft neurological features
awaiting clinical diagnosis (Paulsen and Conybeare, 2005). Apathy is a distressing
psychiatric feature of HD, regularly reported by spouses, family members and friends.
Typified by a reduction in purposeful behaviour, apathy was recently shown, in a longitudinal
study to progressively worsen throughout disease course (Thompson et al., 2013). In addition,
in the same study, irritability was shown to be very common in HD individuals, with 80% of
patients exhibiting poor temper control and almost 50% reporting some level of physical
aggression. Obsessive and compulsive features are also observed in 20 to 50% of HD patients
(Anderson et al., 2001; Beglinger et al., 2007), while obsessive and compulsive behaviour is
only present in 5.5% of the general population (Degonda and Angst, 1993).
1.14 CLINICAL HD MOTOR FEATURES
Progressive impairments in motor control are a clinical hallmark of HD. Throughout the
course of the disease, two distinct movement disorders typically emerge, an involuntary
(hyperkinetic) movement disorder and a loss of voluntary motor control. The temporal
expression of motor features tends to follow a biphasic pattern, with involuntary movement
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problems presenting early and voluntary movement problems presenting later on in the
disease course.
1.14.1 Hyperkinetic motor features
Chorea is often the most visible sign of HD. By definition, chorea refers to involuntarily
abrupt, asynchronistic movement of the limbs, trunk and/or face. For most adult-onset cases
of HD, chorea is often witnessed early in the disease process. Early manifestations of chorea
often resemble exaggerated ‘fidgetiness’, with low amplitude (electromyography activity),
relatively infrequent, choreic manifestations evident, such as finger flicking, eyebrow raising
and transient facial changes (smiling and grimacing) (Wild and Tabrizi, 2007). In some HD
cases, early choreic manifestations can be effectively managed with pharmaceutical
intervention (i.e. Tetrabenazine) (Pidgeon and Rickards, 2013; Venuto et al., 2012).
However, as the disease progresses, chorea typically worsens (frequency and severity),
becoming less manageable with pharmaceutical intervention. The magnitude and severity of
chorea is often exacerbated by life stressors (workplace and family problems), anxiety,
fatigue and illicit stimulant drugs (Sturrock and Leavitt, 2010). Although disruptive, chorea
in most cases does not severely impair balance, mobility and upper limb function in HD
patients (Sturrock and Leavitt, 2010).
1.14.2 Hypokinetic motor features
While chorea is inconvenient, impairments in voluntary motor control are often viewed as the
most disabling motor aspects of HD. Notable features of the voluntary movement disorder
include impairments in motor learning, motor impersistence, bradykinesia, ataxia and delayed
postural reflexes. These features contribute to a diversity of clinical problems including,
pulmonary dysfunction, swallowing problems, speech impairments, mobility and balance
disturbances and a loss of muscle strength. The onset and progression of these clinical
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problems are salient predictors of facilitated care, nursing home placement and a reduced
quality of life (Helder et al., 2001; Ho et al., 2009; Jankovic and Roos, 2014).
1.14.3 Balance in HD
Balance impairments are a physically disabling trait of HD (Medina et al., 2013; Panzera et
al., 2011; Quinn et al., 2013; Salomonczyk et al., 2010; Tian et al., 1992; Tian et al., 1991)
Clinical and laboratory examinations reveal static and dynamic perturbations in balance in
people living with manifest HD (Medina et al., 2013; Panzera et al., 2011; Quinn et al., 2013;
Salomonczyk et al., 2010; Tian et al., 1992; Tian et al., 1991). Common indications of
balance problems include an increased base of support (Koller and Trimble, 1985; Rao et al.,
2005), excessive postural sway (Reilmann, 2012; Tian et al., 1992; Tian et al., 1991) and
delayed postural reflexes (Medina et al., 2013; Panzera et al., 2011; Salomonczyk et al.,
2010). Evidence indicates that impairments in static and dynamic balance surface early in the
disease process and worsen over time increasing the propensity for falls and subsequent
wheel chair use (Kloos et al., 2012; Rao et al., 2008; Wheelock et al., 2003).
1.14.4 Mobility in HD
Evidence indicates that mobility deficits emerge early in the disease process (Rao et al.,
2008) and progressively worsen over time increasing the likelihood of falls (Quinn and Rao,
2002), assistive aid use (cane, zimmer frame, wheelchair) (Kloos et al., 2012) and nursing
home placement (Wheelock et al., 2003). Mobility deficits include decreases in gait velocity
(Churchyard et al., 2001; Delval et al., 2006; Koller and Trimble, 1985; Rao et al., 2005),
stride length (Bilney et al., 2005; Churchyard et al., 2001; Koller and Trimble, 1985; Rao et
al., 2005) and frequency (Bilney et al., 2005; Churchyard et al., 2001; Delval et al., 2006;
Koller and Trimble, 1985; Rao et al., 2005) as well as increased stride-to-stride variability
(Churchyard et al., 2001; Delval et al., 2006; Rao et al., 2005).
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1.14.5 Muscle strength in HD
Evidence, albeit limited, shows that decreases in muscle strength are also evident in people
with HD (Busse et al., 2008). Busse et al (2008), using hand-held dynamometry, showed
evidence of significant lower limb muscle weakness in people with HD. The origins of
muscular weakness are not known, however neuronal degeneration (Tabrizi et al., 2012;
Tabrizi et al., 2011a; Tabrizi et al., 2013; Vonsattel et al., 1985; Vonsattel, 2008),
mitochondrial abnormalities, and muscular pathology (Kosinski et al., 2007) as well as
sedentary behaviour may all contribute to its development. Muscular weakness, particularly
in the lower limbs contributes to impairments in balance and mobility as well as an increased
likelihood of falls (Aziz and Roos, 2013; Cruickshank et al., 2014).
1.15 ADDITIONAL CLINICAL HD FEATURES
The presence of non-central nervous system abnormalities are increasingly being recognised
in people with HD. Common peripheral aspects of the disease include weight loss, skeletal
muscle atrophy, bone mineral density loss, sleep disturbances and cardiac dysfunction
(Goodman et al., 2008; van der Burg et al., 2009).
Weight loss is perhaps the most common peripheral feature in HD (Aziz et al., 2008; Aziz
and Roos, 2013). Clinical investigations of weight loss have shown that it surfaces in
premanifest HD and worsens over time resulting in profound cachexia by late stage HD
(Mochel et al., 2007; Robbinsa et al., 2006; Sanberg et al., 1981; Trejo et al., 2005; Trejo et
al., 2004). Aetiological factors underpinning weight loss are not well understood, however
several lines of evidence from rodent models of HD implicate changes in metabolism
(Goodman et al., 2008; Mochel et al., 2007; van der Burg et al., 2008), hormonal
irregularities (Andreassen et al., 2002; Björkqvist et al., 2005; Boesgaard et al., 2009) and
malabsorption along the digestive tract (van der Burg et al., 2011). Weight loss has been
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shown to be associated with a faster rate of disease progression in people with HD (Myers et
al., 1991), and may therefore represent a useful clinical endpoint for evaluating disease
modifying strategies.
Skeletal muscle wasting is also evident in people with HD (Kosinski et al., 2007; Trejo et al.,
2004). Histological examinations of skeletal muscle have shown muscle fibre degeneration
(Kosinski et al., 2007), abnormal muscle fibre morphology (Arenas et al., 1998) and enlarged
mitochondria (Kosinski et al., 2007). Histochemical and in vivo imaging studies have
additionally shown evidence of respiratory chain dysfunction, cytochrome c release,
increased caspase activity, increased lactate production, decreased adenosine triphosphate
synthesis and a reduced phosphocreatine to phosphate ratio, implicating mitochondrial
dysfunction as a potential mediator of skeletal muscle wasting (Arenas et al., 1998;
Ciammola et al., 2011; Koroshetz et al., 1997; Lodi et al., 2000; Turner et al., 2007). The
molecular events mediating mitochondrial dysfunction are not currently known. However,
direct interaction between mitochondria and mutant huntingtin (Bossy-Wetzel et al., 2008;
Orr et al., 2008) as well as a decrease in the expression of peroxisome proliferator-activated
receptor-γ (PPARγ) coactivator-1α (PGC-1α) may at least in part underlie mitochondrial
dysfunction (Chaturvedi et al., 2009).
Recent evidence also suggests that bone mineral density loss may also be a feature in HD
(Goodman and Barker, 2011). Using dual-energy x-ray absorptiometry, Goodman and Barker
(2011) showed that bone mineral density is decreased in people with premanifest HD relative
to healthy controls. The mechanisms underpinning bone mineral density loss are yet to be
elucidated. However, it may arise as a side effect of medication, a lack of physical activity or
hormonal irregularities.
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1.16 CLINICAL MANAGEMENT OF HD
Discovery of the CAG mutation in 1993 was met with great excitement and a belief that HD
could soon be medically solved. Unfortunately, twenty one years on, a cure or disease
modifying therapy has yet to be unveiled. In the absence of a cure or disease modifying
therapy, pharmaceutical interventions have been used, and remain the main treatment for
people suffering with HD.
1.16.1 Pharmaceutical management of clinical features in HD
Drug agents are commonly used to treat HD (Ross and Tabrizi, 2011). However there are no
effective drug agents for treating cognitive symptoms in HD (Mason and Barker, 2009;
Nance, 2012; Novak and Tabrizi, 2010; Ross and Tabrizi, 2011; Venuto et al., 2012). There
is also a dearth of peer reviewed evidence indicating that drug agents are effective for treating
psychiatric symptoms in people with HD (Pidgeon and Rickards, 2013). Evidence does
however indicate that drug agents are effective in alleviating chorea in HD. In a recent
guideline document, the American Academy of Neurology found level B evidence for the
efficacy of tetrabenazine, amantadine and riluzole to treat chorea in people with manifest HD
(Armstrong and Miyasaki, 2012).
In summary, there is limited evidence to support the use of drug agents for treating the
clinical features in HD. In addition, there is no validated evidence showing that drug agents
are effective for treating pathological mechanisms underpinning HD. Furthermore, many
drug agents are associated with unwanted side effects such as malaise, sedation and a
depressive mood state, which may predispose individuals to falls and suicidal ideation. Drug
agents nevertheless remain the mainstay approach for managing symptoms of HD.
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1.16.2 Promising neuroprotective therapies for HD
A number of pharmaceutical compounds with disease-modifying properties have been
identified over the past twelve years. Unfortunately, none have to date, demonstrated true
disease-modifying effects in people with HD. There are, however, many promising
compounds on the horizon (Burgunder, 2013; Dominguez and Munoz-Sanjuan, 2014;
Schapira et al., 2014).
The most advanced compounds with potential disease-modifying properties include creatine
monohydrate, PBT2 (a metal protein-attenuating compound) and cysteamine bitartrate. In a
recent phase II trial, creatine monohydrate was found to be safe, well tolerated and associated
with a significant reduction in cortical and striatal atrophy in forty-seven HD gene carriers
(Rosas et al., 2014). While peer review evidence is not yet available, a recent press release by
Prana Biotechnology LTD reported benefits in executive function in individuals with
manifest HD taking PBT2 (Huntington Study Group, 2015). Raptor Pharmaceuticals has also
recently released intermediate findings from their 36 month phase II trial of cysteamine
bitartrate (Raptor Pharmaceuticals, 2014). The intermediate findings indicate that cysteamine
bitartrate has a positive effect on motor function. While positive, subsequent phase III
investigations are required to recapitulate these findings in larger cohorts of individuals with
HD.
A number of alternative pharmaceutical strategies are also being investigated. The most
promising strategy involves lowering the expression of the mutant Htt protein with antibody
compounds or by inhibiting gene expression with RNA interference and antisense RNA
oligonucleotides (Sah and Aronin, 2011). RNA interference has been shown to decrease
mutant Htt expression and ameliorate the phenotype in mouse models and non-human
primates (Grondin et al., 2012; Kordasiewicz et al., 2012; McBride et al., 2011). Direct
infusion of antisense RNA oligonucleotides into the lateral ventricle of mouse models has
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similarly been shown to repress the expression of mutant Htt (Carroll et al 2011). While
positive, many challenges still need to be overcome to ensure success in the clinic, such as
the delivery of these compounds to appropriate sites, assessing the distribution of these
compounds centrally and determining safe, long term doses of these compounds (Dominguez
and Munoz-Sanjuan, 2014).
Another therapeutic approach involves increasing PGC-1α activity via PPARs activators
thereby restoring metabolic homeostasis (Chandra et al., 2014). PPAR agonist, bezafibrate
has been shown to reduce striatal atrophy and the loss of medium spiny neurons in the
striatum, as well as improve survivability and rotarod performance in the R6/2 mouse model
(Johri et al., 2012). Activation of sirtuin 1 and 3 with nicotinamide riboside has also been
shown to increase the expression of BDNF and PGC-1α and improve the motor phenotype of
the R6/1 mouse model of HD (Hathorn et al., 2011).
Other promising therapeutic approaches include histone deacetylase and kynurenine 3monoxygenase inhibitors (Dominguez and Munoz-Sanjuan, 2014). Histone deacetylase
inhibitors encourage acetyl tagging of histones facilitating normalised gene expression and
mutant Htt clearance (Bürli et al., 2013). Kynurenine 3-monoxygenase inhibitors increase the
expression of kynurenic acid, a neuroprotective metabolite, and decrease the expression of 3hydroxykynurenine (3-HK) and quinolinic acid (QA) metabolites in the brain. The use of
such compounds has been shown to improve survivability in R6/2 mice (Zwilling et al.,
2011).
In summary, there are many promising pharmaceutical compounds with disease modifying
properties being trialled now. Unfortunately, history has shown that many of these
compounds will not be successful (futility and/or safety) (Bates et al., 2014). Furthermore, if
successful, many of these compounds could take up to a decade to become publicly available.
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Therefore identifying and developing treatments that can be implemented in the short term is
of paramount importance.
1.17 LIFESTYLE FACTORS AND HD
Accumulating evidence indicates that lifestyle factors can have a profound impact on the
onset and progression of HD. Recent evidence by Bonner-Jackson et al (2013b) showed that
greater cognitive reserve (composite of premorbid intellectual level, occupational status, and
years of education) was associated with a slower rate of volume loss in the caudate nucleus
and putamen in HD gene carriers. Lopez et al (2011) in another study reported a significant
association between better clinical UHDRS scores and a higher level of education in
individuals with manifest HD. In an earlier investigation by Trembath and colleagues (2010),
greater sedentary behaviour was also found to be associated with an earlier motor onset in
HD gene carriers.
A wealth of evidence also indicates that environmental factors influence the age of onset,
clinical presentation and progression in HD (Anca et al., 2004; Friedman et al., 2005;
Georgiou et al., 1999; Wexler, 2004). In a landmark investigation conducted in Venezuela,
Wexler et al (2004) found that after controlling for the CAG repeat expansion (accounts for
40-70% of variability in the age of onset), environmental modifiers accounted for 60% of the
remaining variability in the age of onset. Clinical case reports and general observations of
monozygotic twins have reported similar findings. In particular, Friedman et al (2005)
observed a seven year difference in the age of onset between monozygotic twins, despite
identical genotypes (39 CAG repeats). Authors found evidence that smoking and exposure to
pollutants contributed to discrepancies in the age of onset between these twins. Georgiou et al
(1999) in another investigation reported marked phenotypic differences between
monozygotic twins. In particular, one twin (A) displayed more pronounced motor
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impairments, while the other twin (B) had more pronounced impairments in attention.
Interestingly, this investigation further reported that twin B had a more rapid rate of
deterioration that twin A. Similar to Friedman et al (2005), authors concluded that epigenetic
pre and postnatal environmental factors may have influenced the different clinical profiles in
the twins.
These findings indicate that lifestyle factors influence the onset, progression and expression
of HD. Lifestyle interventions may therefore have a positive impact on disease progression as
well as clinical expression in people with HD.
1.18 ENVIRONMENTAL ENRICHMENT AND MOUSE MODELS OF HD
Numerous studies over the last decade have investigated the effectiveness of environmental
enrichment as a treatment approach in HD R6/1, R6/2 and N171-82Q mouse models (for a
comprehensive overview of the genetic and phenotypic characteristics of the mouse models
see Appendix 1). The first such study was conducted by van Dellen and colleagues (2000)
who demonstrated the effectiveness of environmental enrichment in delaying the onset of HD
in male R6/1 mice. Statistically significant reductions in cerebral volume degeneration were
noted, along with significant improvements in static horizontal rod deficits. Additionally,
significant reductions in rear paw clasping rates were noted. Hockly et al (2002) also
investigated three levels of environmental enrichment in R6/2 mice and similarly utilised
rotarod assessments and post mortem brain volume to measure benefits. R6/2 mice at 4
weeks of age were randomly placed in non-enriched, minimally-enriched or highly-enriched
living conditions until 12 weeks of age. Quantitative testing at 4, 8 and 12 week intervals
revealed delayed rotarod deficits (p<10-5) and statistically significant improvements in grip
strength (p=0.03) in R6/2 mice in enriched environments relative to non-enriched mice.
Enriched R6/2 mice also had delayed peristriatal cerebral volume loss, supporting the
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previous findings by van Dellen and colleagues (Hockly et al., 2002; van Dellen et al., 2000).
Schilling et al (2004) found the same using the N171-82Q mouse model of HD. Mice placed
in environmentally enriched cages (with exercise wheels and hiding tubes) for three weeks
exhibited a 73% improvement in the rotarod assessment compared to non-enriched mice in
standard cages (p<0.0001). Further longitudinal studies (21 weeks) revealed longer life
expectancy in mice in enriched environments relative to mice in standard caging (Lazic et al.,
2006).
Following on from their earlier studies, van Dellen et al (2008) investigated the effectiveness
of environmental stimulation relative to that of exercise alone in R6/1 HD transgenic mouse
models. Motor performance measures and quantitative brain volume assessments taken at 5
and 9 months showed that mice in standardised housing failed the static horizontal rod test
while both the environmentally enriched and wheel running groups showed a delay in static
horizontal rod deficits. Greatest improvements were exhibited by those mice in the
environmentally enriched housing; the environmentally enriched group showed no deficits on
the static horizontal rod test at 160 days, whereas the wheel running group exhibited an 80%
deficit. In addition only the environmentally enriched housing group exhibited statistically
significant improvements on the accelerating rotarod test (p<0.001). Lastly neither
environmental enrichment nor wheel running housing conditions ameliorated shrinkage of the
striatum and anterior cingulate cortex, or brain volume at nine months of age. These results
indicate that environmental enrichment and wheel running effectively improve motor
performance in the R6/1 mouse models, without changing the chronic brain atrophy that is
seen in this murine model of HD (Van Dellen et al., 2008).
Several other studies have now documented the neurological benefits of environmental
enrichment. Spires et al (2004) rescued deficits in, Dopamine-and cAMP-regulated
phosphoprotein, Mr 32 kDA (DDARP-32) and brain derived neurotrophic factor (BDNF) in
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the striatum of R6 mice housed in environmentally enriched cages, which was important
given that DDARP32 is primarily involved in the regulation of dopamine signalling, whilst
BDNF may play a crucial role in some aspects of adult neurogenesis, synaptic plasticity and
cell survival (Lee et al., 2002; Zuccato et al., 2001). In this last respect, Lazic and colleagues
(2006) documented increased hippocampal neurogenesis and neuronal maturation in R6/1
mouse models reared in an environmentally enriched cage.
Whilst these results are positive, it is important to note that animal models of HD do not
recapitulate the human HD condition. It is currently not known whether environmental
enrichment strategies will be beneficial for people living with HD. To date only a handful of
uncontrolled studies have evaluated the effects of environmental and/or lifestyle approaches
in individuals with HD. The effects of environmental and/or lifestyle approaches have been
beneficial in individuals with other neurodegenerative diseases such as multiple sclerosis
(MS) and Parkinson’s disease (PD) and provide a rationale for such interventions to be used
in HD.
1.19

LIFESTYLE

INTERVENTIONS

IN

NEURODEGENERATIVE

DISEASES
Accumulating evidence indicates that multidisciplinary rehabilitation is beneficial for people
living with other neurodegenerative disorders, such as MS and PD (Asano et al., 2014; Beer
et al., 2012; Khan et al., 2007; Khan et al., 2011; Parashos, 2012; Post et al., 2011; Prizer and
Browner, 2012; van der Marck and Bloem, 2014).
Many studies have now shown that multidisciplinary rehabilitation is beneficial for people
living with MS. In particular, short term multidisciplinary rehabilitation has been found to
have positive effects on disability (Craig et al., 2003; Freeman et al., 1997; Judica et al.,
2011), physical impairment (Judica et al., 2011), fatigue (Judica et al., 2011; Sacco et al.,
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2011), gait (Sacco et al., 2011; Salhofer-Polanyi et al., 2013), transfer skills (Patti et al.,
2003), bladder impairment (Khan et al., 2010), sphincter control (Freeman et al., 1997), selfcare (Freeman et al., 1997; Patti et al., 2003), mood (Patti et al., 2002), social function (Patti
et al., 2002) and quality of life (Patti et al., 2002) in people with MS. Longer duration
multidisciplinary rehabilitation interventions have similarly reported improvements in
disability (Khan et al., 2008), fatigue (Di Fabio et al., 1998) and functional independence
(Kidd et al., 1995) in people living with MS.
Multidisciplinary rehabilitation has also been reported to be beneficial for people suffering
with PD. Short duration multidisciplinary rehabilitation interventions (ranging from 21 days
to two months) have been reported to improve disability (Frazzitta et al., 2015), dyskinesia
(Frazzitta et al., 2012a; Frazzitta et al., 2013), transfer skills (Ellis et al., 2008; Frazzitta et al.,
2015), mobility (Ellis et al., 2008; Frazzitta et al., 2015; Trend et al., 2002), balance
(Frazzitta et al., 2014), voice articulation (Trend et al., 2002), speech (Trend et al., 2002),
depression (Trend et al., 2002), mood (Guo et al., 2009), activities of daily living (Guo et al.,
2009), upper extremity function (Ellis et al., 2008) and quality of life (Guo et al., 2009;
Tickle‐Degnen et al., 2010; Trend et al., 2002) in people living with PD. Recent evidence
also shows that short duration multidisciplinary rehabilitation can improve clinical measures
of disease progression (Unified Parkinson’s Disease Rating Scale Version II & III) as well as
increase serum BDNF levels ((Frazzitta et al., 2012b; Frazzitta et al., 2013; Frazzitta et al.,
2015; Frazzitta et al., 2014). Longer duration multidisciplinary rehabilitation interventions
have similarly reported benefits in people with PD, including improvements in motor
function (Carne et al., 2005a; Carne et al., 2005b), depression (Marck et al., 2013),
psychosocial functioning (Marck et al., 2013) and quality of life (Marck et al., 2013).
Collectively, these findings indicate that multidisciplinary rehabilitation is useful for treating
a diversity of problems in people with neurodegenerative disorders such as MS and PD.
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1.20 MULTIDISCIPLINARY REHABILITATION AND HD
Multidisciplinary rehabilitation is an interdisciplinary approach for treating clinical
conditions. It typically comprises cognitive and motor exercises as well as social interaction
in conjunction with pharmaceutical treatment. Specialised interdisciplinary teams often
design, deliver and evaluate the therapeutic utility of multidisciplinary rehabilitation
interventions for people with clinical conditions. The type, number and experience of
specialists differ in each clinical setting considerably. Multidisciplinary rehabilitation is used
to treat clinical features in other neurodegenerative disorders such as MS and PD that do not
respond to pharmaceutical treatment alone (Parashos, 2012; Veenhuizen and Tibben, 2009).
Expert opinion, preclinical evidence and clinical findings in other neurodegenerative
disorders suggest that multidisciplinary rehabilitation may have a positive impact on
symptoms and perhaps the disease processes involved in HD (Bates et al., 2014; Nance,
2012; Spires et al., 2004; van Dellen et al., 2000; Veenhuizen and Tibben, 2009). Despite this
positive sentiment, few studies have evaluated the therapeutic effectiveness of
multidisciplinary rehabilitation for people living with HD. Preliminary evidence however
suggests that multidisciplinary rehabilitation is safe, well tolerated and beneficial for people
with HD (Piira et al., 2013; Veenhuizen et al., 2011; Zinzi et al., 2007).
Zinzi and colleagues (2007) were the first group to evaluate the effectiveness of
multidisciplinary rehabilitation in people with HD. In this study, multidisciplinary
rehabilitation comprised six days of high intensity training, conducted for three weeks, three
times a year, for two years. Significant improvements in balance, gait and functional capacity
were found as a result of the intervention.
In another study, Veenhuizen et al (2011) evaluated the effect of an outpatient
multidisciplinary care program in twenty individuals with manifest HD. Individualised
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multidisciplinary care models were prescribed to patients after consultation with a specialised
multidisciplinary team (physician, psychologist, speech and language therapist, social
worker, occupational therapist and case manager). Multidisciplinary care models were
revised every six months to ensure that models were stimulating and achievable. Following
eighteen months of outreaching multidisciplinary rehabilitation, patients, carers, and health
care professionals were asked to complete a survey on the effectiveness of the program.
Results of the survey showed that patients, carers and health care professionals were
appreciative and perceived the program to be beneficial. Moreover, caregivers felt that the
multidisciplinary rehabilitation program prolonged the time that patients lived at home.
More recently, Piira et al (2013) investigated the effectiveness of an inpatient
multidisciplinary rehabilitation intervention in thirty seven individuals with manifest HD.
The multidisciplinary rehabilitation intervention comprised five times per week therapy
(physiotherapy, occupational therapy, hydrotherapy and resistance exercise) for eight hours,
for three weeks, three times during a year. Significant improvements in gait balance, physical
quality of life, anxiety and depression were found in patients after the multidisciplinary
rehabilitation intervention.
These preliminary findings indicate that multidisciplinary rehabilitation is safe, well
tolerated, and beneficial for motor and psychiatric features of HD. While informative, the
previously mentioned trials lacked a control group limiting the validity of the conclusions
derived. In addition, previous trials have not evaluated the impact of multidisciplinary
rehabilitation on neuropathological features of the disease. It is therefore clear that additional
evidence from randomised controlled investigations is required to confirm and expand on
these promising findings.
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1.21 THEORETICAL FRAMEWORK
There is no cure or disease modifying strategy, and available pharmaceutical agents only
provide partial relief of motor and psychiatric features of the disease. Prospective
observational evidence indicates that lifestyle factors influence the onset and progression of
clinical features as well as the rate of striatal volume loss in individuals with HD. Evidence
from preclinical studies additionally shows that environmental enrichment preserves
peristriatal structures, improves the clinical phenotype and survival of HD transgenic mouse
models. Lastly, emerging evidence shows that rehabilitation programs can have major effects
on clinical features, neuronal function and disease progression in those suffering with MS and
PD.
Despite these findings and expert recommendations, only three studies have investigated the
effectiveness of multidisciplinary rehabilitation in people suffering with HD. These studies
have shown that multidisciplinary rehabilitation can have favourable effects on motor
function, mood, anxiety and physical quality of life. While encouraging, additional work is
required to confirm and expand on these uncontrolled findings and determine its true effects
on disease course. Studies investigating the factors underlying more debilitating aspects of
HD are also required.
Mobility and balance impairments contribute to a loss of ambulation and nursing home
placement in HD. Despite these serious health implications, no study has investigated the
factors that contribute to impairments in mobility and balance. Identifying factors that
contribute to these impairments should inform the design of multidisciplinary rehabilitation
interventions. The first aim of this thesis was therefore to investigate the factors that
contribute to impairments in mobility and balance in people with manifest HD.
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Accumulating evidence suggests that resistance training is beneficial for those living with
neurodegenerative disorders. However, consensus regarding its utility still remains
contentious among health care professionals. To better inform the present study and provide
greater clarification for health care professionals, the therapeutic utility of resistance training
on clinical aspects of neurodegenerative disorders was investigated through a literature
review.
The ultimate aim of this thesis was to confirm and expand on previous findings by
comprehensively evaluating the effects of multidisciplinary rehabilitation on motor control,
cognitive function, mood, body composition and quality of life in patients with manifest HD.
This thesis also aimed to investigate, for the first time, the effects of multidisciplinary
rehabilitation on neurodegeneration in cortical and sub-cortical structures and how this relates
to cognitive function in individuals with manifest HD using magnetic resonance imaging.
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1.22 HYPOTHESIS AND AIMS
The overarching hypothesis of this thesis is that multidisciplinary rehabilitation improves
clinical and neuropathological features of HD.
Study 1 Aim:
To identify factors that contribute to impairments in balance and mobility in HD.
Study 2 Aim:
To systematically evaluate the quality of published evidence on the effects of
resistance exercise for individuals with neurodegenerative disorders.
Study 3 Aim:
To determine the effects of multidisciplinary rehabilitation on body composition,
postural control, depression, quality of life and disease status in individuals with
manifest HD.
Study 4 Aim:
To determine the effects of multidisciplinary rehabilitation on motor function and lean
tissue mass in individuals with HD.
Study 5 Aim:
To determine the effects of multidisciplinary rehabilitation on structural brain changes
and cognitive function in individuals with manifest HD.
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2.1 ABSTRACT
Mobility and balance problems are common and often debilitating features of Huntington’s
disease (HD). In this exploratory study we aimed to investigate the influence of disease
severity, severity of motor deficits, lower limb muscle strength, cognition, executive function,
lean muscle mass and reactivity on mobility and balance.
Twenty-two individuals with HD were recruited from the North Metropolitan Area Mental
Health Service, Perth, Australia. Pertinent demographic, genetic and disease progression
information was recorded prior to testing. Balance was assessed using dynamic and static
balance tasks. Mobility was assessed using self-paced and fast-paced mobility measures.
Cognitive and executive measures were used to assess verbal learning and memory,
information processing speed, attention, response inhibition and cognitive flexibility. Lower
limb muscle strength was evaluated by maximal isokinetic and isometric voluntary
contractions. Lean tissue mass was quantified using Dual-energy X-ray absorptiometry.
Reactivity was measured using Moyart equipment.
Univariate and multivariate linear regression statistical models were used to examine the
influence of these measures on mobility and balance. Univariate analyses showed that disease
severity as well as measures of information processing speed, attention, cognitive flexibility,
response inhibition and lower limb strength, were strongly related with mobility and balance.
Additionally multivariate analyses showed that disease severity, cognitive flexibility and
knee flexion strength together were better able to explain mobility and balance performance
than any single measure (50%-85%).
In conclusion, our preliminary results suggest that as well as disease severity, cognitive and
executive impairment and reduced lower limb strength contribute significantly to mobility
and balance problems.
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2.2 INTRODUCTION
Problems with balance and mobility are commonly reported by individuals suffering with
HD. Problems occur early in the disease course and worsen with disease progression (Rao et
al., 2008). Impairments in balance and mobility often predict nursing home placement,
increase the likelihood for falls and can severely impact on health related quality of life (Rao
et al., 2005; Reilmann et al., 2012).
There are no clinically proven treatment strategies for addressing balance and mobility
problems in people with HD. Previous studies examining mobility and balance in people with
HD have documented decreases in gait velocity and stride length, increases in stride-to-stride
variability, double support time and step time, and increased postural sway (Delval et al.,
2007; Delval et al., 2006; Delval et al., 2008; Hausdorff et al., 1998; Hausdorff et al., 1997;
Panzera et al., 2011; Tian et al., 1991). While providing a vivid description of mobility and
balance issues, previous studies have failed to investigate clinical features that contribute to
mobility and balance problems in HD.
Studies in people with Parkinson’s disease (PD) have reported strong associations between
muscle power and strength and performance on balance and mobility tasks (Nocera et al.,
2010; Paul et al., 2013b; Schilling et al., 2009). Task dependent relationships between
cognition and mobility and balance have also been documented in PD (Paul et al., 2013b).
Similar associations have been reported in people with multiple sclerosis (MS) (D'Orio et al.,
2012; Hoang et al., 2014; Kalron et al., 2011; Sosnoff et al., 2013b). In the elderly, age
related losses of lean tissue have been reported to strongly predict mobility and balance
problems (Krause et al., 2012). Individuals with HD, in addition to displaying movement
symptoms, exhibit progressive cognitive and executive impairment (Stout et al., 2012;
Tabrizi et al., 2009; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013) as well as
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skeletal muscle atrophy throughout the disease course (Robbinsa et al., 2006; Thompson et
al., 2013), which may similarly adversely impact on balance and mobility.
Emerging evidence suggests that in HD, reduced muscle strength, cognitive and executive
problems as well as skeletal muscle atrophy are remediable to interdisciplinary rehabilitation
approaches (Bonner-Jackson et al., 2013b; Khalil et al., 2013; Thompson et al., 2013). This
exploratory study therefore aimed to investigate the influence of motor, cognitive, executive
and body composition features of the disease on mobility and balance performance in people
with HD as a better understanding of the contribution of these deficits to balance and
mobility may lead to improved therapies in HD.
2.3 MATERIALS AND METHODS
2.3.1 Ethics approval
This study was approved by the Human Research Ethics Committee at Edith Cowan
University and the North Metropolitan Area Mental Health Service (NMAMHS) Human
Research Ethics Committee. All participants provided written informed consent.
2.3.2 Participants
Sixty-two potential participants were identified using the Neuroscience Unit database of the
NMAMHS. Participants were only included if they had received a positive genetic test, were
formally diagnosed as symptomatic (Unified Huntington’s Disease Rating Scale Total Motor
Score [UHDRS-TMS] ≥ 5), and had the ability to follow verbal or written instruction.
Participants were not included if they had recent substance abuse, an unstable psychiatric
state, confounding neurological condition or concomitant physical injury.
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2.3.3 Study procedures
Participants were evaluated over two weekends at Edith Cowan University using a variety of
mobility and balance tasks as well as cognitive, executive, lower limb muscle strength, lean
tissue mass and reactivity measures. All assessments were performed by accredited
independent examiners.
2.3.4 Outcome measures
Dynamic and static balance was examined using the berg balance scale (BBS), sensory
organisation test (SOT) and the repeated sit to stand test (RSST). Mobility over short and
long distances was quantified using the timed walk test (TWT) and the six minute walk test
(6MWT) (Quinn et al., 2013). These measures have previously been demonstrated to be
reliable in individuals with HD (Khalil et al., 2010; Quinn et al., 2013).
2.3.5 Predictor measures
Disease severity and severity of motor abnormalities were quantified using the disease burden
score and the UHDRS-TMS. Cognition and executive function was examined using a variety
of clinically validated measures. The Hopkins Verbal Learning Test-Revised (HVLT-R) was
used to measure verbal learning and memory (Brandt, 1991; Thompson et al., 2013).
Information processing speed and attention were examined using the Symbol Digit
Modalities Test (SDMT) (Smith, 1973; Thompson et al., 2013). Response inhibition and
cognitive flexibility were examined using the Delis-Kaplan Executive Function System (DKEFS) Colour Word Interference Test (CWIT) and Trail Making Trials (TMT) (Thompson et
al., 2013). Reactivity was measured using a visual response task. Dual-energy X-ray
absorptiometry (DEXA; Hologic Discovery A) was used to quantify lean tissue mass (g)
(Goodman and Barker, 2011; Thompson et al., 2013). Lower limb muscle strength was
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quantified using a maximal voluntary isometric and isokinetic knee flexion and extension
contractions with automated dynamometry (Biodex, System 3, USA). Isokinetic knee
extension and flexion strength was examined using 180°·s-1 (fast) and 30°·s-1 (slow)
maximum voluntary contraction (MVC) test protocols. Isometric knee extension and flexion
strength were also measured at 60° flexion. Individuals performed three maximal voluntary
contractions for each strength protocol.
2.4 STATISTICAL ANALYSIS
Data is presented as mean, range and standard deviation (SD). Associations between balance
and mobility tasks (outcome variables), disease severity, severity of motor abnormalities and
measures of cognition, executive function, lower limb strength, lean tissue mass and
reactivity (predictor variables) were determined using univariate linear regression analysis.
Associations between multiple predictor variables and balance and mobility were then
determined using multivariate linear regression. The results of the univariate linear regression
analysis showed that measures of disease severity, attention, information processing speed,
cognitive flexibility and response inhibition associated strongly with balance and mobility
tasks. These predictor variables were entered into a multivariate linear regression model and
assessed for association with each of the mobility and balance tasks. Backward selection
estimation was then used to obtain the most significant multivariate model. Statistical
significance was set at p 0.05. All statistical analyses were performed using STATA version
9.1.
2.5 RESULTS
Of the sixty-two potential participants, twenty-two individuals agreed to voluntarily
participate in the study (Table 2.1.). Of these, 16 were taking antidepressants, 12 antipsychotics and 5 anti-choreic medications. Demographic, disease severity, severity of motor
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abnormalities, cognition, executive function, lower limb strength, lean tissue mass, reactivity,
mobility and balance data are displayed in Tables 2.1 and 2.2.
2.5.1 Balance
Univariate analyses revealed significant associations between disease severity and
performance on balance tasks (18%-50.0% for disease burden score). Moreover, measures of
information processing speed, attention, cognitive flexibility, response inhibition and lower
limb strength were significantly associated with performance on balance tasks (20.3-27% for
correct oral, 18.2%-53.0% for word reading, 26.3%-49.5% for motor speed, 24.5%-42.7% for
60˚ MVC knee flexion; Supplementary Tables 2.3, 2.4 and 2.5). Task dependent associations
between measures of verbal learning and memory and performance on the RSST task were
also found (total recall 21.3%). Lean tissue mass, reactivity and severity of motor
abnormalities were found not to be related to balance task performance (Supplementary
Tables 2.3, 2.4 and 2.5).
Multivariate analyses showed that performance on the BBS was best explained by disease
severity (disease burden score explained 57%; Supplementary Table 2.9). For the SOT,
performance variability was best explained by disease severity and cognitive flexibility
measures (disease burden score and motor speed together explained 50% of variability;
Supplementary Table 2.9). Performance variability on the RSST was best explained by
measures of cognitive flexibility and knee flexion muscle strength (motor speed and 60˚
MVC knee flexion strength together explained 72%; Supplementary Table 2.9).
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Table 2.1 Participant characteristics
Variables

Mean (SD) (n=22)

Range

Age (Years)

50.85 ± 9.24

30.3-70

Disease Duration

3.95 ± 4.26

0.3-17.3

CAG (n)

44.22 ± 2.99

39-51

Disease Burden Score

427.22 ± 118.05

269.5-596

UHDRS-Total Motor
Score

26.45 ± 12.41

5-45

CAG (n), cytosine-adenine-guanine repeat length, UHDRS, Unified Huntington’s Disease
Rating Scale
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Table 2.2 Study participant performance on outcome measures
Study Assessments
Mean (SD)
Predictor Variables
Cognition Assessments
SDMT
Correct Written
26.33 ± 10.57
Incorrect Written
1.66 ± 1.95
Correct Oral
29.71 ± 13.40
Incorrect Oral
1.85 ± 2.34
HVLT-R
Total Recall
16.52 ± 6.20
Delayed Recall
5.13 ± 2.35
Retention
77.00 ± 22.59
Recognition Discrimination Index
8.00 ± 3.08
D-KEFS TMT
Visual Scanning
35.42 ± 15.83
Number Sequencing
59.57 ± 21.84
Letter Sequencing
79.10 ± 55.56
Number-Letter Sequencing
142.00 ± 54.24
Motor Speed
65.44 ± 35.16
D-KEFS CWIT
Colour Naming
44.05 ± 15.72
Word Reading
35.14 ± 13.81
Inhibition
89.42 ± 33.52
Lower Limb Strength Measures
30°·s-1MVC Knee Extension
127.23 ± 54.36
180°·s-1MVC Knee Extension
71.05 ± 29.92
-1
30°·s MVC Knee Flexion
71.88 ± 32.44
180°·s-1 MVC Knee Flexion
50.19 ± 19.33
60° MVC Knee Extension
157.30 ± 49.06
60° MVC Knee Flexion
65.46 ± 18.73
Body Composition Assessment
Lean Tissue Mass
52224.47 ± 10332.29
Reactivity Assessments
Visual Reaction Time (DOM)
0.69 ± 0.24
Visual Reaction Time (NON)
0.67 ± 0.25
Outcome Variables
Balance Assessments
SOT
54.04 ± 15.63
BBS
46.59 ± 7.83
RSST
28.62 ± 12.76
Mobility Assessments
TWT (Fast-paced)
6.17 ± 2.81
TWT (Self-paced)
8.10 ± 2.63
6MWT
466.19 ± 127.37
DOM= dominant hand, NON= non-dominant hand
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Range

10.00-48.00
0.00-6.00
8.00-60.00
0.00-7.00
4.00-30.00
1.00-9.00
33.00-129.00
2.00-15.00
16.00-70.00
33.00-124.00
31.00-234.00
61.00-239.00
18.00-147.00
22.00-78.00
20.00-73.00
40.00-186.00
40.80-217.10
20.90-128.45
15.60-138.95
14.30-96.00
71.10-238.95
14.80-100.25
34362.20-68907.30
0.34-1.20
0.26-1.21

22.00-80.00
26.00-56.00
12.00-64.00
3.08-16.72
5.90-17.18
87.00-630.00

2.5.2 Mobility
Univariate analyses showed significant associations between disease severity and
performance of mobility tasks (disease burden score 43%-50%). Measures of attention,
information processing speed, cognitive flexibility, response inhibition and lower limb
strength measures were also associated with mobility task performance (correct oral 20%40.1%, word reading 34.1%-52.2%, motor speed 26.7%-52.8%, 60˚ MVC knee flexion
strength 43%-60%; Supplementary Tables 2.6, 2.7 and 2.8). Task dependent associations
between verbal learning and memory and mobility task performance were also evident (total
recall, 19.5%; Supplementary Tables 2.6, 2.7 and 2.8). There was no evidence of associations
between lean tissue mass, reactivity or severity of motor abnormalities and performance on
mobility tasks (Supplementary Tables 2.6, 2.7 and 2.8).
Multivariate analyses revealed that when measures were collectively considered, disease
severity, cognitive flexibility and knee flexion strength measures explained a significantly
greater proportion of performance variability on mobility tasks than any single measure
(TWT-SP 85%, TWT-FP 72%, 6MWT 85%; Supplementary Table 2.9).
2.6 DISCUSSION
This study found that disease severity, lower limb muscle strength, cognition and executive
function significantly influenced performance on balance and mobility tasks, while reactivity
and lean tissue mass did not. Furthermore, this study showed that when all measures were
collectively considered, the factors most critically related to performance on balance and
mobility tasks were disease severity, cognitive flexibility and knee flexion strength, and
together these measures better explained balance and mobility performance than any single
measure.
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An important finding of this study was that cognition and executive function significantly
influenced performance on balance and mobility tasks. Similar findings have been found in
people suffering from PD (Herman et al., 2014; Paul et al., 2013a; Paul et al., 2013b) and
mild cognitive impairment (MCI) (Persad et al., 2008). Paul et al (2013a; 2013b) in two
recent studies showed that executive function and cognition significantly influenced balance
and falls in people with PD. Persad et al (Persad et al., 2008), in a similar study found that
cognition and executive function were strongly related to balance and mobility in people with
MCI. These findings highlight that deterioration of cognitive and executive function
adversely impacts upon balance and mobility in people with neurodegenerative diseases.
The relationship of lower limb strength with balance and mobility task performance was not
unexpected. Interestingly though, we found that relationships were often dependent on the
muscle group involved and the type of contraction performed, with the 60˚ MVC knee
flexion measure demonstrating significant association with all balance and mobility tasks.
Both 30°·s-1 MVC knee flexion and 180°·s-1 MVC knee flexion measures similarly
demonstrated strong associations with performance on mobility tasks but not balance tasks.
Broekmans et al (2013a) in a similar study found knee flexion strength to strongly predict
walking capacity in people with MS. Knee flexor involvement during stabilization and
mobility tasks in healthy individuals is well established (Chandler et al., 1998; Hughes et al.,
2001; Pavol et al., 2002), and likely explains our findings. Multidisciplinary interventions
have been shown to improve lower limb strength and perception of balance in people with
HD (Thompson et al., 2013), therefore mobility and balance problems may be amenable to
such interventions.
As expected, a strong relationship was observed between disease severity and performance
on balance and mobility tasks, indicating a significant contribution of HD progression to
movement disability. Of interest, is the finding that severity of motor abnormalities, as
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measured by the UHDRS-TMS, was not significantly associated with performance on
balance and mobility tasks. This finding has important clinical implications for the
assessment of balance and mobility in HD. It illuminates the importance of identifying
specific measures to supplement the UHDRS-TMS that can more sensitively quantify balance
and mobility decrements.
Lean tissue mass and reactivity demonstrated negligible associations with mobility and
balance. This was an unexpected finding, considering that studies in PD have reported
reactivity and lean muscle mass to be important clinical determinants of balance and mobility
performance (Dibble et al., 2006; Paul et al., 2013a; Paul et al., 2013b). Discrepancies
between findings are likely due to pathological and clinical differences between PD and HD
(Jankovic, 2008; Sturrock and Leavitt, 2010), as well as methodological and sample size
differences between the studies.
Our findings result from a relatively small sample of individuals with manifest HD, most of
whom were taking medication, as such our findings should be interpreted with a degree of
caution.
2.7 CONCLUSION
Here we provide preliminary evidence that disease severity, lower limb weakness, cognitive
impairment and executive dysfunction significantly influence mobility and balance in people
with HD. Moreover, we show that key clinical features, when considered together, better
explain performance on balance and mobility tasks than any single measure. Findings while
preliminary, provide insight into the multiple clinical features that contribute to balance and
mobility problems in HD, and provide a venue for targeted multidisciplinary rehabilitation
strategies.
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2.9 SUPPLEMENTARY DATA
Supplementary Table 2.3 Univariable associations between impairments (Predictor
Variables) and performance on the BBS (Outcome Measure)
Predictor Variable

Adjusted R2 (%)

P Value

Unstandardised B (95%
CI)

BBS
Demographic Variables
Age
0.6
0.728
-0.066(-0.460:0.327)
Disease Duration
0.6
0.713
-0.152(-1.00:0.701)
CAG repeat
9.9
0.154
-0.824(-1.98:0.334)
*
Disease Burden Score
34
0.004
-0.038(-0.0639:-0.0137)
UHDRS-TMS
2.7
0.467
-0.094(-0.036:0.172)
Cognitive Measures
SDMT
Correct written
14.5
0.088
0.285(-0.047:0.618)
*
Correct Oral
22.1
0.031
0.278(0.027:0.528)
HVLT-R
Total Recall
9.2
0.181
0.38(-0.19:0.97)
Delayed Recall
7.2
0.226
0.89(-0.60:2.38)
Retention
0.3
0.795
-0.02(-0.181:0.141)
Recognition Discrimination
8.2
0.194
0.73(-0.404:1.864
Index
D-KEFS TMT
Visual Scanning
4.2
0.371
-0.104(-0.34:0.133)
Number Sequencing
17.3
0.061
-0.152(-0.313:0.007)
Letter Sequencing
15.5
0.086
-0.057(-0.124:0.000)
Number-Letter Sequencing
0.2
0.879
-0.007(-0.11:0.103)
*
Motor Speed
26.3
0.030
-0.121(-0.22:-0.13)
D-KEFS CWIT
Colour Naming
15.2
0.099
-0.204(-0.45:0.042)
Word Reading
22.4
0.030*
-0.271(-0.51:-0.029)
Inhibition
13.5
0.122
-0.09(-0.207:0.026)
Lower Limb Strength Measures
30°·s-1 MVC Knee Extension
4.5
0.343
0.03(-0.035:0.096)
-1
180°·s MVC Knee
3
0.440
0.045(-0.07:0.16)
Extension
30°·s-1 MVC Knee Flexion
10.5
0.141
0.07(-0.028:0.18)
180°·s-1 MVC Knee Flexion
12.3
0.110
0.141(-0.035:0.318)
60˚ MVC Knee Extension
0.1
0.849
0.00(-0.06:0.08)
60˚ MVC Knee Flexion
13
0.018*
0.154(-0.042:0.351)
Body Composition Measures
Lean Tissue Mass
0.5
0.753
0.00 (-0.00:0.00)
Reactivity Measures
Visual Reaction Time (DOM)
2.4
0.492
0.00 (-0.00:0.00)
Visual Reaction Time (NON)
4.2
0.357
-6.42(-20.63:7.78)
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level
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Supplementary Table 2.4 Univariable associations between impairments (Predictor
Variables) and performance on the SOT (Outcome Measure)
Predictor Variable

Adjusted R2
(%)

P Value

Unstandardised B (95%
CI)

SOT (composite score)
Demographic Variables
Age
0.1
0.850
-0.0721(-0.859:0.715)
Disease Duration
0.6
0.730
-0.286(-1.99:1.418)
CAG repeat
12.9
0.101
-1.87(-4.15:0.400)
*
Disease Burden Score
29.4
0.009
-0.071(-0.123:-0.0198)
UHDRS-TMS
7.5
0.218
-0.316(-0.83:0.202)
Cognitive Measures
SDMT
Correct Written
15.4
0.079
0.56(-0.07:1.21)
*
Correct Oral
27
0.015
0.596(0.127:1.06)
HVLT-R
Total Recall
14.7
0.086
0.95(-0.147:2.047)
Delayed Recall
10.9
0.133
2.19(-0.72:5.11)
Retention
0.2
0.813
0.037(-0.28:0.359)
Recognition Discrimination
16.3
0.062
2.04(-0.11:4.2)
Index
D-KEFS TMT
Visual Scanning
6.8
0.254
-0.263(-0.73:0.204)
Number Sequencing
17.3
0.061
-0.15(-0.31:0.007)
Letter Sequencing
15.5
0.086
-0.057(-0.124:0.009)
Number-Letter Sequencing
0.2
0.879
-0.007(-0.11:0.103)
Motor Speed
26.3
0.030*
-0.121(-0.22:-0.013)
D-KEFS CWIT
Colour Naming
3.7
0.434
-0.183(-0.66:029)
*
Word Reading
18.2
0.050
-0.47(-0.95:0.007)
Inhibition
6.7
0.275
-0.11(-0.34:0.103)
Lower Limb Strength Measures
30°·s-1 MVC Knee Extension
4.2
0.360
0.058(-0.07:0.19)
180°·s-1 MVC Knee Extension
3
0.434
0.091(-0.148:0.331)
30°·s-1 MVC Knee Flexion
9.8
0.154
0.151(-0.061:0.364)
180°·s-1 MVC Knee Flexion
10.4
0.143
0.26(-0.096:0.617)
60˚ MVC Knee Extension
4.2
0.355
0.065(-0.079:0.211)
*
60˚ MVC Knee Flexion
24.5
0.026
0.427(0.055:0.798)
Body Composition Measures
Lean Tissue Mass
0.1
0.865
0.00(-0.00:0.00)
Reactivity Measures
Visual Reaction Time (DOM)
0.4
0.758
3.65(-20.75:28.05)
Visual Reaction Time (NON)
4.8
0.325
11.16(-11.91:34.24)
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level
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Supplementary Table 2.5 Univariable association between impairments (Predictor
Variables) and performance on the RSST (Outcome measure)
Predictor Variable

Adjusted R2 (%)

P Value

Unstandardised B
(95% CI)

RSST
Demographic Variables
4
0.373
0.275(-0.354:0.906)
Age
Disease Duration
0.0
0.897
0.0876(-1.307:1.482)
1.0
0.649
0.438(-1.541:2.418)
CAG repeat
*
Disease Burden Score
18
0.050
0.045(0.000:0.0914)
3.9
0.379
0.186(-0.245:0.618)
UHDRS-TMS
Cognitive Measures
SDMT
Correct Written
22
0.032*
-0.58(-1.10:-0.056)
*
Correct Oral
20.3
0.041
-0.43(-0.85:-0.02)
HVLT-R
Total Recall
21.3
0.032*
-0.98(-1.88:-0.094)
Delayed Recall
7.8
0.208
-1.511(-3.93:0.913)
Retention
0.7
0.697
0.049(-0.212:0.3121)
Recognition Discrimination
17.5
0.053
-1.73(-3.48:0.021)
Index
D-KEFS TMT
Visual Scanning
10.9
0.143
0.273(-0.101:0.647)
Number Sequencing
10.4
0.154
0.192(-0.079:0.464)
*
Letter Sequencing
22.51
0.035
0.114(0.009:0.219)
Number-Letter Sequencing
0.0
0.967
-0.003(-0.177:0.171)
*
Motor Speed
49.5
0.001
0.26(0.121:0.400)
D-KEFS CWIT
Colour Naming
25
0.029*
0.33(0.039:0.63)
*
Word Reading
53
0.000
0.68(0.377:0.99)
Inhibition
7.3
0.264
0.085(-0.070:0.241)
Lower Limb Strength Measures
30°·s-1 MVC Knee Extension
4.1
0.363
-0-047(-0.155-0.059)
-1
180°·s MVC Knee Extension
15
0.075
-0.165(-0.34:0.01)
-1
30°·s MVC Knee Flexion
16.8
0.058
-0.161 (-0.32:0.006)
-1
180°·s MVC Knee Flexion
15.7
0.068
-0.261(-0.544:0.020)
60˚ MVC Knee Extension
2.7
0.466
-0.042(-0.162:0.077)
*
60˚ MVC Knee Flexion
42.7
0.002
-0.465(-0.731:-0.198)
Body Composition Measures
Lean Tissue Mass
0.1
0.865
0.00(-0.00:0.00)
Reactivity Measures
0.4
0.758
3.65(-20.75:28.05)
Visual Reaction Time (DOM)
4.8
0.325
11.16(-11.91:34.24)
Visual Reaction Time (NON)
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level
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Supplementary Table 2.6 Univariable association between impairments (Predictor
Variables) and performance on the 6MWT (Outcome measure)
Predictor Variable

Adjusted R2 (%)

P Value

Unstandardised B
(95% CI)

6MWT
Demographic Variables
Age
6.0
0.281
-3.315(-9.57:2.94)
2.9
0.461
-5.27(-19.95:9.40)
Disease Duration
CAG repeat
7
0.246
-11.01(-30.25:8.23)
*
41.2
0.002
-0.675(-1.06:-0.288)
Disease Burden Score
18
0.056
-4.05(-8.2:0.108)
UHDRS-TMS
Cognitive Measures
SDMT
Correct Written
37.9
0.003*
7.41(2.86:11.97)
Correct Oral
40.1
0.002*
6.07(2.56:9.58)
HVLT-R
Total Recall
19.5
0.045*
9.07(0.229:17.922)
Delayed Recall
15.21
0.081
21.00(-2.80:44.82)
Retention
0.2
0.828
0.282(-2.39:2.95)
Recognition Discrimination
13.4
0.102
16.38(-3.59:36.36)
Index
D-KEFS TMT
Visual Scanning
24
0.028*
-4.55(-8.56:-0.546)
*
Number Sequencing
21.4
0.040
-2.83(-5.52:-0.143)
Letter Sequencing
31.6
0.012*
-1.32(-2.32:-0.32)
Number-Letter Sequencing
0.0
0.950
-0.062(-2.23:2.11)
*
Motor Speed
52.8
0.001
-2.81(-4.28:-1.35)
D-KEFS CWIT
Colour Naming
45
0.002*
-5.309(-8.311:-2.306)
*
Word Reading
52.2
0.000
-6.66(-9.72:-3.60)
*
Inhibition
26.4
0.024
-1.90(-3.53:-0.27)
Lower Limb Strength Measures
30°·s-1 MVC Knee Extension
7.1
0.242
0.63(-0.462:1.722)
-1
180°·s MVC Knee
14
0.094
1.59 (-0.295:3.479)
Extension
30°·s-1 MVC Knee Flexion
25.2
0.020*
1.96 (0.341:3.59)
180°·s-1 MVC Knee Flexion
21.9
0.033*
3.04(0.28:5.80)
60˚ MVC Knee Extension
1.8
0.558
0.373(-0.936:1.683)
*
60˚ MVC Knee Flexion
44.2
0.002
4.74(2.01:7.47)
Body Composition Measures
Lean Tissue Mass
0.2
0.828
0.00(-0.00:0.00)
Reactivity Measures
Visual Reaction Time
-167.21(10
0.162
(DOM)
407.8:73.38)
Visual Reaction Time (NON)
16.7
0.066
-203.17:14.78)
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level
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Supplementary Table 2.7 Univariable association between impairments (Predictor
Variables) and performance on the TWT (Self Paced) (Outcome Measure)
Predictor Variable

Adjusted R2
(%)

P Value

Unstandardised B
(95% CI)

TWT (Self Paced)
Demographic Variables
Age
2.6
0.482
0.048(-0.092:0.189)
Disease Duration
5.1
0.325
0.155(-0.166:0.4763)
CAG repeat
13.4
0.103
0.336(-0.074:0.747)
*
Disease Burden Score
50
0.000
0.0164(0.008:0.0243)
UHDRS-TMS
13
0.115
0.075(-0.019:0.170)
Cognitive Measures
SDMT
Correct Written
0.17
0.059
-0.11(-0.22:0.004)
*
Correct Oral
20
0.042
-0.094(-0.18:-0.003)
HVLT-R
Total Recall
10.2
0.158
-0.14(-0.35:0.061)
Delayed Recall
12.5
0.116
-0.422(-0.95:0.11)
Retention
0.0
0.911
-0.003(-0.062:0.056)
Recognition Discrimination
8.5
0.199
-0.28(-0.74:0.165)
Index
D-KEFS TMT
Visual Scanning
12.8
0.121
0.073(-0.021:0.168)
Number Sequencing
11.8
0.139
0.046(-0.016:0.109)
Letter Sequencing
10.3
0.180
0.017(-0.008:0.043)
Number-Letter Sequencing
0.7
0.806
0.005(-0.047:0.058)
*
Motor Speed
26.7
0.034
0.045(0.003:0.086)
D-KEFS CWIT
Colour Naming
8.5
0.199
-0.28(-0.74:0.165)
*
Word Reading
34.1
0.009
0.108(0.031:0.185)
*
Inhibition
29.3
0.011
0.110(0.028:0.192)
Lower Limb Strength Measures
30°·s-1 MVC Knee Extension
6.8
0.251
-0.013(-0.03:0.10)
-1
180°·s MVC Knee Extension
11.2
0.139
-0.031(-0.073:0.011)
-1
30°·s MVC Knee Flexion
6.8
0.251
-0.013(-0.037:0.010)
-1
180°·s MVC Knee Flexion
14.6
0.087
-0.055(-0.119-0.008)
60˚ MVC Knee Extension
5.6
0.300
-0.014(-0.042:0.013)
*
60˚ MVC Knee Flexion
43
0.002
-0.104(-0.165:-0.043)
Body Composition Measures
Lean Tissue Mass
1.5
0.588
0.00(-0.00:0.00)
Reactivity Measures
Visual Reaction Time (DOM)
2.4
0.502
1.81(-3.73:7.36)
Visual Reaction Time (NON)
7.8
0.217
3.09(-1.98:8.16)
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level
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Supplementary Table 2.8 Univariable associations between impairments (Predictor
Variables) and performance on the TWT (Fast Paced) (Outcome Measure)
Predictor Variable

Adjusted R2
(%)

P Value

Unstandardised B
(95% CI)

TWT (Fast Paced)
Demographic Variables
7
0.246
0.073(-0.055:0.202)
Age
9.6
0.171
0.199(-0.094:0.492)
Disease Duration
8.5
0.200
0.25(-0.144:0.646)
CAG repeat
*
43
0.001
0.0142(0.006:0.0221)
Disease Burden Score
13.6
0.100
0.073(-0.015:0.161)
UHDRS-TMS
Cognitive Measures
SDMT
Correct Written
16.7
0.067
-0.10(-0.211:0.007)
Correct Oral
18.33
0.053
-0.084(-0.169:0.001)
HVLT-R
Total Recall
16.2
0.071
-0.17(-0.35:0.015)
*
Delayed Recall
20.1
0.037
-0.51(-0.98:-0.034)
Retention
1.2
0.63
-0.012(-0.067:0.042)
Recognition Discrimination Index
11.8
0.128
-0.318(-0.735:0.099)
D-KEFS TMT
Visual Scanning
16.9
0.072
0.078(-0.00:0.164)
Number Sequencing
11.11
0.151
0.042(-0.016:0.100)
Letter Sequencing
16.0
0.089
0.02(-0.00:0.043)
Number-Letter Sequencing
0.2
0.897
0.002(-0.042:0.047)
*
Motor Speed
35.3
0.012
0.047(0.012:0.083)
D-KEFS CWIT
Colour Naming
29
0.017*
0.08(0.017:0.160)
*
Word Reading
43.4
0.001
0.125(0.056:0.194)
Inhibition
15.5
0.095
0.030(-0.005:0.066)
Lower Limb Strength Measures
30°·s-1 MVC Knee Extension
7.7
0.221
-0.013(-0.036:0.008)
-1
180°·s MVC Knee Extension
9.8
0.165
-0.027(-0.067:0.012)
-1
*
30°·s MVC Knee Flexion
19.3
0.046
-0.035(-0.07:-0.00)
-1
180°·s MVC Knee Flexion
11.6
0.132
-0.045(-0.106:0.015)
60˚ MVC Knee Extension
4.8
0.338
-0.012(-0.039:0.014)
*
60˚ MVC Knee Flexion
60
0.000
-0.112(-0.16:-0.06)
Body Composition Measures
Lean Tissue Mass
1.2
0.634
0.00(-0.00:0.00)
Reactivity Measures
Visual Reaction Time (DOM)
1.1
0.645
1.16(-4.05:6.39)
Visual Reaction Time (NON)
4.5
0.352
2.20(-2.63:7.03)
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level
54

Supplementary Table 2.9 Associations between impairments (Predictor Variables) and task
performance (Outcome Measure) from multiple Multivariable regression models
Adjusted R2
(%)

p-value

Unstandardised B (95%
CI)

57

0.001

-0.051 [-0.076: -0.026]

50

0.020
0.093

-0.073 [-0.133:-0.0138]
-0.177 [-0.388:0.034]

60˚ MVC Knee Flexion
Motor Speed
Performance on mobility tasks
TWT (Self Paced)

72

0.011
0.002

-0.314 [-0.544: -0.085]
0.577 [0.238:0.896]

Disease Burden Score
60˚ MVC Knee Flexion
Motor Speed
TWT (Fast Paced)

85

0.002
0.003
0.052

0.010 [0.004: 0.016]
-0.067 [-0.105: -0.029]
0.020 [-0.000:0.0404]

Disease Burden Score
60˚ MVC Knee Flexion
Motor Speed
6MWT

72

0.001
0.028
0.041

0.015 [0.007:0.024]
-0.062 [-0.116:-0.007]
0.021 [-0.000:0.0403]

Disease Burden Score
60˚ MVC Knee Flexion
Motor Speed

85

0.002
0.039
0.002

-0.519 [-0.802:-0.237]
1.975 [0.114: 3.83]
-1.76 [-2.759:-0.768]

Predictor Model
Performance on balance tasks
BBS
Disease Burden Score
SOT
Disease Burden Score
Motor Speed
RSST
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3.1 ABSTRACT
Background: Strength training has, in recent years, been shown to be beneficial for people
with Parkinson’s disease and multiple sclerosis. Consensus regarding its utility for these
disorders nevertheless remains contentious among healthcare professionals. Greater clarity is
required, especially in regards to the type and magnitude of effects as well as the response
differences to strength training between individuals with Parkinson’s disease or multiple
sclerosis.
Objective: To examine the effects, magnitude of those effects and response differences to
strength training between patients with Parkinson’s disease or multiple sclerosis.
Data Sources: A comprehensive search of electronic databases including PEDro, PubMED,
EMBASE, Cochrane Central Register of Controlled Trials, and CINAHL was conducted
from inception to July 2014.
Study Eligibility: English articles investigating the effect of strength training for individuals
with neurodegenerative disorders were selected. Strength training trials that met the inclusion
criteria were found for individuals with Parkinson’s disease or multiple sclerosis.
Participants: Individuals with Parkinson’s disease or multiple sclerosis.
Intervention: Strength training interventions included traditional (free weights/machine
exercises) and non-traditional programs (eccentric cycling).
Study Appraisal: Included articles were critically appraised using the PEDro scale.
Results: Of the five hundred and seven articles retrieved, only twenty articles met the
inclusion criteria. Of these, fourteen were randomised and six were non-randomised
controlled articles in Parkinson’s disease or multiple sclerosis. Six randomised and two non-
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randomised controlled articles originated from three trials and were subsequently pooled for
systematic analysis. Strength training was found to significantly improve muscle strength in
people with Parkinson’s disease (15%-83.2%) and multiple sclerosis (4.5%-36%). Significant
improvements in mobility (11.4%) and disease progression were also reported in people with
Parkinson’s disease after strength training. Furthermore, significant improvements in fatigue
(8.2%), functional capacity (21.5%), quality of life (8.3%), power (17.6%) and
electromyography activity (24.4%) were found in individuals with multiple sclerosis after
strength training.
Limitations: Heterogeneity of interventions and study outcomes in Parkinson’s disease and
multiple sclerosis trials.
Conclusions: Strength training is useful for increasing muscle strength in Parkinson’s disease
and to a lesser extent multiple sclerosis.
Implications of key findings: Strength training is a useful adjunct treatment for Parkinson’s
disease and multiple sclerosis.
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3.2 INTRODUCTION
Neurodegenerative disorders such as Parkinson’s disease and multiple sclerosis represent a
major medical concern for health professionals and national healthcare bodies (Nance, 2012).
Both disorders result from progressive neuronal dysfunction and neuronal cell death leading
to progressive disability and eventual death (Lin and Beal, 2006). Classical signs and
symptoms customary to both disorders include motor problems, cognitive impairment,
behavioural disturbances and systemic abnormalities (Benedict and Zivadinov, 2011;
Mitchell and Borasio, 2007; Olanow et al., 2009).
There is no cure and few cost effective drug agents for treating people with Parkinson’s
disease or multiple sclerosis (Evans et al., 2011; Lu et al., 2012). Recent advances in
understanding the pathogenic mechanisms responsible for each disorder may aid in the
identification and development of cost effective disease modifying agents in the future
(Noyes et al., 2011). However, cost effective treatments, with disease modifying properties
and symptomatic benefits are required in the short term.
Accumulating evidence suggests that strength training is a useful therapy for addressing
many of the clinical features that present in individuals with neurodegenerative disorders
(Falvo et al., 2008; Hindle et al., 2013; Kjølhede et al., 2012). By definition, strength training
refers to an intervention, in which participants train a muscle or group of muscles against an
external resistance (Esco, 2013). While evidence suggests that lower limb strength training
(i.e. leg press, knee extension and knee flexion) is beneficial for individuals with Parkinson’s
disease and multiple sclerosis (Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas et al., 2010b;
Dalgas et al., 2013; Dodd et al., 2011; Schilling et al., 2010; Shulman et al., 2013), consensus
regarding the effects, magnitude of those effects and disease dependent responses remain
contentious. By contrast, the therapeutic utility of strength training is well recognised in the
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elderly (Nelson et al., 2007), individuals with mild cognitive impairment and in those that
have suffered a stroke. Health benefits associated with strength training in elderly individuals
include improvements in strength (Fiatarone et al., 1990; Nelson et al., 1994), cardiorespiratory capacity (Pereira et al., 2012), functional capacity (Mangione et al., 2010; Pereira
et al., 2012), muscle activity (Cadore et al., 2013), body composition (Avila et al., 2010),
mood (Pereira et al., 2013), cognition (Cassilhas et al., 2007; Liu-Ambrose et al., 2010),
health related quality of life (Levinger et al., 2007) and enhanced hemodynamic activity on
functional magnetic resonance imaging tasks (Nagamatsu et al., 2012). In individuals who
have suffered a stroke, strength training has been found to improve muscular strength, upper
and lower limb function and performance on functional tasks (Ada et al., 2006; Harris and
Eng, 2010; Ouellette et al., 2004). Improvements in selective attention, conflict resolution,
associative memory and regional patterns of functional brain activity have also been observed
after strength training in seniors with mild cognitive impairment (Nagamatsu et al., 2012).
In the last two years, three systematic reviews have evaluated the effects of strength training
in either Parkinson’s disease or multiple sclerosis (Brienesse and Emerson, 2013; Kjølhede et
al., 2012; Lima et al., 2013). Findings from these reviews suggest that strength training is
useful for improving muscle strength and some measures of functional capacity in these
disorders. Since the publication of these reviews, a number of randomised controlled trials
have been published (Brienesse and Emerson, 2013; Kjølhede et al., 2012; Lima et al., 2013),
somewhat limiting the informative capacity of previous reviews. Previous systematic reviews
have also included trials with confounding supplementary interventions (i.e. creatine
monohydrate and balance training) (Brienesse and Emerson, 2013; Lima et al., 2013) as well
as trials without a disease control or comparison group (Brienesse and Emerson, 2013;
Kjølhede et al., 2012). These methodological limitations may have led to an inaccurate
appraisal of the effects of strength training as a therapy in individuals with Parkinson’s
60

disease or multiple sclerosis. It is of vital importance that systematic reviews accurately
evaluate experimental therapies like strength training as such documents inform health
professionals.
In this systematic review we provide the most recent evidence to support a robust evaluation
of the effect of strength training in people with Parkinson’s disease or multiple sclerosis.
Unlike previous reviews, our study evaluates the effect of strength training alone, in people
with Parkinson’s disease or multiple sclerosis. In addition, our study only selects trials that
included individuals with multiple sclerosis or Parkinson’s disease in the control or
comparison group. Moreover, our study evaluates through a meta-analysis, the magnitude of
strength improvements in individuals with multiple sclerosis or Parkinson’s disease in
response to strength training. Finally, unlike previous reviews, our study explores whether
differences in response to strength training exist between individuals with multiple sclerosis
or Parkinson’s disease.
3.3 MATERIAL AND METHODS
3.3.1 Search strategy
A comprehensive search of electronic databases was conducted from inception to July 2014.
Electronic searches were performed using PEDro, PubMED, EMBASE, Cochrane Central
Register of Controlled Trials, and CINAHL databases. The search strategy utilised a
population, intervention, comparison and outcome (PICO) approach (Moher et al., 2010). The
population key words were “Parkinson’s disease”, “multiple sclerosis”, Alzheimer’s disease,
amyotrophic lateral sclerosis, Huntington’s disease and spinocerebellar ataxia; the
intervention key words were “strength training”, “progressive strength training”, “resistance
training”, “weight training” and “strengthening programs”; and the outcome key words
included “strength”, “disease severity”, “gait”, “balance”, “fatigue”, “functional capacity”,
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“mood” and “quality of life”. This initial search only found trials on strength training in
individuals with Parkinson’s disease or multiple sclerosis.
As this was a literature review and did not involve the recruitment and assessment of patients,
ethical approval was not necessary.
3.3.2 Eligibility criteria
Randomised controlled trials and non-randomised controlled trials that examined the effect of
strength training in individuals suffering with multiple sclerosis or Parkinson’s disease were
included in the review. Strength training was defined as an intervention in which participants
exercised a muscle or group of muscles against an external resistance (Esco, 2013). Eligible
studies included those examining the effect of strength training in individuals with multiple
sclerosis and Parkinson’s disease. Exclusion criteria were as follows: (1) case studies; (2)
observational studies; (3) studies with healthy controls or healthy comparison groups; and (5)
studies employing supplementary intervention therapies in addition to or different from
strength training.
3.3.3 Data extraction
Two independent authors (T.C and A.R) extracted data from the included studies. A
specialised extraction form was designed and recorded the following methodological details
for each study:


Publication details: authors and year of publication.



Details of the study: study design and number of participants, experimental and
control interventions and reported outcomes (controls and experimental).



Participant characteristics: disease population, disease status and age.
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Specific intervention details: intervention groups, mode of strength training, targeted
anatomical regions, setting in which the study was conducted, level of supervision,
duration of the intervention (weeks), frequency of strength training, specific exercises
employed, exercise intensity, number of sets and repetitions performed for each
exercise, rest taken between sets and exercises and the progression method used for
strength training interventions.



Moderator variables: participant retention and dropouts, participant adherence and
adverse effects associated with strength training.

Corresponding authors of studies were contacted as necessary for supplementary information
not detailed in the publication. In cases where authors did not respond or did not provide
supplementary methodological information pertaining to their publication, a not reported
(NR) statement was assigned.
3.3.4 Quality assessment
All articles that satisfied the pre-defined inclusion criteria were independently rated for
quality by two reviewers (T.C and A.R) using the Physiotherapy Evidence Database (PEDro)
scale (Maher et al., 2003). The PEDro scale is an eleven points scale designed to examine the
methodological quality of intervention studies. The scale evaluates the following
methodological aspects: (1) specific eligibility criteria, (2) randomisation allocation, (3)
concealed allocation, (4) baseline demographic similarities, (5) participant blinding, (6)
therapist blinding, (7) outcome assessor blinding, (8) whether more than 85% of participants
completed follow up for at least one primary outcome, (9) intention to treat analysis, (10)
between group statistical comparisons and (11) point estimates and variability for at least one
of the primary outcome measures. When rating each study, only criteria two-eleven are
considered for the PEDro scale. Initial discrepancies between the independent authors were
63

resolved by consensus. In instances where discrepancies could not be resolved a final
decision was made by another independent author (M.Z).
3.3.5 Data analysis and synthesis
For analysis, studies were categorised according to disease. The heterogeneity of populations
and extensive variety of reported outcomes prevented a meta-analysis for all outcomes, with
the exception of strength. While fifteen articles reported on strength as an outcome (Corcos et
al., 2013; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; Dibble et al., 2006;
Dibble et al., 2009; Dodd et al., 2011; Fimland et al., 2010; Hass et al., 2012; Medina-Perez
et al., 2014; Sabapathy et al., 2011; Schilling et al., 2010; Shulman et al., 2013), three articles
by Dalgas et al (Dalgas et al.; 2010b; 2013) and two articles by Dibble et al (2006; 2009)
appeared to originate from the same trial. Strength data from three articles by Dalgas et al
(2009; 2010b; 2013) were pooled together into a single effect size for a better interpretation
of the effects of strength training on strength as an outcome. Standardised effect sizes were
calculated for the meta-analysis using pre and post strength mean values for each group
(intervention and comparison) (Hedges and Olkin, 1985). Effect sizes were corrected for the
magnitude of sample size of each study as suggested by Hedges and Olkin (1985). The risk of
publication bias in trials was examined statistically using the egger regression test, with a
significant publication bias considered to be p≤0.10. All statistical analyses were performed
using STATA 9.1 (StataCorp LC, Texas, USA).
3.4 RESULTS
3.4.1 Articles included
The database search strategy and results are presented in Figure 3.1. Five hundred and seven
articles were identified by the initial search strategy. Four hundred and seventy one of the
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identified articles were excluded based on their title. The abstracts of the remaining thirty-six
articles were evaluated and six articles were excluded (Figure 3.1). Full texts of the remaining
thirty articles were retrieved and reviewed, resulting in the exclusion of ten articles (Figure
3.1). Of the twenty articles included in the systematic review, eight appeared to originate
from three separate trials. Subsequently the extracted and reviewed data is representative of
fifteen independent trials.

507 Potential Articles Identified From Initial Database Searches
471 Articles Excluded Based On Title

93 Duplicated Articles

352 Articles Not Relevant

14 Review Articles

5 Not Resistance Weight Bearing

6 Additional Complementary Therapy
36 Article Abstracts Retrieved For Evaluation

6 Articles Excluded

1 Not Comparable Outcomes

4 Not Resistance Weight Bearing

1 Home based & Not Weight Bearing

30 Full Text Articles Retrieved For Evaluation

10 Articles Excluded

8 Did Not Possess A Valid Comparison
Group

2 Qualitative Studies

20 Articles Systematically Evaluated

8 Articles Excluded For Meta-analysis

5 Did Not Examine Strength

3 Articles originated from the same trial

12 Articles Examining Strength Included In The Meta-Analysis

Figure 3.1 Flowchart for selection of studies and included meta-analysis
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3.4.2 Methodological quality
The methodological quality of included trials varied considerably in both Parkinson’s disease
and multiple sclerosis populations. PEDro scores ranged from four to eight points in both
Parkinson’s disease (Bloomer et al., 2008; Corcos et al., 2013; Dibble et al., 2006; Dibble et
al., 2009; Hass et al., 2012; Paul et al., 2014; Prodoehl et al., 2015; Sage et al., 2011;
Schilling et al., 2010; Shulman et al., 2013) and multiple sclerosis trials (Broekmans et al.,
2011; Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013;
DeBolt and McCubbin, 2004; Dodd et al., 2011; Fimland et al., 2010; Medina-Perez et al.,
2014; Sabapathy et al., 2011) (Table 3.1).
3.4.3 Participants characteristics
The number of trials included was eight in Parkinson’s disease (Bloomer et al., 2008; Corcos
et al., 2013; Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012; Paul et al., 2014;
Prodoehl et al., 2015; Sage et al., 2011; Schilling et al., 2010; Shulman et al., 2013) and
seven in multiple sclerosis (Broekmans et al., 2011; Dalgas et al., 2010a; Dalgas et al., 2009;
Dalgas et al., 2010b; Dalgas et al., 2013; DeBolt and McCubbin, 2004; Dodd et al., 2011;
Fimland et al., 2010; Medina-Perez et al., 2014; Sabapathy et al., 2011). Disease population,
study design, number of participants, stage of disease, mean age and standard deviation, trial
intervention and trial outcomes are shown in Tables 3.2 and 3.3.

66

Table 3.1 Trial inclusions rated according to the PEDro scale

Trials

PEDro criteria
#6
#7

#1

#2

#3

#4

#5

Paul et al (2014)

Yes

Yes

Yes

Yes

Yes

No

PRET-PD RCT Corcos et al
(2013) & Prodoehl et al
(2015)

Yes

Yes

Yes

Yes

No

Shulman et al (2013)

Yes

Yes

No

Yes

Sage et al (2011)

Yes

Yes

No

Bloomer et al (2008)

Yes

Yes

Hass et al (2012)

Yes

Schilling et al (2010)
Dibble et al (2006; 2009)

Total Score

#8

#9

#10

#11

Yes

No

Yes

Yes

Yes

8/10

No

Yes

Yes

No

Yes

Yes

7/10

Yes

Yes

No

No

No

Yes

Yes

6/10

Yes

No

No

No

Yes

Yes

Yes

Yes

7/10

No

Yes

No

No

No

No

No

Yes

Yes

4/10

Yes

No

Yes

No

No

No

Yes

Yes

Yes

Yes

6/10

Yes

Yes

No

Yes

No

No

No

No

Yes

No

Yes

4/10

Yes

No

No

Yes

No

No

No

Yes

Yes

Yes

Yes

6/10

Medina-Perez et al (2014)

Yes

Yes

No

Yes

No

No

No

Yes

Yes

Yes

Yes

6/10

Dalgas et al (2010a; 2009;
2010b; 2013)

Yes

Yes

Yes

Yes

No

No

Yes

No

Yes

Yes

Yes

6/10

Dodd et al (2011)

Yes

Yes

Yes

Yes

No

No

Yes

Yes

Yes

Yes

Yes

8/10

Broekmans et al (2011)

Yes

Yes

Yes

Yes

No

No

No

Yes

No

No

Yes

6/10

Fimland et al (2010)

Yes

Yes

No

Yes

No

No

No

No

No

Yes

Yes

4/10

Sabapathy et al (2011)

Yes

Yes

No

Yes

No

No

No

Yes

No

Yes

Yes

5/10

De Bolt et al (2004)

Yes

Yes

No

Yes

No

No

No

Yes

No

Yes

Yes

6/10

Parkinson’s disease
RCT

non-RCT

Multiple Sclerosis
RCT

Non-RCT

RCT randomised controlled trial, non-RCT non-randomised controlled trial
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Table 3.2 Overview of trials of strength training interventions in individuals with Parkinson’s disease or multiple sclerosis

Reference

Experimental/
control (n)

Stage of disease

Experimental
Intervention

Mean age (SD)

Control/Comparison
Intervention

Measures/ Results

Parkinson’s disease
RCT
Power ↑
Strength ↑
Movement speed ↑
Falls →
Balance →
Mobility →
Functional capacity →
UPDRS-III ↑
Strength ↑
Quality of life →
Balance ↑*
Mobility ↑*
Functional capacity →
Mobility ↑*
Strength ↑
UPDRS-III (motor) ↑*
Falls →
Fatigue →
Quality of life →
Mood →

Paul et al (2014)

Exp=20
Con=20

Hoehn & Yahr

Exp=68.1 ± 5.6
Con=64.5 ± 7.4

Lower Body
RE/Machine
(non-continuous)

Sham low intensity
exercises trunk/lower
body

PRET-PD RCT
Corcos et al
(2013) &
Prodoehl et al
(2015)

Exp=24
mFC=24

Hoehn & Yahr
I-V

Exp= 59.0 ± 4.6
mFC=58.6 ± 5.6

Full Body RE/ Machine
& Free Weights
(non-continuous)

Modified fitness counts

Shulman et al
(2013)

Exp=28
LIT=26
HIT=26

Hoehn & Yahr
I-III

Exp=65.3 ± 11.3
LIT=65.8 ± 11.5
HIT=66.1 ± 9.7

Lower Body RE/
Machine
(non-continuous)

Low Intensity Treadmill
High Intensity Treadmill

Sage et al
(2011)

Exp=18
Con=18
Aerobic=17
Aquatic=12
SAFEx=24

NR

Exp=68.7 ± 8.3
Con=68.6 ± 8.1
Aerobic=65.8 ± 9-9
Aquatic=63.1 ± 9.2
SAFE=68.0 ± 11

Whole body work out
(non-continuous)

Daily living activities

UPDRS-III ↑*

Bloomer et al
(2008)

Exp=8
Con=8

Hoehn & Yahr
I-II

Exp= 61.0 ± 2.0
Con= 57.0 ± 3.0

Lower Body RE/
Machine
(non-continuous)

Standard care

Oxidative & antioxidant
markers ↑

Non-RCT
Hass et al

Exp=9

Hoehn & Yahr

Exp= 67 ± 8.0

Lower Body & Core/

Standard care

Mobility ↑

68

Strength ↑

(2012)

Con=9

I-III

Con= 64 ± 7.0

Machine & Theraband
(non-continuous)

Schilling et al
(2010)

Exp=9
Con=9

Hoehn & Yahr
I-II/III

Exp= 61.3 ± 8.6
Con= 57.0 ± 7.1

Lower Body/ Machine
(non-continuous)

Standard care

Dibble et al
(2006; 2009)

Exp=10
Con=9

Hoehn & Yahn
I-III

Exp=64.3 ± 9.6
Con= 67.0 ± 10.2

Eccentric resistance
training ergometer
(continuous)

Standard care

Exp=30
Con=12

EDSS: 1.0-6.0

Exp= 49.6 ± 11.0
Con= 46.2 ± 7.5

Lower Body/Machine
(non-continuous)

Standard Care

Exp=19
Con=19

EDSS: 3.0-5.5
DC: RR

Exp= 49.1 ± 8.4
Con= 47.7 ± 10.4

Lower Body/Machine
(non-continuous)

Standard care

Exp= 39
Con= 37

AID: 2,3 or 4
DC: RR

Exp= 47.7 ± 10.8
Con= 50.4 ± 9.6

Lower Body/Machine
(non-continuous)

Standard Care

Exp=11
Exp+ES=11
Con=14

EDSS: 2.0-6.5

Exp=4.5 ± 1.3
Exp+ES=4.4 ± 0.9
Con=4.1 ± 1.1

Lower Body/Machine
(non-continuous)

Normal living habits

Strength ↑
Functional capacity →
Mobility ↑*
Balance →
Strength ↑
Quadriceps muscle volume ↑*
UPDRS-III (motor) →
Quality of life ↑
Mobility ↑
Functional capacity (TUG) ↑
(stair descent)
↑*

Multiple sclerosis
RCT
Medina-Perez et
al (2014)

Dalgas et al
(2010a; 2009;
2010b; 2013)

Dodd et al
(2011)

Broekmans et al
(2011)
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Strength ↑
Power ↑
Muscle Endurance →
EMG activity ↑
Strength ↑
Thigh Volume ↑*
Fatigue ↑*
Mood ↑*
Quality of life (physical) ↑*
CSA II/IIa muscle fibres ↑*
Functional capacity ↑*
Strength ↑
Muscle Endurance ↑
Fatigue ↑
Quality of life (physical
domain) ↑
Mobility →
Strength ↑
Mobility →
Balance ↑

Fimland et al
(2010)

Exp=7
Con=7

EDSS: 2.0-6.5
DC: NR

Exp= 53.0 ± 4.0
Con= 54.0 ± 2.0

Lower Body/Machine
(non-continuous)

Standard care

Strength ↑
EMG activity↑
Motor output ↑

Non-RCT

Sabapathy et al
(2011)

Exp=15
END=6

DeBolt et al
(2004)

Exp= 19
Con=17

DSS: 1-3
DC: RR, SP, PP

Exp= 55.0 ± 7.0

Upper & Lower Body &
Core
(non-continuous)

Endurance Exercise

Balance →
Mobility →
Strength →
Mood →
Quality of Life →
Fatigue →
MSIS physical→
MSIS psychological →

EDSS: 2.0-6.0

Exp=51.6 ± 7.2
Con=47.8 ± 10.5

Weighted vest
Home based resistance
training
(non-continuous)

Standard care

Leg extensor power ↑
Functional capacity →
Balance →

↑ indicates significant improvement, → indicates no significant change, ↓ indicates significant deterioration, ↑* time effect, RCT = randomised
controlled trial, non-RCT = non-randomised controlled trial, Exp = experimental group, Con = control group, RE = resistance exercise, ES =
electro-stimulation, UPDRS-III = Unified Parkinson’s Disease Rating Scale Version-III, END = endurance training, SAFE = sensory attention
focused-exercise, AID = ambulation index score, DC = disease course, RR = relapse remitting, EDSS = expanded disability status scale, DSS =
disease steps scale, SP = secondary progressive, P = Primary progressive, EMG = electromyography, CSA= cross sectional area, MSIS =
multiple sclerosis impact scale

70

Table 3.3 Summary details of the specific strength training interventions used in Parkinson’s disease or multiple sclerosis trials
Trial

Location

Supervision

Duration

Frequency

Exercises

Multi vs
Single Joint

Intensity

Sets

Repetitions

Rest

Progression

Single-joint

1st set 40%
(1RM)
2nd set 50%
(1RM)
3rd set 60%
(1RM)

3 Sets

8 Reps

NR

5%

Multi-joint
& singlejoint

1st 8
Weeks
(30-40%
1RM
upper
body/5060% 1RM
lower body
2nd 8
Weeks
(7080%1RM)

1st 8
Weeks (3
sets)

1st 8 Weeks
(8 reps)
NR

5% or as
allowed by
equipment

Multi-joint
& singlejoint

RCT (Parkinson’s disease)

Paul et al
(2014)

University
Lab

PRET-PD
RCT Corcos
et al (2013)
& Prodoehl
et al (2015)

NR

Shulman et
al (2013)

Supervised
(ratio NR)

12 Weeks

Twice
Weekly

Leg
extension,
knee flexion,
hip flexion,
hip
abduction
Chest Press,
Lat Pull
Down,
Reverse
Flys, Leg
Press, Hip
Extension,
Biceps Curl,
Rotary Cuff,
Shoulder
Press, Tricep
Extension,
Back
Extension,
Knee
Extension
Leg Press,
Leg
Extension,
Leg Curl

1:1 1st 6
months
TA 18
months

104 Weeks

Medical
Centre

Supervised
(ratio NR)

12 Weeks

Thrice
Weekly

Sage et al
(2011)

Community
based training
facilities

Supervised
1:8 /1:10

12 Weeks

Thrice
Weekly

Whole body
workout

Bloomer et
al (2008)

NR

Supervised
(ratio NR)

8 Weeks

Twice
Weekly

Leg Press,
Leg Curl,
Calf press

Twice
Weekly
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2nd 8
Weeks (2
sets)

2nd 8 Weeks
(12 reps)

NR

2 Sets

10 Reps

NR

NR

Multi-joint
& singlejoint

NR

3 Sets

10-15 Reps

NR

NR

Multi-joint
& single
joint

NR

3 Sets

5-8 Reps

2-3
minutes

5-10%

Non-RCT (Parkinson’s disease)

Hass et al
(2012)

Schilling et
al (2010)

Dibble et al
(2006;
2009)

NR

Supervised
(ratio NR)

NR

Supervised
(ratio NR)

NR

Supervised
(ratio NR)

10 Weeks

Twice
Weekly

Leg Press,
Knee
Extension &
Flexion,
Abdominal
Curl, Back
Extension,
Seated Calf
Raise

8 Weeks

Twice
Weekly

Leg Press,
Leg Curl,
Calf Raises

12 weeks

Thrice
Weekly

Eccentric
resistance
training
ergometer

Twice
Weekly

Knee
extension
(bilateral,
concentric/e
ccentric)
Leg Press,
Knee
Extension &
Flexion, Hip
Flexion &
Extension
Leg Press,
Knee

Multi-joint
& single
joint

Multi-joint
& single
joint

Multi-joint
& single
joint

70% 1RM

NR

2 Sets

12-20 Reps

5
minutes

10%

3 Sets

First 2 Sets
8 Reps
Third Set 58

NR

5-10%
Week 1-2: 5
mins
Week 3: 510 mins
Week 4: 1015 mins
Week 5-12:
15-30 mins

Rate of
Perceived
Exertion 713

1 set

-

-

35-70%
(MVIC)

3 Sets

8-13 Reps

3
minutes

NR

Multi-joint
& single
joint

NR

Weeks 14 3 Sets;
Weeks 510 4 Sets;
Weeks
11-12 3
Sets

Weeks 1-2
10 Reps;
Weeks 3-6
12 Reps;
Weeks 7-8
10 Reps;
Weeks 9-12
8 Reps

2-3
minutes
(sets +
exercise)

NR

Multi-joint
& single

NR

2 Sets

10-12 Reps

2
minutes

NR

RCT (multiple sclerosis)
MedinaPerez et al
(2014)

Dalgas et al
(2010a;
2009;
2010b;
2013)
Dodd et al
(2011)

Rehabilitation
Centre

Supervised
(ratio NR)

12 Weeks

NR

Supervised
1:2/1:4

12 Weeks

Twice
Weekly

Community
Gym

Supervised
3:12

10 Weeks

Twice
Weekly
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Single-joint

Extension &
Flexion, Calf
Raises,
Reverse Leg
Press

Broekmans
et al (2011)

Fimland et
al (2010)

NR

Supervised
1:3

NR

Supervised
(ratio NR)

joint

20 Weeks

50 training
sessions
(~60) min

Leg Press
Leg
extension
Leg Curl

Multi-joint
& single
joint

1-2 week:
minimal
reps
3-6: 5060% 1RM
7-8: 60%
1RM
9-10: 60%
1RM
11: 60%
1RM
12-14: 15
RM
15-17: 12
RM
18-20:10
RM

3 Weeks

Five Times
Weekly

Leg Press &
Seated Calf
Raise

Multi-joint
& single
joint

85-90%
1RM

4 Sets

4 Reps

1-2
minutes

NR

Multi-joint
& single
joint

NR

2-3 Sets

6-10 Reps

0.5-1
minute

NR

Multi-joint
& single

NR

Weeks 1
&32

Weeks 1 &
3 8-12 Reps;

NR

_

1-2: 1
3-6: 1
7-8: 2
9-10: 2
11: 2
12-14: 2
15-17: 2
18-20: 2

1-2: 10
3-6: 10
7-8: 10
9-10: 12
11: 12
12-14: 15
15-17: 12
18-20: 10

NR

NR

Non-RCT (multiple sclerosis)

Sabapathy
et al (2011)

Health Facility

Supervised
(ratio NR)

8 Weeks

Twice
Weekly

DeBolt et al
(2004)

Home Based

NR

8 Weeks

Thrice
weekly

Chest Press,
Seated Row,
Shoulder
Abduction,
Sit to Stand,
Lunges, Hip
Abduction,
Step Ups &
Tandom
Stance
Chair raises
Forward
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lunges
Step-ups
Heel toe
raise
Leg curls

joint

NR = Not reported, RCT = randomised controlled trial, Non-RCT = non randomised controlled trial
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Sets;
Weeks 2
&43
Sets;
Weeks 58 2 Sets

Weeks 2 &
4 8-12 Reps;
Weeks 5-8
8-10 Reps

3.4.4 Intervention characteristics
Of the eight trials conducted in individuals with Parkinson’s disease (Bloomer et al., 2008;
Corcos et al., 2013; Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012; Paul et al.,
2014; Prodoehl et al., 2015; Sage et al., 2011; Schilling et al., 2010; Shulman et al., 2013)
(five randomised controlled trials (Bloomer et al., 2008; Corcos et al., 2013; Paul et al., 2014;
Prodoehl et al., 2015; Sage et al., 2011; Shulman et al., 2013) and three non-randomised
controlled trials (Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012; Schilling et al.,
2010)), five used lower body strength training interventions (Bloomer et al., 2008; Dibble et
al., 2006; Dibble et al., 2009; Paul et al., 2014; Schilling et al., 2010; Shulman et al., 2013),
two used a full body strength training intervention (Corcos et al., 2013; Prodoehl et al., 2015;
Sage et al., 2011) and one used a lower body and core strength training intervention (Hass et
al., 2012) (Tables 3.2 and 3.3). Training protocols ranged from two to twenty-four months of
twice to thrice weekly training (Bloomer et al., 2008; Corcos et al., 2013; Dibble et al., 2006;
Dibble et al., 2009; Hass et al., 2012; Paul et al., 2014; Prodoehl et al., 2015; Sage et al.,
2011; Schilling et al., 2010; Shulman et al., 2013). Only two trials conducted in individuals
with Parkinson’s disease reported on the level of supervision for strength training
interventions (Corcos et al., 2013; Prodoehl et al., 2015; Sage et al., 2011).
Of the seven trials conducted in multiple sclerosis (Broekmans et al., 2011; Dalgas et al.,
2010a; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; DeBolt and McCubbin,
2004; Dodd et al., 2011; Fimland et al., 2010; Medina-Perez et al., 2014; Sabapathy et al.,
2011) (five randomised controlled trials (Broekmans et al., 2011; Dalgas et al., 2010a; Dalgas
et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; Dodd et al., 2011; Fimland et al., 2010;
Medina-Perez et al., 2014) and two non-randomised controlled trials (DeBolt and McCubbin,
2004; Sabapathy et al., 2011)), five trials trained the lower body (Broekmans et al., 2011;
Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; Dodd et al.,
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2011; Fimland et al., 2010; Medina-Perez et al., 2014) and two trials trained the full body
(DeBolt and McCubbin, 2004; Sabapathy et al., 2011) (Tables 3.2 and 3.3). Intervention
protocols utilised in multiple sclerosis trials ranged from three weeks to six months of two to
five times weekly training (Broekmans et al., 2011; Dalgas et al., 2010a; Dalgas et al., 2009;
Dalgas et al., 2010b; Dalgas et al., 2013; DeBolt and McCubbin, 2004; Dodd et al., 2011;
Fimland et al., 2010; Medina-Perez et al., 2014; Sabapathy et al., 2011). Of the seven trials
conducted in individuals with multiple sclerosis, only three trials reported on the level of
supervision for strength training interventions (Broekmans et al., 2011; Dalgas et al., 2010a;
Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; Dodd et al., 2011).
3.4.5 Risk of bias
Statistical examination using the egger regression test revealed no publication bias (p=0.131).
3.4.6 Intensity and progression of resistance exercise
Two randomised (Corcos et al., 2013; Paul et al., 2014; Prodoehl et al., 2015) and two nonrandomised controlled trials (Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012)
conducted in Parkinson’s disease reported on the intensity of strength training performed
throughout the intervention, while three randomised controlled trials (Broekmans et al., 2011;
Fimland et al., 2010; Medina-Perez et al., 2014) reported on the intensity of strength training
in multiple sclerosis. The progression of strength training was reported by three randomised
(Bloomer et al., 2008; Corcos et al., 2013; Paul et al., 2014; Prodoehl et al., 2015) and three
non-randomised controlled trials (Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012;
Schilling et al., 2010) in Parkinson’s disease. In contrast, there were no trials that reported on
the progression of strength training in multiple sclerosis.
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3.4.7 Participant retention, adherence, and adverse events
Participant retention ranged from 75% to 100% in Parkinson’s disease trials (Bloomer et al.,
2008; Corcos et al., 2013; Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012; Paul et
al., 2014; Prodoehl et al., 2015; Sage et al., 2011; Schilling et al., 2010; Shulman et al., 2013)
and from 73.3% to 100% in multiple sclerosis trials (Broekmans et al., 2011; Dalgas et al.,
2010a; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; DeBolt and McCubbin,
2004; Dodd et al., 2011; Fimland et al., 2010; Medina-Perez et al., 2014; Sabapathy et al.,
2011) (Table 3.4). Four trials in multiple sclerosis ([Medina-Perez et al (2014) strength
training group 95.4%; control group NR], [Dodd et al (2011) strength training group 92%;
control group 62%], [Broekmans et al (2011) ~99% all groups] and [DeBolt et al (2004)
strength training group 95%]) and one trial in Parkinson’s disease reported on participant
adherence (Paul et al (2014) strength training group 84.1%; control group 94.1%) (Table 3.4).
Five trials in Parkinson’s disease (Corcos et al., 2013; Hass et al., 2012; Paul et al., 2014;
Prodoehl et al., 2015; Sage et al., 2011; Shulman et al., 2013) and six trials in multiple
sclerosis (Broekmans et al., 2011; Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas et al.,
2010b; Dalgas et al., 2013; Dodd et al., 2011; Fimland et al., 2010; Medina-Perez et al., 2014;
Sabapathy et al., 2011) reported on adverse events (Corcos et al., 2013; Hass et al., 2012;
Paul et al., 2014; Prodoehl et al., 2015; Sage et al., 2011; Shulman et al., 2013), with only
minor or clinically unrelated medical issues reported (Table 3.4).
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Table 3.4 Summary of retention, adherence and adverse events in Parkinson’s disease or multiple sclerosis strength training trials
Trial
Reference

Participant Retention

Dropouts

Participant Adherence

Adverse Events

RE: 18/20 (90%)

RE: 2/20 (10%)

RE: 84.1%

RE: pelvic fracture (UTI), low
back pain

CG: 18/20 (90%)

CG: 2/20 (10%)

CG: 94.1%

RE: 19/24 (79.2%)

RE: 5/24 (20.8%)

CG: 16/24 (66.6%)

CG: 8/24 (33.3%)

RE: 22/28 (78.5%)

RE: 6/28 (11.5%)

CG: 22/26 (84.6%)

CG: 4/26 (15.4%)

CG: 23/26 (88.4%)

CG: 3/26 (11.6%)

RE 18/18 (100%)

RE: 0/10 (0%)

CG: 18/18 (100%)

CG: 0/10 (0%)

RE: 6/8 (75%)

RE: 2/8 (25%)

CG: 7/8 (87.5%)

CG: 1/8 (12.5%)

RE: 9/9 (100%)

RE: 0/9 (0%)

CG: 9/9 (100%)

CG: 0/9 (0%)

RE: 8/9 (88.8%)

RE: 1/9 (11.2%)

CG: 7/9 (77.7%)

CG: 2/9 (22.3%)

RE: 10/10 (100%)

RE: 0/10 (0%)

CG: 9/10 (90%)

CG: 1/10 (10%)

Parkinson’s disease
RCT

Paul et al (2014)
PRET-PD RCT Corcos et al
& Prodoehl et al (2015)

Shulman et al (2013)

Sage et al (2011)

Bloomer et al (2008)

NR

CG: exacerbated hernias (UTI)
RE: 1 (wrist pain)
CG: 1 (back surgery)

NR

No serious adverse events

NR

No adverse events

NR

NR

NR

No adverse events

NR

NR

NR

NR

non-RCT

Hass et al (2012)
Schilling et al (2010)
Dibble et al (2006; 2009)
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Multiple sclerosis
RCT
Medina-Perez et al (2014)
Dalgas et al (2010a; 2009;
2010b; 2013)
Dodd et al (2011)

Broekmans et al (2011)

Fimland et al (2010)

RE: 30/30 (100%)

RE: 0/30 (0%)

RE: 95.4%

CG: 12/12 (100%)

CG: 0/12 (0%)

CG: NR

RE: 15/19 (78.9%)

RE: 4/9 (21.1%)

CG: 16/19 (84.2%)

CG: 3/19 (15.8%)

RE: 36/39 (92.3%)

RE: 3/39 (7.7%)

RE: 92%

CG: 31/37 (83.7%)

CG: 6/37 (16.3%)

CG: 62%

EXP: 11/11 (100%)

EXP: 0/11 (0%)

EXP+ES: 10/11 (90%)

EXP+ES: 1/11 (9%)

CON: 12/14 (86%)

CON: 2/14 (14%)

RE: 7/7 (100%)

RE: 0/7 (0%)

CG: 7/7 (100%)

CG: 0/7 (0%)

RE: 11/14 (73.3%)

RE: 3/14 (26.6%)

CG: 5/6 (83.3%)

CG: 1/6 (16.7%)

NR

No adverse events
RE: 1 (lower back pain)
No adverse events
Severe relapse

~99% all groups

Perceived lack of time to continue
Mild stroke (unrelated)

NR

No adverse events

NR

No adverse events

95%

NR

Non-RCT
Sabapathy et al (2011)
DeBolt et al (2004)

RE: 19/20 (95%)

RE: 1/20 (5%)

CG: 17/17 (100%)

CG: 0/17 (0%)

RE resistance exercise, CG comparison group, NR not reported
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3.4.8 Outcomes measures
Strength as an outcome measure in Parkinson’s disease
Three randomised controlled trials evaluated the effect of strength training on strength in
people with Parkinson’s disease (Corcos et al., 2013; Paul et al., 2014; Shulman et al., 2013).
Strength was evaluated across trials using one repetition maximum (1RM) and maximum
voluntary isometric contraction (MVIC) protocols with torque transducers, pneumatic
resistance machines and dynamometers. Corcos et al (2013) found a significant improvement
in elbow flexor muscle strength (1RM, 15%) in the strength training group, whilst off
medication, after twenty-four months of upper and lower body resistance training. No
significant differences in strength were found for the control group in this trial. Shulman et al
(2013) in another trial found a significant improvement in leg press and leg extension
strength (1RM, 16%) in individuals within the strength training group, but not in the high or
low intensity treadmill training groups, after three months of thrice weekly resistance
training. Paul et al (2014) also reported a significant improvement in lower limb strength
(1RM, leg extension, 14.6%; knee flexion, 18.6%; hip flexion, 39.8%; hip abduction, 33.9%)
and power (leg extension, 17.3%; knee flexion, 20.6%; hip flexion, 46.3%; hip abduction,
43.1%) in the strength training group in comparison to the sham comparison group after 12
weeks of lower body resistance training.
Three non-randomised controlled trials also evaluated the effect of strength training on
strength and found significant improvements (Dibble et al., 2006; Dibble et al., 2009; Hass et
al., 2012; Schilling et al., 2010). Hass et al (2012), after ten weeks of twice weekly lower
body strength training, found a significant improvement in knee extension (1RM, 76%) and
knee flexion (1RM, 57%) strength in the intervention group, but not in the control group.
Schilling et al (2010) in another trial reported a significant improvement in leg press strength
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(1RM, 22%) in the intervention group, whereas the control group showed no significant
differences. Dibble et al (2006; 2009) similarly reported a significant improvement in
quadriceps muscle strength (MVIC) in the more (average torque 23%; peak torque 18%) and
less affected leg (average torque 16%; peak torque 83.2%) in the strength training
intervention group only.
Strength as an outcome in multiple sclerosis
Five randomised controlled trials reported on strength as an outcome after strength training
(Broekmans et al., 2011; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; Dodd
et al., 2011; Fimland et al., 2010; Medina-Perez et al., 2014), with all five trials reporting
significant improvements in strength. Strength was evaluated across trials using MVIC,
maximum voluntary dynamic contraction (MVDC) and 1RM strength protocols with
pneumatic resistance machines, dynamometers and the Leg Extensor Power Rig. MedinaPerez et al (2014) reported a significant improvement in knee extension strength (MVIC,
7.7%) and power (40% MVIC, 15.6%) in the intervention group, but not in the control group
after twelve weeks of strength training. Significant improvements in leg press strength (1RM,
15%) in the intervention group, but not the control group were also reported by Dodd et al
(2011) after strength training. Broekmans et al (2011) in line with Medina-Perez et al (2014),
reported significant improvements in isometric strength in the knee flexors and extensors
(MVIC, average knee extension 45° change: 10.8, average knee extension 90° change: 10,
average knee flexor 45° change: 4, average knee flexion 90° change: 2.3) in the intervention
group as a result of strength training. In another trial, Dalgas et al (2010a; 2009; 2010b; 2013)
reported significant improvements in isokinetic, isometric and angular impulse knee extensor
and flexor strength in the intervention group ([Dalgas et al (2013), MVIC at 70° knee flexion;
knee extension: 13.2%, knee flexion: 13.8%], [Dalgas et al (2010b); MVDC, knee extension
90º: 4.5%; knee extension 180º:10.2%; knee flexion 90º: 21.3%; knee flexion 180º: 18.6%],
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[Dalgas et al (2009), MVIC, knee extension: 15.7%, knee flexion: 21.3%]), but not in the
control group as a result of resistance training. Dalgas et al (2009) additionally reported a
significant improvement in leg press strength. Fimland et al (2010) in another trial reported a
significant improvement in plantar flexion strength (MVIC, 36%) in the strength training
intervention group, but not in the control group. In a non-randomised controlled trial, DeBolt
et al (2004) reported a significant improvement in leg extensor power (24%) in the
intervention group, whereas the disease control group showed no changes after strength
training.
In addition to muscle strength, significant study specific improvements in gait, clinical
disease progression, functional capacity, quality of life, oxidative biomarkers, mood, fatigue,
falls, skeletal muscle volume and electromyography activity were observed after strength
training in individuals with multiple sclerosis or Parkinson’s disease (Bloomer et al., 2008;
Broekmans et al., 2011; Corcos et al., 2013; Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas
et al., 2010b; Dalgas et al., 2013; DeBolt and McCubbin, 2004; Dibble et al., 2006; Dibble et
al., 2009; Dodd et al., 2011; Fimland et al., 2010; Hass et al., 2012; Medina-Perez et al.,
2014; Paul et al., 2014; Prodoehl et al., 2015; Sabapathy et al., 2011; Sage et al., 2011;
Schilling et al., 2010; Shulman et al., 2013).
Parkinson’s disease measures
Unified Parkinson Disease Rating Scale Version 3
Three randomised (Corcos et al., 2013; Sage et al., 2011; Shulman et al., 2013) and one nonrandomised controlled trial (Dibble et al., 2009) conducted in Parkinson’s disease evaluated
the effect of strength training on clinical disease progression using the Unified Parkinson’s
Disease Rating Scale Version 3. Corcos et al (2013) reported a significant improvement on
the Unified Parkinson’s Disease Rating Scale Version 3 in the intervention group (7.4 point
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decrease), but not in the control group after twenty-four months of strength training. Shulman
et al (2013) in another study similarly reported a significant improvement on the motor
subscale of the Unified Parkinson’s Disease Rating Scale Version 3 in the strength training
group. Furthermore, Sage et al (2011) found a significant improvement on the Unified
Parkinson’s Disease Rating Scale Version 3 in the strength training group. Dibble et al (2009)
by contrast found no improvement on the Unified Parkinson’s Disease Rating Scale Version
3 in the intervention group after strength training.
Functional Mobility
Three randomised (Paul et al., 2014; Prodoehl et al., 2015; Shulman et al., 2013) and three
non-randomised controlled trials (Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012;
Schilling et al., 2010) evaluated the effect of strength training on mobility in individuals with
Parkinson’s disease. Mobility was assessed across trials using the 10 Meter Timed Walk Test,
6 Minute Walk Test, 50 Feet Walk Test and Timed Up and Go. Paul et al (2014) did not
report significant changes in mobility after strength training. In contrast, Prodoehl et al
(2015) and Shulman et al (2013) found significant improvements in mobility as a result of
strength training. The three non-randomised controlled trials (Dibble et al., 2006; Dibble et
al., 2009; Hass et al., 2012; Schilling et al., 2010) that reported on mobility as an outcome
also documented improvements.
Balance
Two randomised (Paul et al., 2014; Prodoehl et al., 2015) and two non-randomised controlled
trials (Sabapathy et al., 2011; Schilling et al., 2010) examined the effect of strength training
on balance outcomes in Parkinson’s disease. Balance was evaluated across trials using a
variety of outcomes including the Single Leg Stance, Choice Stepping Task, Berg Balance
Scale, Functional Reach Test, 5 Time Sit To Stand Test and the Activities-specific Balance
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Confidence scale. Paul et al (2014) did not find a significant improvement in balance as a
result of strength training. Prodoehl et al (2015) by contrast reported a significant
improvement in balance after strength training. Both non-randomised controlled trials
(Sabapathy et al., 2011; Schilling et al., 2010) were unable to find a significant improvement
in balance after strength training.
Functional Capacity
One randomised trial (Corcos et al., 2013) examined the effect of strength training on
functional capacity. Corcos et al (2013) assessed functional capacity using the modified
Physical Performance Test and reported no significant changes after strength training in the
intervention or control group.
Quality of Life
Two randomised (Corcos et al., 2013; Shulman et al., 2013) and one non-randomised
controlled trial (Dibble et al., 2009) evaluated the effect of strength training on quality of life.
All three trials assessed quality of life using the 39-Item Parkinson’s Disease Questionnaire.
Both randomised controlled trials (Corcos et al., 2013; Shulman et al., 2013) did not report a
significant improvement in quality of life after strength training. Dibble et al (2009) by
contrast reported a significant improvement in quality of life in the intervention group after
strength training.
Oxidative and Anti-oxidant Markers
One randomised controlled trial (Bloomer et al., 2008) in Parkinson’s disease measured
changes in blood oxidant and anti-oxidant marker levels and reported significant increases in
anti-oxidant marker levels (superoxide dismutase [9.9%] and glutathione peroxidase [1.8%])
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and a significant reduction in oxidative stress marker levels (malondialdehyde [15%] and
hydrogen peroxide [16%]).
Mood
One randomised controlled trial (Shulman et al., 2013) evaluated the effect of strength
training on mood in Parkinson’s disease. Shulman et al (2013) found no significant changes
in mood after strength training using the Beck Depression Inventory.
Fatigue
One randomised controlled trial (Shulman et al., 2013) evaluated the effect of strength
training on fatigue in Parkinson’s disease. Shulman et al (2013) used the 16-item Parkinson
Fatigue Scale and found no significant change in fatigue after strength training in the strength
training intervention group or high and low intensity treadmill intervention groups.
Falls
Two randomised controlled trials (Paul et al., 2014; Shulman et al., 2013) evaluated the effect
of strength training on falls in people with Parkinson’s disease. Falls were assessed using the
New Freezing of Gait Questionnaire (Paul et al., 2014) and Falls Efficacy Scale (Shulman et
al., 2013). No trial reported a significant effect on falls outcomes after strength training.
Skeletal Muscle Volume
One non-randomised controlled trial (Dibble et al., 2006) evaluated the effect of strength
training on quadriceps muscle volume in Parkinson’s disease. Dibble et al (2006) found a
significant increase in quadriceps muscle volume using magnetic resonance imaging after
strength training in the intervention group only.
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Multiple sclerosis
Functional Mobility
Two randomised (Broekmans et al., 2011; Dodd et al., 2011) and two non-randomised
controlled trials (DeBolt and McCubbin, 2004; Sabapathy et al., 2011) evaluated the effect of
strength training on functional mobility in multiple sclerosis. Functional mobility was
assessed across trials using the 2 Minute Walk Test, 10 Meter Walk Test, Timed 25 Foot
Walk and Timed Up and Go. No trial reported a significant improvement in mobility as a
result of strength training.
Balance
One randomised (Broekmans et al., 2011) and two non-randomised (DeBolt and McCubbin,
2004; Sabapathy et al., 2011) controlled trials evaluated the effect of strength training on
balance in multiple sclerosis. Balance was evaluated across trials using the Functional Reach
Test (Broekmans et al., 2011; Sabapathy et al., 2011), Four Square Step Test (Sabapathy et
al., 2011) and AccuswayPLUS force platform (DeBolt and McCubbin, 2004). Broekmans et al
(2011) reported a significant improvement in balance in the intervention group only as a
result of strength training. However, Sabapathy et al (2011) and DeBolt et al (2004) did not
find significant improvements in balance after strength training.
Functional Capacity
One randomised controlled trial (Dalgas et al., 2009) evaluated the effect of strength training
on functional capacity outcomes in multiple sclerosis. Dalgas et al (2009) reported a
significant improvement in functional capacity (computed as ¼ [Chair Stand Test
Stand Test

pre]

+ [Stair Climb Test post / Stair Climb Test
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pre]

post /

+ [10 Meter Walk Test

Chair

post

/10

Meter Walk Test pre] + [6 Minute Walk Test post / 6 Minute Walk Test pre] × 100) as a result of
strength training.
Quality of Life
Two randomised (Dalgas et al., 2010a; Dodd et al., 2011) and one non-randomised controlled
trial (Sabapathy et al., 2011) reported on quality of life outcomes after strength training in
multiple sclerosis. Quality of life was assessed across trials using the Short Form-36 (Dalgas
et al., 2010a; Sabapathy et al., 2011) and the World Health Organisation Quality of LifeBREF (Dodd et al., 2011). Dodd et al (2011) and Dalgas et al (2010a) reported a significant
improvement in quality of life in the intervention group as a result of strength training. In
contrast, Sabapathy et al (2011) found no significant improvement in quality of life after
strength training.
Electromyography Activity
Two randomised controlled trials (Dalgas et al., 2013; Fimland et al., 2010) assessed the
effect of strength training on electromyography activity during maximum voluntary isometric
contractions. Dalgas et al (2013) recorded surface electromyography signals from the Vastus
Lateralis, Rectus Femoris and Semitendinosus during maximal voluntary isometric
contractions of the knee flexors and extensors (assessed at 70° knee flexion), using bipolar
electrodes. The upper electrode of each pair was placed at the midpoint between the Spina
Iliaca anterior superior and patellar basis. After twelve weeks of strength training, Dalgas et
al (2013) found significant improvements in maximal isometric (μV) knee extension and
knee flexion activity (Semitendinosus: 27.6%; Vastus Lateralis: 27%; Rectus Femoris: 28%)
in the intervention group, but not the control group. Fimland et al (2010) recorded surface
electromyography activity during maximum voluntary isometric contractions of the plantar
flexors (ankle positioned at 90°), using bipolar surface electrodes placed according to Surface
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Electromyography

for

the

Non-Invasive

Assessment

of

Muscles

(SENIAM)

recommendations. Fimland et al (2010) reported significant improvements (15%) in surface
electromyography activity of the plantar flexors after three weeks of strength training in the
intervention group in comparison to the control group.
Skeletal Muscle Volume and Architecture
Only one randomised controlled trial (Dalgas et al., 2010b) measured changes to thigh
volume, muscle fibre numbers, type and size. Muscle biopsies of the Vastus Lateralis (middle
portion) were taken to assess changes in muscle fibre number, type and size. Dalgas et al
(2010b) reported a significant increase in the cross sectional area of type II and IIa vastus
lateralis muscle fibres after strength training in the intervention group only.
Fatigue
Two randomised (Dalgas et al., 2010a; Dodd et al., 2011) and one non-randomised controlled
trial (Sabapathy et al., 2011) evaluated the effect of strength training on fatigue in multiple
sclerosis. Fatigue was assessed across trials using a variety of outcomes including the
Modified Fatigue Scale and Fatigue Severity Scale, Multidimensional Fatigue Inventory.
Dodd et al (2011) reported a significant improvement in the level of fatigue experienced
(24%) after ten weeks of twice weekly strength training. Similar findings were reported by
Dalgas et al (2010a), who reported a 10% improvement in the level of fatigue experienced
after strength training. Sabapathy et al (2011) also reported a significant improvement in the
level of fatigue experienced as a result of strength training.
Mood
One randomised (Dalgas et al., 2010a) and one non-randomised controlled trial (Sabapathy et
al., 2011) examined the effect of strength training on mood outcomes in multiple sclerosis.
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Dalgas et al (2010a) reported significant improvements (-2.4 points) in mood using the Major
Depression Inventory as a result of strength training. In contrast, Sabapathy et al (2011)
found no significant changes in mood using the Beck Depression Inventory after strength
training.
Muscle Endurance
Two randomised controlled trials (Dodd et al., 2011; Medina-Perez et al., 2014) evaluated the
effect of strength training on muscle endurance in multiple sclerosis. Medina-Perez et al
(2014) measured muscle endurance as the maximum number of repetitions that a participant
could perform during a single set of knee extension using a load of 40% of the maximum
voluntary isometric contraction, while Dodd et al (2011) measured endurance by counting the
number of repetitions that a participant could complete on the seated leg press and reverse leg
press using a load of 50% of 1 RM. Medina-Perez et al (2014) did not find a significant
change in muscle endurance in the intervention or control group after strength training. In
contrast, Dodd et al (2011) reported a significant improvement in muscle endurance in the
intervention group relative to the control group after strength training.
3.5 DISCUSSION
This review found that strength training is useful for improving muscle strength in
Parkinson’s disease and to a lesser extent multiple sclerosis. Evidence also showed that
strength training is helpful for improving clinical measures of disease progression and
mobility in Parkinson’s disease. However, the evidence is unclear regarding the efficacy of
strength training on falls, quality of life, fatigue, functional capacity and balance in
Parkinson’s disease. In multiple sclerosis, strength training was also found to improve
fatigue, quality of life, muscle power, electromyography activity and functional capacity.
However, its effect on balance and mood remains equivocal.
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An increase in strength was the most consistently reported benefit of strength training in
people with Parkinson’s disease and multiple sclerosis. A meta-analysis of the extracted
strength data revealed that strength training had a larger effect on strength in people with
Parkinson’s disease (d=0.87) than multiple sclerosis (d=0.33) (Figure 3.2). Different
pathological mechanisms underpinning impairments in strength in each disease are likely to
account for this discrepancy. For instance, impairments in strength in multiple sclerosis are
thought to be mediated by central (de Haan et al., 2000; Ng et al., 2004) (spinal and
supraspinal mechanisms) and muscular deficits (Carroll et al., 2005; Garner and Widrick,
2003; Kent-Braun et al., 1997), while in Parkinson’s disease impairments in strength are
thought to result from central deficits only (Bridgewater and Sharpe, 1998; Corcos et al.,
1996; Yanagawa et al., 1989). This finding suggests that strength training may only produce
meaningful benefits in strength in people with Parkinson’s disease.
Strength training trials in Parkinson’s disease also reported improvements in mobility. The
improvements were reported on short and longer duration mobility assessments, suggesting
that strength training has a favourable effect on multiple aspects of mobility. This finding is
consistent with the supposition that muscle strength strongly predicts mobility in people with
Parkinson’s disease (Allen et al., 2010; Paul et al., 2013b). Surprisingly, no improvements in
mobility were reported in individuals with multiple sclerosis after strength training. This
finding was unexpected, as the strength training interventions in Parkinson’s disease and
multiple sclerosis trials, for the most part, used similar training frequencies (two-three times
per week), resistance exercises (leg press, knee extension, knee flexion and calf raises) and
sets per exercise (two-three). This may indicate that strength training is not capable of
improving mobility in individuals with multiple sclerosis. The inability to improve mobility
may be explained by the smaller improvements in strength observed in individuals with
multiple sclerosis. Indeed, recent findings show that muscle strength significantly predicts
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performance on mobility tasks in individuals with multiple sclerosis (Broekmans et al.,
2013b). Alternatively, it is possible that the strength training interventions used in the
multiple sclerosis trials were unable to provide a stimulus sufficient to improve mobility in
multiple sclerosis, and perhaps more intense or specific training interventions may be
required.
In addition, strength training was found to have a positive effect on disease progression in
people with Parkinson’s disease (Unified Parkinson’s Disease Rating Scale-Version 3).
Interestingly, improvements in disease progression were observed in a cohort with mild to
advanced disability that were not on medication, suggesting that strength training alone, may
be capable of positively impacting on disease progression in individuals at all stages of
Parkinson’s disease. The positive effect of strength training on disease progression may have
been mediated by favourable central changes. For instance, recent evidence shows that
repetitive force generation increases neuronal activation in the basal ganglia, thalamus,
parietal cortex, cerebellum and motor cortex (Dai et al., 2001; Dettmers et al., 1995; Ehrsson
et al., 2000; Florin et al., 2013). Furthermore, emerging evidence has shown that exercise
interventions can increase regional brain volume and structural connectivity in patients with
Parkinson’s disease and other neurodegenerative disorders (Bonzano et al., 2014; Burciu et
al., 2013; Prosperini et al., 2014b; Sehm et al., 2014). Further studies are required to confirm
the latter remarks.
In multiple sclerosis trials, improvements in strength were accompanied by significant
improvements in fatigue, quality of life, muscle power, maximal electromyography activity
and functional capacity. The reported improvements in fatigue are of clinical interest given
that 33-75% of individuals with multiple sclerosis suffer from fatigue (Berger et al., 2013;
Comi et al., 2001; Freal et al., 1984). Nevertheless this finding was not surprising, given that
exercise has previously been reported to improve fatigue in multiple sclerosis (Andreasen et
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al., 2011). The improvements in fatigue may in part explain the benefits observed in quality
of life, especially considering that fatigue is an important predictor of quality of life in people
with multiple sclerosis (Amato et al., 2001; Kargarfard et al., 2012). The increases in muscle
power and maximal electromyography activity are consistent with the observed
improvements in strength. The reported improvements in lower limb strength, fatigue and
muscle power likely contributed to the improvement in functional capacity documented by
Dalgas et al (2009). Indeed, recent findings have shown that strength (Broekmans et al.,
2013a), fatigue (Motl et al., 2013) and muscle power (Paul et al., 2013b) significantly
influences functional capacity in individuals with multiple sclerosis and other
neurodegenerative disorders.
It is important to note that most trials included in this systematic review recruited individuals
with mild to moderate disability. The higher level of disability in individuals at advanced
stages of Parkinson’s disease or multiple sclerosis may have led researchers to only include
individuals at early to middle stages of both diseases. The same level of benefits after
strength training may not be possible in individuals at more advanced stages of Parkinson’s
disease or multiple sclerosis. Future trials assessing the effect of strength training in
individuals with Parkinson’s disease and multiple sclerosis with a severe level of disability
are therefore warranted.
In general, the trials displayed adequate methodological quality, with PEDro scores ranging
from four to eight in both diseases. The major methodological shortcomings found using the
PEDro scale included a failure to report concealed allocation (criteria 3), participant blinding
(criteria 5), therapist blinding (criteria 6), and outcome assessor blinding (criteria 7). It is
important to acknowledge that it is often not possible to blind participants or therapists to
exercise or group allocation (Foley et al., 2006). Trial scores generated using the PEDro scale
may therefore underestimate the quality of evidence.
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In addition to evaluating trials using the PEDro scale, we also performed a critical appraisal
of specific intervention characteristics important to strength training trials. This appraisal
found that specific intervention characteristics were typically well detailed, with the
exception of the level of supervision and strength training intensity. The lack of data reported
on the level of supervision and the intensity of strength training performed is of concern in
particular, as a high level of supervision as well as an appropriate intensity of strength
training is required to maximise therapeutic benefits and avoid potential injury (Dalgas et al.,
2007). The poor level of reporting on strength training progression in multiple sclerosis trials
is also concerning, given that modulating the progression of strength training is important to
avoid injury and training plateaus (Medicine, 2013). The inadequate reporting of participant
adherence in both disease populations was also worrisome, as it does not enable internal and
external examination of what dose of strength training is required to maximise therapeutic
benefits and avoid injury in such populations.
Based on our findings and American College of Sports Medicine guidelines, we recommend
that individuals with multiple sclerosis or Parkinson’s disease perform progressive submaximal strength training(whole body single and multi-joint resistance exercises) on at least
two non-consecutive days per week for an hour under direct supervision (e.g. physiotherapist,
exercise physiologist, strength and conditioning specialist) to improve muscle strength and
other disease specific clinical features (Parkinson’s disease: mobility and disease progression;
multiple sclerosis: fatigue, quality of life, muscle power, maximal electromyography activity
and functional capacity).
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Limitations
Lack of consistent reporting and heterogeneity of study outcomes between trials made it
difficult to draw firm conclusions beyond improvements in muscle strength with respect to
the benefits of strength training for individuals with multiple sclerosis or Parkinson’s disease.
3.6 CONCLUSION
Trials investigating the effect of strength training in individuals with Parkinson’s disease or
multiple sclerosis are in their infancy. Nevertheless, benefits in strength were found after
strength training in individuals with Parkinson’s disease and, to a lesser extent, in multiple
sclerosis. Some evidence was also found to suggest that strength training has a positive effect
on clinical disease progression and mobility in individuals with Parkinson’s disease.
Similarly, some evidence showed that strength training is beneficial for muscle power,
maximum electromyography activity, fatigue, functional capacity and quality of life in
individuals with multiple sclerosis. Additional trials employing high quality methodological
designs are required to confirm and expand on these findings. Such trials may provide
evidence based rationale for using strength training as a therapy for other neurodegenerative
disorders such as Alzheimer’s disease and Huntington’s disease.
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Figure 3.2 Meta-analysis of trials that measured muscle strength
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4.1 ABSTRACT
Background
Despite advances in the understanding of Huntington’s disease (HD), treatment remains
symptomatic. Multidisciplinary rehabilitation, however, appears to impact disease
progression. Here we show the feasibility, safety and efficacy of a nine-month
multidisciplinary rehabilitation program in a small cohort of early-to-middle-stage HD
patients.
Methods
Twenty HD patients were assigned to two groups, equally matched for cognitive and motor
scores. One group received the intervention, whilst the other served as control. The UnifiedHuntington’s-Disease-Rating-Scale-Total-Motor-Score was the primary outcome measure.
Neurocognitive/psychological tests, body composition, postural stability, strength and quality
of life assessments were secondary outcome measures.
Results
The intervention reduced motor and postural stability deterioration, with minor improvements
in depression, cognition and quality of life.

Significant gains were observed for fat-free

mass and strength.
Conclusion
This pilot study suggests that a prolonged multidisciplinary rehabilitation program in earlyto-middle-stage HD is feasible, well-tolerated and associated with therapeutic benefit. Further
explorative, larger studies are warranted.
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4.2 INTRODUCTION
Huntington’s disease (HD) is a neurodegenerative disorder characterised by progressive
motor, behavioural and cognitive impairments. No cure or disease-modifying therapies exist
(Nance, 2012), and treatment remains symptomatic. There is an urgent need, therefore, to
identify therapies capable of impacting on the disease.
Multidisciplinary rehabilitation has improved gait, balance, depression, quality of life (QOL)
and cognition in people with Alzheimer’s and Parkinson’s disease (Ellis et al., 2008; Trend et
al., 2002; Wade et al., 2003), yet few studies have examined multidisciplinary rehabilitation
in HD. The most extensive study to-date examined the effect of an intense, intermittent twoyear program in 40 early-to-middle-stage HD patients (Zinzi et al., 2007). The program was
feasible, well-tolerated and associated with positive motor benefits. Similarly, another study
in HD demonstrated that 18 months of multidisciplinary care was feasible and perceived as
beneficial (Veenhuizen et al., 2011).
We therefore designed and implemented a nine-month multidisciplinary rehabilitation
program, and assessed the effect on motor function, cognition, depression, body composition,
postural stability and QOL in a small cohort of early-to-middle-stage HD patients to evaluate
its feasibility, safety and efficacy.
4.3 METHODS
4.3.1 Design
Twenty early-to-middle-stage HD patients were assigned to two equal groups based on
cognitive and motor scores, with the intervention group randomly assigned. Research was
conducted in accordance with the Declaration of Helsinki, with informed consent provided.
Ethics approval was granted by the Human Research Ethics Committee of Edith Cowan
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University and the North Metropolitan Area Mental Health Service (NMAMHS). This project
was

registered

with

the

Australian

New

Zealand

Clinical

Trial

Registry

(ACTRN12610000218099).
4.3.2 Participants
Participants in Perth, Australia were recruited utilising NMAMHS databases. Inclusion
criteria included a positive genetic test, clinical disease diagnosis (Unified-Huntington’sDisease-Rating-Scale-Total-Motor-Score [UHDRS-TMS] ≥5), ability to follow verbal
instruction and perform sub-maximal exercise. Exclusion criteria included recent substance
abuse, an unstable psychiatric or medical condition, or confounding neurological conditions.
Medication was adjusted by physicians where necessary.

Some individuals in the

intervention (I) and control (C) groups commenced new medication; anti-psychotics (I 2; C
2), anti-depressants (I 0; C 1), anxiolytics (I 1; C 2) and anti-dyskinetics (I 0; C 1).
4.3.3 Outcome Measures
The primary outcome measure was the UHDRS-TMS, performed by J.L. Secondary outcome
measures, assessed over one day per timepoint, are detailed below. All assessors except
occupational therapists (OTs) were blinded.
Body composition was quantified using Dual Energy X-Ray Absorptiometry (Hologic
Discovery A). Postural stability/balance assessments utilised the Sensory Organisation Test
(Neurocom SMART Balance Master) and the Activities-Specific Balance Confidence (ABC)
Scale. Strength was assessed throughout rehabilitation. Neurocognitive/psychological tests
included Symbol Digit Modalities Test (SDMT), Hopkins Verbal Learning Test-Revised
(HVLT-R), D-KEFS Colour Word Interference Test and Trail Making Trials, Beck
Depression Inventory-II (BDI-II). The Goal Attainment Scale (GAS) examined achievement
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of patient-derived goals. QOL perceptions were evaluated using the SF-36v2 Health
Questionnaire and Huntington's-Disease-Quality-of-Life-Battery-for-Carers (HDQOL-C).
4.3.4 Intervention
Following baseline data analysis, exercise physiologists and physiotherapists designed
clinical and home-based exercise programs, and OTs formulated personalised patient-focused
programs targeting deficits detected by psychologists.
The clinical exercise program comprised supervised group sessions (nine-months, onceweekly; 5 minute warm-up, 10 minutes aerobic exercise, 40 minutes resistance exercise, 5
minute cool-down) in an exercise clinic. A tailored, self-monitored home-based exercise
program (six-months, three-times weekly) was employed after careful instruction. OT
programs were provided for one hour per fortnight, for six-months.
4.4 STATISTICAL ANALYSIS
Student’s independent or paired t-tests assessed continuous variables. Mann Whitney U and
Fischer’s Exact tests assessed ordinal variables. Results are reported as mean ± standard error
of the mean (SEM), with p<0.05 considered significant. Effect size calculations (Cohen’s d),
performed using G*Power Software Version 3.0.10 (Faul et al., 2007), were interpreted as
small (d=0.20), medium (d=0.50) or large (d=0.80).
4.5 RESULTS
Fifty-six HD patients were approached, and twenty-five volunteered to participate. Three
withdrew prior to randomisation (frailty, falls, delusions) and two prior to completion (no
wish to continue; I 1: C 1), with one participant transferred to the control group due to an
adverse medication reaction. No statistical between-group differences existed for baseline
demographics, depression, motor or cognitive assessments (Table 4.1). Participants
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demonstrated high adherence to clinical exercise and OT sessions (85%), and moderate
adherence to the home-based exercise program (56%). No adverse events were reported.
Rehabilitation produced a medium-large effect on UHDRS-TMS scores (Figure 4.1a),
impacting on chorea (medium-large effect) and tandem walking (p=0.015) components.
Significant between-group differences were observed for fat mass, fat-free mass, lower/upper
body strength, written errors (SDMT) and for the walking-up-and-down-stairs component of
the ABC-UK, with a large effect for the walking-around-the-house component (Table 4.1;
Figure 4.1b-d). Small-to-medium effects were noted for D-KEFS, HVLT-R, BDI-II, QOL
and postural stability (Table 4.1; Figure 4.1). GAS revealed partial or complete achievement
of goals in 7 of 9 intervention participants.
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Table 4.1 Participant Characteristics (n; I=9; C=11).
Variable
Intervention
Control
p
Demographics
53.8 ±2.9
52.2 ±2.6
>0.05
Age (Years)
43.1 ±1.1
43.7 ±0.7
>0.05
CAG (n)
399.0 ±53.7
416.1 ±23.3
>0.05
CAG Index
Body composition
Baseline
Final
Baseline
Final
p
52.1 ±3.9
53.4 ±4.2
55.4 ±3.2
54.6 ±2.9
0.047
Fat-Free Mass (kg)
21.6 ±2.5
22.5 ±2.6
21.9 ±2.6
20.4 ±2.6
0.014
Fat Mass (kg)
73.7 ±4.6
75.8 ±5.0
77.3 ±3.8
75.0 ±3.3
0.017
Total Mass (kg)
2
26.2 ±1.3
26.9 ±1.4
27.1 ±1.3
26.7 ±1.3
0.070
Body Mass Index (kg/m )
Bone Mineral Density
1.1 ±0.0
1.1 ±0.0
1.1 ±0.0
1.1 ±0.0
>0.05
(g/cm3)
SDMT
Written
30.0 ±4.9
27.4 ±3.9
25.4 ±3.3
23.3 ±2.8
>0.05
Correct
2.6 ±0.8
1.2 ±0.3
0.6 ±0.3
1.4 ±0.6
0.042
Incorrect
Oral
35.8 ±5.4
30.8 ±5.3
25.9 ±3.2
28.0 ±3.4
>0.05
Correct
3.0
±0.9
2.1
±0.8
5.6
±5.0
1.0
±0.4
>0.05
Incorrect
HVLT-R
19.2 ±1.8
16.3 ±2.6
14.3 ±1.7
14.7 ±1.6
>0.05
Total Recall
5.9 ±0.7
5.8 ±1.3
5.4 ±0.7
4.5 ±0.7
>0.05
Delayed Recall
80.3 ±7.7
75.9 ±10.8
85.3 ±5.9
68.7 ±10.1
>0.05
Retention
8.3 ±0.9
7.3 ±1.3
7.3 ±0.9
7.9 ±1.0
>0.05
RDI
D-KEFS
TMT
34.3 ±5.3
43.2 ±6.7
31.4 ±3.5
36.8 ±4.2
>0.05
Visual Scanning
55.6
±6.2
63.8
±9.6
59.9
±5.8
57.5
±7.7
>0.05
Number Sequencing
67.9 ±14.0
71.0 ±14.3
78.2 ±17.0
65.2 ±11.3
>0.05
Letter Sequencing
144.3 ±27.8
192.0 ±27.1
122.2 ±17.9
>0.05
Number/Letter Switching 150.4 ±21.7
54.1
±9.4
61.4
±11.2
69.5
±11.
8
60.8
±7.7
>0.05
Motor Speed
CWIT
46.6 ±6.7
50.63 ±8.2
42.8 ±4.4
47.8 ±5.8
>0.05
Colour Naming
33.8 ±3.8
33.25 ±4.1
30.2 ±3.1
29.9 ±3.7
>0.05
Word Reading
90.9 ±16.9
90.9 ±17.0
87.3 ±7.0
86.2 ±8.1
>0.05
Inhibition
10.8 ±3.2
5.6 ±1.6
12.9 ±2.6
10.0 ±2.5
>0.05
BDI-II
ABC-UK
Walking around the house
81.1 ±8.7
87.1 ±6.0
81.4 ±5.9
75.6 ±9.6
0.077
63.3
±12.9
72.7
±12.6
71.8
±8.2
63.3
±13.4
0.024
Walking up or down stairs
ABC-UK, Activities-specific Balance Confidence Scale; BDI-II, Beck depression InventoryII; CAG, cytosine-adenine-guanine; CWIT, Colour Word Interference Test; D-KEFS, DelisKaplan Executive Function System; HVLT-R, Hopkin’s Verbal Learning Test-Revised; RDI,
Recognition Discrimination Index; SDMT, Symbol Digit Modalities Test; TMT, Trail
Making Trials.
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a

b

c

d

%; P

197.9; 0.005

175.5; 0.052

225.9; 0.094

e

%; P

209.2; 0.004

188.6; 0.004

235.1; 0.094

f

Figure 4.1 (a-f) Changes to clinical outcomes after multidisciplinary rehabilitation
a) Unified-Huntington’s-Disease-Rating-Scale-Total-Motor-Score at baseline and final
assessment (n; I=9; C=11); b-d) Strength outcomes for upper and lower body (n; I=9; C=11);
values are shown for the intervention group as a whole, and for female and male sub-groups
to indicate gender response. Percentage of overall change (%) and statistical significance (p)
from commencement of maximal training (point 3) to final assessment are also indicated; e)
Changes in postural stability at final assessment relative to baseline (n; I=9; C=11); f)
Changes in SF-36v2 health scores at final assessment relative to baseline (n; I=9; C=11).
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4.6 DISCUSSION
This pilot study demonstrates the feasibility and safety of a nine-month multidisciplinary
rehabilitation program in twenty HD patients. Relative to control subjects, intervention
recipients exhibited reduced motor and postural stability deterioration, and significant
increases in fat-free mass and strength. Strength improvements have not been reported todate, perhaps because previous programs spanned only eight weeks (Khalil, 2012). The
minimal impact on cognitive outcomes observed here may be obscured by lack of sensitivity
of testing procedures, normally requiring large sample sizes (Stout et al., 2012). Changes in
QOL perceptions reflected functional outcomes.
Although positive, the pilot study has significant limitations, including lack of long-term
follow-up (precluding examination of a carry-over effect on cessation), limited sample size,
and low frequency of supervised rehabilitation, optimally requiring two-three sessions per
week. Assessment tools may also lack sensitivity to detect subtle changes.
In conclusion, we demonstrate that early-to-middle-stage HD patients can successfully
participate in prolonged multidisciplinary rehabilitation as an adjunct to medication and
further explorative, larger studies are warranted. Encouragingly, despite the small sample size
and low exercise frequency, small improvements were detected. Future studies would benefit
from more frequent rehabilitation, including a high-intensity aerobic component (Baker et al.,
2010) to maximise cognitive improvements.

105

4.7 ACKNOWLEDGEMENTS
We thank the participants and their families, staff of the Neurosciences Unit, Huntington’s
WA, Kyle Smith, Paul Crabtree and Tapan Rai for assistance.

The generous assistance of

the gyms (ECU Vario Health & Wellness Institute, South Lakes Leisure Centre, ECU Sport
& Fitness Centre and Positive Fit) is gratefully acknowledged.

106

CHAPTER 5 The Impact of Multidisciplinary Rehabilitation on Muscle Mass and
Motor Function in Individuals with Huntington’s disease

Submitted: British Journal of Sports Medicine, 2015 February 16th
Travis M Cruickshank, School of Medical Sciences, Edith Cowan University, Perth,
Australia, t.cruickshank@ecu.edu.au
Alvaro R Reyes, School of Medical Sciences, Edith Cowan University, Perth, Australia,
a.reyes@ecu.edu.au
Luis E Penailillo, School of Kinesiology & Research Centre, Faculty of Medicine,
Universidad Finis Terrae, Santiago Chile, lpenailillo@uft.cl
Jennifer A Thompson, School of Medical Sciences, Edith Cowan University, Perth, Australia,
jentl@iinet.net.au
Roger A Barker, John van Geest Centre for Brain Repair, Cambridge, UK; School of Medical
Sciences, Edith Cowan University, Perth, Australia, rab46@hermes.cam.ac.uk
Mel R Ziman, School of Medical Sciences, Edith Cowan University, Perth, Australia; School
of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia,
m.ziman@ecu.edu.au
Corresponding author: Travis Cruickshank, School of Medical Sciences, Edith Cowan
University, 270 Joondalup Drive, Joondalup, Australia. tel: (+61 8) 6304 3416 fax: (+61 8)
6304 2626 email: t.cruickshank@ecu.edu.au

107

5.1 ABSTRACT
Background: Progressive neurological dysfunction with secondary muscle wasting and
weakness is a physically disabling trait of Huntington’s disease (HD) that contributes to
impairments in functional capacity. Preliminary evidence suggests that multidisciplinary
rehabilitation is useful for treating impairments in functional capacity and therapeutically
addressing body composition abnormalities in individuals with manifest HD. Resistance
exercise also appears helpful for increasing muscular strength and lean tissue mass in other
neurodegenerative disorders. The purpose of this study was to evaluate the utility of a
multidisciplinary rehabilitation intervention encompassing resistance exercise on muscle
wasting and weakness and related functional impairments in individuals with HD.
Methods: Twenty-two participants with manifest HD were recruited and randomly assigned
to an intervention or control group. Participants in the intervention group were provided with
a nine month multidisciplinary rehabilitation intervention, while those in the control group
maintained their usual care. Participants were assessed using muscle wasting (loss of lean
tissue mass), lower extremity muscle strength, balance and mobility measures before and
after the trial. Paired t-tests were used to examine changes within each group for muscle
wasting, lower extremity muscle strength, balance and mobility measures. Unpaired t-tests
were used to examine changes in relative values between groups for muscle wasting, lower
extremity muscle strength, balance and mobility measures.
Results: Significant increases in muscle strength in the knee extensors and flexors were
found in the intervention group. The intervention group also displayed significantly greater
lean tissue mass than the control group after multidisciplinary rehabilitation. Furthermore, a
significant deterioration in mobility was observed in the control group, whereas the
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intervention group showed no such changes. There were no significant changes in balance in
either group.
Conclusions: Multidisciplinary rehabilitation is useful for improving muscular strength in the
lower extremities as well as preserving lean tissue mass and mobility in manifest HD.
Trial Registration: This study was registered with the Australian New Zealand Clinical Trial
Registry (ACTRN12610000218099)
Keywords: balance, mobility, muscle strength, muscle mass, Huntington’s disease
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5.2 BACKGROUND
Huntington’s disease (HD) is a chronic neurodegenerative disorder of the nervous system.
Over the course of the disease individuals suffer from progressive neurological deficits
leading to secondary muscle wasting (Kosinski et al., 2007; Turner et al., 2007) and weakness
(Busse et al., 2008; Kosinski et al., 2007). The development of these clinical features
contributes to functional impairments (Cruickshank et al., 2014), a reduced quality of life (Ho
et al., 2009) and nursing home placement (Rao et al., 2005).
Muscular wasting has been described previously in patients and rodent models of HD (Aziz
and Roos, 2013; Ribchester et al., 2004; Sanberg et al., 1981). The mechanisms underpinning
it are not yet clear, however lifestyle passivity, mitochondrial dysfunction (Rivera-Sánchez et
al., 2014), transcriptional dysregulation (Luthi-Carter et al., 2002a; Strand et al., 2005) and
myocyte defects (van der Burg et al., 2009) are thought to be the primary aetiological factors.
Muscular wasting and associated weakness, particularly in the lower extremities (Busse et al.,
2008; Kosinski et al., 2007), contributes to impairments in functional capacity (Cruickshank
et al., 2014).
Recent evidence from our group shows that muscular weakness in the lower extremities
contributes to impairments in balance and mobility in individuals with manifest HD
(Cruickshank et al., 2014). Similar findings have been reported in individuals with other
neurodegenerative disorders (Broekmans et al., 2013a; Paul et al., 2013b). In particular, Paul
et al (Paul et al., 2013a; Paul et al., 2013b) showed that muscle weakness in the lower
extremities contributes to impaired balance and mobility as well as falls in individuals with
Parkinson’s disease (PD). Furthermore, Broekmans et al (Broekmans et al., 2013a) showed
that lower extremity muscle strength is a significant predictor of walking capacity in
individuals with multiple sclerosis.
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Therapeutic strategies that positively impact on muscle weakness/mass and the underlying
aetiological mechanisms may favourably impact on functional capacity in individuals with
HD. Accumulating evidence suggests that multidisciplinary rehabilitation is a useful
therapeutic approach for treating functional impairments that present in HD. For example,
Zinzi et al (2007) reported improvements in balance and mobility in a small sample of
individuals with HD after twelve months of intensive, intermittent, multidisciplinary
rehabilitation. More recently, Piira et al (2013) found improvements in mobility, balance,
mood and quality of life after twelve months of intensive tri-monthly multidisciplinary
rehabilitation. Finally recent work by our group has shown that weekly multidisciplinary
rehabilitation over nine months favourably impacts on weight loss and adipose tissue loss in
individuals with manifest HD (Thompson et al., 2013). When assessed separately, resistance
exercise has been shown to increase lean tissue mass and muscular strength in individuals
with multiple sclerosis and PD (Dalgas et al., 2009; Dalgas et al., 2010b; Dibble et al., 2006;
Shulman et al., 2013). Multidisciplinary rehabilitation interventions encompassing resistance
exercise may therefore be useful for treating muscular wasting and weakness as well as
related functional impairments in individuals with HD.
The objective of this study was to evaluate the utility of a nine month multidisciplinary
rehabilitation intervention, encompassing resistance exercise, on lean tissue mass, muscle
strength, balance and mobility in individuals with manifest HD.
5.3 METHODS
5.3.1 Study design
The present study was a nine month randomised controlled pilot trial. A simple
randomisation procedure was used to assign participants to an intervention or a control group,
using computer generated random numbers. Participants in the intervention group were
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provided with a nine month multidisciplinary rehabilitation intervention, while participants in
the control group were asked to maintain their usual care throughout the trial. After the trial,
participants in the control group were provided with the same nine month multidisciplinary
rehabilitation intervention for ethical purposes. Both groups were tested at baseline (pre-trial)
and after nine months (post-trial) using lean tissue mass, lower extremity muscle strength,
mobility and balance measures.
5.3.2 Study approval, registration, and patient consent
Ethical approval was granted by the Human Research Ethics Committees at Edith Cowan
University and North Metropolitan Area Mental Health Service (NMAMHS). Written
informed consent was provided by all study participants. This study was registered with the
Australian New Zealand Clinical Trial Registry (ACTRN12610000218099).
5.3.3 Participants
Potential participants were identified using the Neuroscience Unit database of the North
Metropolitan Area Mental Health Service (NMAMHS). Inclusion criteria included a family
history of HD, a positive genetic test for the HD mutation (CAG >39), manifest disease
(Unified Huntington’s Disease Rating Scale-Total Motor Score [UHDRS-TMS] ≥5), the
capacity to follow written or verbal instruction, the ability to perform sub-maximal aerobic
and resistance exercise and aged 18 years or older. Participants were excluded if they had
recent drug or alcohol abuse, possessed a confounding neurological condition or concomitant
physical condition which was a contraindication for exercise.
5.3.4 Multidisciplinary rehabilitation intervention
The trial intervention was designed following baseline assessment by physical therapists,
exercise physiologists and occupational therapists. The intervention was designed to target
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muscular wasting and weakness in the lower extremities as well as balance and mobility. The
intervention comprised a clinical exercise program, home based exercise program and
fortnightly occupational therapy. The clinical exercise program consisted of once weekly
aerobic and resistance exercise for an hour in a clinical exercise centre. The home-based
exercise program (to be performed thrice weekly) consisted of muscle strengthening and fine
motor exercises. The home-based exercise program was only provided to participants after
careful instruction and familiarisation. Occupational therapy consisted of cognitive and
functional exercises designed to enhance cognitive and functional independence (see
Supplementary Tables 5.4, 5.5 and 5.6).
5.3.5 Study procedures
Participants were examined by formally trained assessors. The same assessors were used at
baseline and at the nine month assessment time point to ensure the reliability of collected
data. All assessors were blinded to group allocation.
5.3.6 Outcome measures
Lean tissue mass
Total lean tissue mass was quantified to evaluate muscle wasting using dual-energy X-ray
Absorptiometry (Hologic, Inc, Waltham, MA)(Goodman and Barker, 2011; Thompson et al.,
2013).
Lower extremity muscle strength
Maximum voluntary contraction of knee flexors and extensors was examined using isokinetic
and isometric strength test protocols with automated dynamometry (Biodex Medical Systems,
Shirley, NY, USA). Automated dynamometry has been previously shown to be a reliable
measure of muscle strength changes in people with neurodegenerative disorders (Dalgas et
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al., 2009). Prior to testing, participants were comfortably seated and safely secured using two
padded chest straps and one padded waist strap. Additional straps were placed just above the
knee and ankle to secure the tested limb and restrict extraneous movement. Once securely
seated, participants were positioned with their lateral condyle aligned with the dynamometers
axis of rotation. Participants were then instructed to perform three sub-maximal isokinetic
extension and flexion contractions at 30%, 50% and 70% of their perceived maximum
voluntary contraction (MVC). Isokinetic and isometric muscle strength testing was performed
shortly after the individuals performed the sub-maximal contractions. Isokinetic muscle
strength protocols examined knee extensor (KE) and knee flexor (KF) and muscle strength at
180°·s-1 (fast) and 30°·s-1 (slow) velocities. Isometric knee extensor and flexor muscle
strength was also examined at 60° of knee flexion. Each individual performed three
contractions per test, with one minute separating each testing protocol. The average of the
two highest values recorded was used for statistical analysis.
Mobility
Changes to fast and self-paced walking were examined using the 10 m Timed Walk Test
(Quinn et al., 2013). Fast-paced walking was also examined using the 4 m Timed Walk Test.
Time was recorded for both tests using a standard stopwatch. Walking endurance was
assessed using the 6 Minute Walk Test (Quinn et al., 2013). The total distance travelled for
the 6 Minute Walk Test was recorded using a trundle wheel. These measures were
specifically chosen as they have previously been documented to be reliable measures of
mobility performance in people with manifest HD (Khalil et al., 2010; Quinn et al., 2013).
Balance
Changes to dynamic and static balance were assessed using the Berg Balance Scale (BBS)
and the 10 repetition Chair Stand Test (CST) (Khalil et al., 2010; Quinn et al., 2013). Time
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taken to complete the CST was recorded using a standard stopwatch. Participants performed
two trials for each assessment. These measures were specifically chosen as they have
previously been documented to be reliable measures of mobility performance in people with
manifest HD (Khalil et al., 2010; Quinn et al., 2013).
5.4 STATISTICAL ANALYSIS
Changes within each group for lean tissue mass, lower extremity muscle strength, mobility
and balance outcomes were examined using a paired t-test. An unpaired t-test was used to
assess relative changes in lean tissue mass, muscle strength, mobility and balance between
groups. Relative changes were calculated as the mean difference between pre-trial and posttrial values. Data are presented as mean and standard deviations. Statistical examination of
the data was performed with STATA version 9.1 (Stata Corp, 4905 Lakeway Dr, Texas
77845 USA).
5.5 RESULTS
Between January 2010 and May 2010 sixty six individuals with manifest HD were identified
and invited to participate in this research trial. Twenty five (38%) satisfied the inclusion
criteria and consented to participate. Three participants (12%) withdrew prior to
randomisation (due to frailty, excessive falls and delusions) and three (13.6%) before the
conclusion of the trial (did not want to continue) (see Figure 5.1).
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Enrolment

Assessed for eligibility (n=66)

Excluded (n=44)
 Did not meet inclusion criteria (n=4)
 Declined to participate (n=32)
 Other reasons (n=8)

Randomised (n=22)

Allocation
Allocated to intervention group
(n=11)
 Received allocated intervention
(n=9)

Allocated to control group (n=11)
 Participated as a control
(n=10)

Follow-Up
Lost to follow-up (n=2)
 Severe mental health issues
(n=1)
 Discontinued intervention (did
not enjoy the intervention (n=1)

Lost to follow-up (n=1)
 Presented with a confounding
neurological condition (n=1)

Analysis
Analysed (n=9)

Analysed (n=10)

Figure 5.1 Participant recruitment and study flow
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Participants in the intervention group displayed high adherence to the supervised clinical
program (85%), moderate adherence to the home based program (56%), and high adherence
to occupational therapy sessions (84.2%).
Table 5.1 displays demographic data and information on disease severity, disease duration,
and the severity of motor abnormalities (UHDRS-TMS) in the intervention and control
groups. Table 5.2 displays changes in medication and supplements throughout the study.
Figure 5.2 and Table 5.3 show measures of lean tissue mass, muscular strength in the lower
extremities and balance and mobility before and after the trial and relative changes in these
values. There were no significant differences between groups at baseline for demographics,
disease severity, disease duration, severity of motor abnormalities or for any of the recorded
outcome measures.
Table 5.1 Participant demographics at baseline (Mean ± SD)

Variable

Intervention group

Control group

p value

No. (M/F)

9 (4/9)

10 (6/4)

Age (years)

53.77 ± 8.56

50.80 ± 7.81

NS

CAG (n)

43.11 ± 3.25

44.1 ± 1.96

NS

Disease Burden
Score

399.40 ± 161.33

428.20 ± 71.57

NS

UHDRS-TMS

24.88 ± 13.56

25.20 ± 12.29

NS

CAG (n), cytosine-adenine-guanine expansion; UHDRS-TMS, Unified Huntington’s Disease
Rating Scale-Total Motor Score; NS, not significant
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Table 5.2 Participant medication and supplements throughout the study

Participants

Trial

Active Follow-up
NA

Intervention Group
Participant 1

Fish Oil

NA

Participant 2

Aripiprazole, Amantadine,
Citalopram, Olanzapine
Folate, Activated B3,
Multivitamins, CoQ10
Haloperidol, Paroxetine,
Atorvastatin
Olanzapine, Escitalopram,
Fish Oil, Vitamin D, Zimtat
Aripiprazole, Escitalopram

NA

Tetrabenazine, Fluoxetine
Atorvastatin, Aspirin,
Prazosin

NA

Telmisartan, Clonazepam,
Olanzapine, Amantadine,
Omega 3
Venlafaxine, Mirtazapine,
Dimebon, Olanzapine
Pariet, Mirtazapine,
Olanzapine, Escitalopram,
Benzhexol, Varenidine
Tartrate
Escitalopram, Olanzapine,
Megafolate, CoQ10

Telmisartan, Vesicare,
Amantadine, Clonazepam,
Olanzapine, Mirtazapine
Venlafaxine, Mirtazapine,
Olanzapine

Participant 3
Participant 4
Participant 5
Participant 6
Participant 7
Participant 8
Participant 9

NA
NA
NA
NA
NA

NA

Control Group
Participant 10
Participant 11

Participant 12

Participant 13
Participant 14

Thyroxine, Escitalopram,
Olanzapine, Multivitamins

Participant 15

Mirtazapine, Thyroxine

Participant 18

Olanzapine, Citalopram,
Mirtazone
Escitalopram, Olanzapine,
Propranolol
Setraline

Participant 19

Cadesartan Cilexitil

Participant 16
Participant 17

NA, not applicable
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Aripiprazole, Olanzapine,
Mirtazapine, Pariet,
Escitalopram, Nitrazepam
Escitalopram, Olanzapine,
Megafolate, CoQ10
Thyroxine, Escitalopram,
Olanzapine, Multivitamins,
Simvastin
Mirtazapine, Escitalopram,
Aripiprazole, Lorazepam,
Iron tables
Olanzapine, Citalopram,
Mirtazone
Aripiprazole, Neurontin
Setraline
-
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Figure 5.2 Changes in lower extremity muscle strength in individuals with manifest HD
The effects of nine months of multidisciplinary rehabilitation on changes in maximum
voluntary contraction (MVC) muscle strength in the knee extensors (KE) and knee flexors
(KF) of individuals with manifest HD. * Indicates significant differences in muscle strength
between baseline and post-intervention.

119

Table 5.3 Changes (mean SD) in lean tissue mass, balance and mobility after nine months of multidisciplinary rehabilitation in the intervention
and control group

Intervention Group (n=9)

Control Group (n=11)

Pre-trial
49763.16 ±
11223.87

Post-trial
51034.46 ±
12210.80

p value

Pre-trial
53885.72 ±
10387.53

Post-trial
52248.34 ±
10387.53

p value

BBS

46.88 ± 9.15

48.11 ± 8.76

0.326

44.9 ± 7.35

44.8 ± 6.35

0.484

CST

28.07 ± 13.16

27.33 ± 11.85

0.427

32.40 ± 12.55

32.00 ± 18.95

0.435

10 m TWT (SP)

8.37 ± 3.68

8.35 ± 4.06

0.472

8.02 ± 1.92

8.61 ± 1.72

0.111

10 m TWT (FP)

6.49 ± 4.38

7.10 ± 3.61

0.187

6.14 ± 1.36

7.09 ± 2.43

0.050*

4 m TWT

3.46 ± 2.53

2.97 ± 1.39

0.134

2.79 ± 0.86

3.35 ± 1.18

0.001*

6MWT

474.37 ± 169.59

449.37 ± 145.68

0.079

443.50 ± 101.62

391.50 ± 132.05

0.024*

Lean tissue mass

0.066

0.060

BBS, Berg Balance Scale; CST, Chair Stand Test; TWT (SP), Timed Walk Test (self-paced), TWT (FP), Timed Walk Test (fast-paced), 4 m
TWT, Four Meter Timed Walk Test, 6MWT, Six Minute Walk Test
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5.5.1 Effects of multidisciplinary rehabilitation
Changes to lean tissue mass
Table 5.3 displays relative changes in lean tissue mass during the trial. There were no
significant changes to lean tissue mass within each group after the nine month trial, however
an examination of the relative changes in lean tissue mass between groups revealed that the
intervention group had significantly greater lean tissue mass after the intervention than the
control group (intervention group: 1271.30g ± 2275.05g; control group: -1637.38g ±
3024.08g; p=0.015).
Changes in maximal lower extremity muscle strength
Figure 5.2 displays changes in maximal lower extremity muscle strength. Knee extensor
muscle strength increased significantly at slow (43.4% p=0.000) and fast velocities (22.3%
p=0.040) in the intervention group, whereas it remained relatively unchanged in the control
group (slow velocity, -3.5% p>0.05; fast velocity, 3.02% p>0.05). Individuals in the
intervention group also displayed increases in knee flexor muscle strength at slow (22.7%;
p=0.056) and fast velocities (26.19%; p=0.027). By contrast, knee flexor muscle strength
decreased or remained unchanged at slow (-13.5%; p>0.05) and fast velocities (0.04%;
p>0.05) in the control group. Increases in isometric muscle strength in the knee extensors
(25.3%; p=0.000) and flexors (21.09%; p=0.025) were also found in the intervention group,
while the control group displayed a slight decrease in isometric knee extensor (-0.07%;
p>0.05) and flexor (-3.36%; p>0.05) muscle strength. An examination of changes in
isokinetic and isometric knee extensor and flexor muscle strength between groups showed
that the intervention group had significantly greater muscle strength than the control group
after nine months of multidisciplinary rehabilitation [KE 180˚ (intervention group: 17.20 Nm
± 19.82 Nm) vs (control group: 1.95 Nm ± 11.23 Nm) p=0.025; KF 180˚ (intervention group:
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12.00 Nm ± 16.10 Nm) vs (control group: 0.20 Nm ± 8.46 Nm) p=0.029; KE 30˚
(intervention group: 44.21 Nm ± 18.33 Nm) vs (control group: -4.66 Nm ± 21.17 Nm)
p=0.000; KF 30˚ (intervention group: 20.65 Nm ± 21.35 Nm) vs (control group: -3.52 Nm ±
7.57 Nm) p=0.001; KE 60˚ (intervention group: 37.66 Nm ± 19.05 Nm) vs (control group: 1.17 Nm ± 22.79 Nm) p=0.000; KF 60˚ (intervention group: 17.92 Nm ± 18.32 Nm) vs
(control group: -2.05 Nm ± 13.79 Nm) p=0.007].
Changes to mobility
Changes in mobility for both groups are displayed in Table 5.3. There were no significant
changes in the 10 m Timed Walk Test, 4 m Timed Walk Test or 6 Minute Walk Test mobility
measures in the intervention group during the trial period. In contrast, the control group
displayed a significant deterioration on the 6 Minute Walk Test (13.2%), the fast-paced
component of the 10 m Timed Walk Test (13.3%) and the 4 m Timed Walk Test (16.7%)
after nine months. An analysis of the relative changes between groups revealed that the
intervention group performed significantly better than the control group on the 4 Meter
Timed Walk Test after nine months [(intervention group -0.49s ± 1.96s) vs (control group
0.56s ± 1.02s) p=0.011].
Changes to balance
Changes to balance for both groups are shown in Table 5.3. There were no significant
changes in balance within or between groups throughout the study.
5.6 DISCUSSION
This study showed that multidisciplinary rehabilitation is useful for increasing muscular
strength in the lower extremities. In addition this study showed that multidisciplinary
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rehabilitation favourably impacts on lean tissue mass and mobility in individuals with
manifest HD.
Previous studies have shown that muscular strength in the lower extremities is significantly
reduced in individuals with manifest HD (Busse et al., 2008). Here we show that muscular
strength is remediable to multidisciplinary rehabilitation. Specifically, we found that muscle
strength in the knee flexors and extensors was significantly increased after multidisciplinary
rehabilitation. The observed increases in lower extremity muscle strength are encouraging,
especially considering that muscle weakness in the lower limbs contributes to balance and
mobility problems in HD (Cruickshank et al., 2014). Increases in muscle strength may be
attributed to the resistance exercise component of the intervention in this study. Studies of
resistance exercise in other neurodegenerative disorders have consistently reported increases
in muscle strength (Corcos et al., 2013; Dalgas et al., 2009; Dalgas et al., 2010b; Shulman et
al., 2013). Taken together these results collectively suggest that interventions encompassing
resistance exercise should be considered for improving muscle strength in individuals with
HD and other neurodegenerative disorders.
Muscle wasting is a well-documented feature of HD that is not amenable to drug therapy
(Aziz and Roos, 2013; van der Burg et al., 2009). In this study, multidisciplinary
rehabilitation was found to favourably impact on lean tissue mass. Despite no baseline
differences, the intervention group illustrated significantly greater lean tissue mass after the
intervention when compared to the control group. This finding extends our previous work,
where significant increases in body weight and fat mass were found following
multidisciplinary rehabilitation (Thompson et al., 2013). The favourable effect of
multidisciplinary rehabilitation on lean tissue is most likely attributable to the resistance
exercise component of the intervention. Indeed there is some literature showing that
resistance exercise increases muscle mass in the elderly (McCartney et al., 1995; Yarasheski
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et al., 1999; Yarasheski et al., 1993) and in those with multiple sclerosis and Parkinson’s
disease (Dalgas et al., 2010b; Dibble et al., 2006). These results suggest that resistance
exercise may be a useful therapeutic strategy for addressing muscle wasting in individuals
with HD as well as for other neurodegenerative disorders.
Similar to earlier investigations, we found that multidisciplinary rehabilitation had a
favourable effect on mobility in individuals with manifest HD (2013; Zinzi et al., 2007). In
particular, we found that mobility was preserved in individuals in the intervention group,
whereas it deteriorated in individuals in the control group. This finding confirms earlier
exploratory findings by Piira et al (2013) and Zinzi et al (2007), who reported improvements
in mobility after a twelve and twenty-four month intensive intermittent multidisciplinary
rehabilitation intervention. Collectively, these findings suggest that multidisciplinary
rehabilitation is a useful strategy for improving mobility in individuals with manifest HD.
In contrast to previous work (2013; Zinzi et al., 2007), we did not find any evidence to
support the use of multidisciplinary rehabilitation for balance problems in individuals with
manifest HD. Specifically, we found that balance was unchanged in the intervention group
and the control group at the conclusion of the study. The short duration of the current
intervention compared with previous studies may have accounted for our inability to find
significant changes in balance in the current sample of individuals with HD. Moreover, the
lack of formalised balance training in our intervention, unlike previous studies (2013; Zinzi et
al., 2007), may have accounted for our inability to also see any such improvements.
Formalised balance training may be necessary to improve balance in people with HD.
The present study is not without limitations. Our findings were collected from a relatively
small sample of individuals with manifest HD. In addition, individuals remained on
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medication throughout the study, which may have influenced some of the favourable effects
associated with this multidisciplinary rehabilitation intervention.
5.7 CONCLUSIONS
This study provides preliminary evidence that multidisciplinary rehabilitation is an effective
treatment strategy for increasing muscular strength in the lower extremities and favourably
impacts on muscular mass and mobility in individuals with manifest HD. We recommend
larger controlled trials to confirm the therapeutic utility of multidisciplinary rehabilitation as
an adjunct treatment approach for reduced muscle strength, muscle wasting and mobility
problems in individuals with HD.
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5.9 SUPPLEMENTARY DATA
Supplementary Table 5.4 Clinical exercise program
Exercise
Mode
Active Warm
Up

Aerobic
Exercise

Resistance
Exercise

Exercises
Utilised
Walking
(Treadmill)
Cycling
(Ergometer)
Step ups
Walking
(Treadmill)
Cycling
(Ergometer)

Multi/Single
Joint
Exercises
Not
Applicable

Duration

Intensity

3-5
minutes

40-60%

Not
Applicable

8-10
minutes

Leg Press

Multi-joint

40
minutes

Knee
Extension

Single-joint

Knee Flexion

Single-joint

Leg
Abduction/
Adduction

Single-Joint

Lat Pull
Down

Multi-joint

Supported
Row

Multi-joint

Chest Press

Multi-joint

Abdominal
Crunches

Single-Joint

Walking
(Treadmill)
Not
Cool Down
Cycling
Applicable
(Ergometer)
Abbreviations: Reps= Repetitions
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3-5
minutes

60-80%

60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps

Progression
Increase warm
up intensity
Decrease
recovery period
Increase intensity
% (cadence/
resistance)
Increase training
volume (kg)
Increase training
volume (kg)
Increase training
volume (kg)
Increase training
volume (kg)
Increase training
volume (kg)
Increase training
volume (kg)
Increase training
volume (kg)

60-80%
2-4 Sets
8-12 Reps

Increase training
volume
(additional
weight)

40-60%

Not Applicable

Supplementary Table 5.5 Home-based exercise program
Exercise
Mode

Fine Motor

Resistance
Exercise

Exercises Utilised

Multi/Single
Joint
Exercise

Duration

Laser tracing
Button tying
Speed/Accuracy
trade-off

Not
Applicable

15 minutes

Knee
Extension/Flexion

Single Joint

45 minutes

Wall Push

Multi-joint

Leg Abduction/
Adduction

Single-joint

Row

Multi-joint

Abdominal
Crunches

Single-joint

ROM, range of motion
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Progression
Increase the
difficulty of
objects traced
Increase the
number and vary
the size of the
buttons tied
Decrease shape
size in the
speed/accuracy
trade-off tasks
Increase
resistance
(Sanctbands)
Progress to pushups on knees and
then to full ROM
push-ups
Increase
resistance
(Sanctbands)
Increase
resistance
(Sanctbands)
Increase time in
eccentric and
concentric
contraction phases

Supplementary Table 5.6 Occupational therapy program
Exercise Modality

Tasks Utilised

Progression
Increase difficulty of cooking

Cooking
Perform laundry without cues
Laundry
Daily Activities
Gardening

Eating

Planning/Organisation

Utilisation of a diary
(written or
electronic)
Planning social
activities

Memory

Facial Recognition

Increased gardening to an
independent state
Improve the use and
manipulation of eating
utensils
Increase the number and
difficulty of tasks throughout
the day

Increase the number of faces
to be recognised

Sudoku

Increase the difficulty of the
Sudoku game

Board Puzzles

Increased the difficulty and
size of puzzle

Boggle

Include time constraints

Mastermind

Include time constraints

Problem Solving
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6.1 ABSTRACT
Background
There is a wealth of evidence detailing grey matter degeneration and loss of cognitive
function over time in individuals with Huntington’s disease (HD). Efforts to attenuate
disease-related brain and cognitive changes have been unsuccessful to date. Multidisciplinary
rehabilitation, comprising motor and cognitive intervention, has been shown to positively
impact on functional capacity, depression, quality of life and some aspects of cognition in
individuals with HD. This exploratory study aimed to evaluate, for the first time, whether
multidisciplinary rehabilitation can slow further deterioration of disease-related brain changes
and related cognitive deficits in individuals with manifest HD.
Methods
Fifteen participants with manifest HD undertook a multidisciplinary rehabilitation
intervention spanning nine months. The intervention consisted of once-weekly supervised
clinical exercise, thrice weekly self-directed home based exercise and fortnightly
occupational therapy. Participants were assessed using MR imaging and validated cognitive
measures at baseline and after nine months.
Results
Participants displayed significantly increased grey matter volume in the right caudate and
bilaterally in the dorsolateral prefrontal cortex after nine months of multidisciplinary
rehabilitation. Volumetric increases in grey matter were accompanied by significant
improvements in verbal learning and memory (Hopkins Verbal Learning-Test). A significant
association was found between grey matter volume increases in the dorsolateral prefrontal
cortex and performance on verbal learning and memory.
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Conclusions
This study provides preliminary evidence that multidisciplinary rehabilitation positively
impacts on grey matter changes and cognitive functions relating to verbal learning and
memory in individuals with manifest HD. Larger controlled trials are required to confirm
these preliminary findings.
Key Words
Cognition, executive function, Huntington’s disease, neuropathology, rehabilitation
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6.2 INTRODUCTION
Huntington’s disease (HD) is a degenerative disorder of the nervous system caused by an
unstable cytosine-adenine-guanine (CAG) expansion in exon 1 of the HTT gene (MacDonald
et al., 1993). Despite progress, there is still no cure and available drug agents only provide
partial relief of motor and psychiatric symptoms. There is, therefore, an urgent need to trial
treatments that can impact on disease-related brain changes and clinical aspects of HD.
Over the last decade, parcellation and voxel based morphometry (VBM) imaging studies
have shown evidence of grey matter (GM) degeneration in cortical and subcortical brain
structures in HD (Dominguez et al., 2013; Georgiou-Karistianis et al., 2013a; Hobbs et al.,
2011). Degeneration of GM is particularly pronounced in the striatum, commencing up to 20
years prior to clinical onset (Georgiou-Karistianis et al., 2013a; Tabrizi et al., 2013). Over the
course of the disease, GM loss becomes more widespread, with atrophy also observed in
frontal and occipital cortices (Dominguez et al., 2013; Tabrizi et al., 2013).
Deficits in cognitive function also arise in HD, even prior to diagnosis, presumably as a result
of the neurodegenerative processes (Stout et al., 2012). In early HD, there are documented
deficits in attention (Georgiou-Karistianis et al., 2012), psychomotor speed (Stout et al.,
2012), working memory (Stout et al., 2012), planning and inhibition (Ho et al., 2003). In the
absence of effective treatments, these deficits worsen over time, negatively impacting on
functional independence and quality of life (Eddy and Rickards, 2013).
The loss of GM has been shown to correlate with a decline in cognitive performance in HD.
Scahill et al (2013) have shown that loss of GM in cortical and subcortical structures
significantly correlates with poorer performance on emotional recognition, working memory
and odour identification tasks. Harrington et al (2014) have further shown that degeneration
of fronto-striatal and fronto-parietal structures correlates with poorer performance on
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attention, processing speed, verbal learning and memory and emotional recognition tasks.
Recent evidence suggests that lifestyle factors significantly influence disease-related brain
and cognitive changes in HD. Bonner-Jackson et al (2013a) have shown that greater cognitive
reserve (computed as the composite of innate intelligence and educational level) is associated
with a slower rate of volume loss in the caudate nucleus and putamen and greater
preservation of cognitive function in pre-manifest HD. Moreover, higher education status is
significantly associated with a better cognitive outcome on the Unified Huntington’s Disease
Rating Scale (UHDRS) in manifest HD (López‐Sendón et al., 2011). Finally, lifestyle
passivity has been shown to significantly influence the onset of symptoms in HD (Trembath
et al., 2010). Treatment strategies that enrich lifestyle may impact on disease-related brain
changes and a loss of cognitive function in HD and warrant further investigation.
Previous studies have shown that environmental enrichment can preserve peristriatal
structures and cognitive function in HD rodent models (van Dellen et al., 2000; Wood et al.,
2010). Moreover, lifestyle interventions, such as multidisciplinary rehabilitation, have been
shown to improve aspects of cognition, functional capacity, depression and quality of life
(Piira et al., 2013; Thompson et al., 2013; Veenhuizen et al., 2011; Zinzi et al., 2007). When
assessed separately, cognitive and motor interventions have also been reported to increase
hippocampal, GM and white matter volume in the elderly and those with neurodegenerative
disorders (Bonzano et al., 2014; Burciu et al., 2013; Erickson et al., 2011; Kühn et al., 2014).
The outlined findings informed our decision to evaluate the utility of multidisciplinary
rehabilitation on disease-related brain changes and cognitive function in manifest HD.
Specifically, we evaluated the effects of multidisciplinary rehabilitation on attenuating GM
loss and associated declines in cognitive function. We hypothesised that multidisciplinary
rehabilitation would increase GM volume in dorsolateral prefrontal cortex (DLPFC), striatum
and hippocampus structures known to be functionally relevant to cognitive function. In
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addition, we expected GM volume increases to be associated with better cognitive outcomes.
6.3 MATERIALS AND METHODS
6.3.1 Study design
The present investigation was a nine month exploratory study on the effects of
multidisciplinary rehabilitation on brain structure and cognition in individuals with manifest
HD. The duration of the intervention was chosen for two reasons: 1) structural changes can
be detected in individuals with manifest HD after six months (Henley et al., 2006), and 2)
evidence has shown that rehabilitation interventions can have favourable effects on brain
structure after two weeks (Burciu et al., 2013).
6.3.2 Study approval, registration, and patient consent
Ethical approval was granted by the Edith Cowan University and North Metropolitan Area
Mental Health Service (NMAMHS) Human Research Ethics Committees. Written informed
consent was provided by all participants.
6.3.3 Participants
Fifteen participants with manifest HD were recruited using the North Metropolitan Area
Mental Health Service Neuroscience Unit Database. Inclusion criteria included a family
history of HD, a positive genetic test for the HD mutation (CAG >39), manifest disease
(Unified Huntington’s Disease Rating Scale-Total Motor Score [UHDRS-TMS] >5), the
capacity to follow written or verbal instruction, the ability to perform sub-maximal aerobic
and resistive exercise and aged 18 years or older. Participants were excluded if they suffered
from recent drug or alcohol abuse, had a confounding neurological condition or concomitant
physical, cardiovascular or respiratory condition which contraindicated exercise. Medication
adjustments were recorded routinely throughout the trial (see Table 6.1).
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Table 6.1 Participant demographics

No

Sex

CAG
length

Age

Disease
Duration
(Years)

DBS

UHDRSTMS

1

Male

46

57

7.6

596

45

2

Male

42

71

9.5

461.5

59

3

Female

46

51

2.3

535.5

18

4

Male

45

47

1.8

446.5

52

5

Female

46

45

4.2

472.5

36

6

Female

44

54

0.9

459

19

7

Female

41

50

0.6

275

25

Mirtazapine, Escitalopram,
Aripiprazole, Lorazepam

8

Male

44

48

1.4

408

58

Aripiprazole, Gabapentin,
Escitalopram, Olanzapine

9

Female

44

50

10.5

433.5

44

Tetrabenazine

10
11
12
13

Female
Male
Female
Male

39
41
43
41

49
61
56
53

3.3
0.9
1.4
17.3

175
335.5
427.5
297

39
13
32
5

Haloperidol, Paroxetine
CoQ10
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Medication (baseline)

Medication (during)

Aripiprazole, Mirtazapine,
Escitalopram
Clonazepam, Olanzapine
Amantadine, Mirtazapine

Aripiprazole
Escitalopram
Clonazepam, Olanzapine
Amantadine, Mirtazapine
Setraline, Creatine, CoQ10,
Venlafaxine, Mirtazapine,
Olanzapine
Aripiprazole, Olanzapine,
Mirtazapine, Escitalopram,
Nitrazepam, Benzhexol

Venlafaxine, Mirtazapine,
Olanzapine
Aripiprazole, Olanzapine,
Mirtazapine, Escitalopram,
Nitrazepam
Olanzapine, Escitalopram,
CoQ10
-

Olanzapine, Escitalopram, CoQ10
Olanzapine, Escitalopram
Mirtazapine, Escitalopram,
Aripiprazole, Lorazepam,
Tetrabenazine, Propranolol
Amantadine, Clonazepam,
Amantadine, Gabapentin,
Pramipexole
Fluoxetine, Tetrabenazine,
Actonel
Haloperidol, Paroxetine
CoQ10

14

Male

44

48

1

408

12

Escitalopram

15

Male

40

68

6.7

310.5

17

Prazosin

Aripiprazole, Escitalopram
Aripiprazole, Atenolol,
Atorvastatin, Clonazepam,
Clopidogrel, Quetiapine,

43.6 ±
52.5 ±
402.7 ±
31.6 ±
4.6 ± 4.8
NA
NA
2.2
6.6
107.7
17.5
DBS, Disease Burden Score (age × [CAG-35.5]), UHDRS-TMS, Unified Huntington’s Disease Rating Scale-Total Motor Score
Summary

8M/7F

137

6.3.4 Multidisciplinary rehabilitation intervention
The intervention was designed after baseline assessment of the participants by an experienced
interdisciplinary team consisting of physical therapists, exercise physiologists, occupational
therapists and strength and conditioning specialists. The intervention consisted of a clinical
exercise program, a home-based exercise program and fortnightly occupational therapy. The
clinical exercise program consisted of supervised weekly aerobic and resistance exercises for
an hour. The home-based exercise program involved thrice weekly self-directed muscle
strengthening and fine motor exercises for an hour. Occupational therapy consisted of a
variety of paper and pencil, verbal planning, memory and problem solving exercises designed
to enhance cognition and executive function (see Supplementary Tables 6.3, 6.4 and 6.5).
Adherence to clinical exercise and occupational therapy sessions were recorded by clinical
exercise specialists and occupational therapists using a training diary. Adherence to the home
based exercise sessions were recorded by patients using a provided training diary.
6.3.5 Outcome measures
Magnetic Resonance Imaging
Structural MR (magnetic resonance) images from 15 participants were acquired at baseline
and 9-month follow-up using a 3T Philips Achieva Scanner and a Philips 8 - channel head
coil (Philips Healthcare. Best, The Netherlands). Structural scans consisted of a T1 3D Turbo
Field Echo (TFE) scan (400x400, 130 slices, 1 × 1 × 1mm voxels, TR = 5.8 ms, TE = 2.7
ms).
Voxel-based morphometry (VBM) was performed on structural MR images to determine
increases and decreases in GM volume between baseline and 9 months. As implemented in
FSL-VBM Version 1.1, the VBM (Douaud et al., 2007), protocol included removal of non-

138

brain tissue from each participant’s images, tissue segmentation into GM, spatial
normalization (non-linearly to MNI 152) at 2 x 2 x 2 mm3 resolution and (non-linear)
registration to a right-left symmetric, study-specific GM template (average of all individual
grey matter images). These images were modulated and then smoothed with a Gaussian
kernel of ~4.6mm full width half maximum (FWHM).
Cognitive and Executive Function Measures
Cognitive performance was evaluated at baseline and at nine months using a variety of
cognitive measures previously shown to be sensitive in HD (Stout et al., 2012; Tabrizi et al.,
2013). The Colour Word Interference Test (CWIT) and Trail Making Test components of the
Delis-Kaplan Executive Function System (D-KEFS) (Delis et al., 2001; Delis et al., 2004)
were used to examine response inhibition and cognitive flexibility. The Symbol Digit
Modalities Test (SDMT) (Smith, 1982) was used to examine information processing speed
and attention. Verbal learning and memory were examined used the Hopkins Verbal Learning
Test-Revised (HVLT-R) (Brandt, 1991). All cognitive assessments were performed by
cognitive raters blinded to the treatment condition.
6.4 STATISTICS
Demographic data are given as means and standard deviations. We used linear regression to
estimate the increase or decrease in GM volume between baseline and 9 months. The
regression model included separate explanatory variables for each participant (for each
subject's mean effect) and age. Analysis was focused on regions of interest (ROIs) defined a
priori based on previous studies in HD shown to be functionally relevant in terms of
cognitive capacity (as reflected in episodic memory performance). ROIs included the
striatum, hippocampus, and dorsolateral prefrontal cortex (DLPFC). Inferential statistics were
carried out using a non-parametric permutation method (as implemented by FSL’s randomise
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tool). Only clusters with >10 contiguous voxels at a significance level of p<0.05 were
considered to be indicative of significant longitudinal change. As we adopted an exploratory
analysis strategy with ROIs clearly defined a priori, no correction for multiple comparisons
was applied. GM volume change was also evaluated beyond the ROIs. In this case, maps
were thresholded at p<0.01 (uncorrected) and voxels were considered significant within
clusters of >10 contiguous voxels. The normality of cognitive data was assessed using the
Schapiro-Wilk test. Changes in cognitive performance were assessed using mean values at
baseline and at nine months with paired t-tests. Statistical significance was set at (p≤0.05).
All statistical analyses were performed using STATA 9.1 (Stata Corp, 4905 Lakeway Dr,
Texas 77845 USA). We then investigated the functional relevance of change in GM volume
in the ROIs, as reflected by associations between significant volume changes and significant
change in performance measures from the HVLT-R (follow-up score minus baseline score):
total recall, delayed recall, retention and the recognition discrimination index (RDI). The
HVLT-R was chosen as dysfunction in recall and recognition memory is an important clinical
feature of HD (Montoya et al., 2006). In order to quantify GM volume change, we created a
single difference image for each participant by subtracting the follow-up from the baseline
smoothed, modulated image generated by the VBM protocol. The relationship between
volume change in ROIs and change in cognitive function was then assessed voxel-wise by
means of FSL’s randomise tool. Age was included as a covariate in all analyses.
6.5 RESULTS
6.5.1 Demographics
Table 6.1 displays demographic data and information on disease duration, disease burden and
severity of motor abnormalities. Participants displayed high adherence to the supervised
clinical program (84.2%), moderate adherence to the home-based program (58.6%) and high
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adherence to occupational therapy sessions (79.2%).
6.5.2 Structural brain changes
Figure 6.1 shows significant volumetric increases in GM in the DLPFC bilaterally and in the
tail of the right caudate nucleus after multidisciplinary rehabilitation. All remaining ROIs,
including the right hippocampus, left putamen and accumbens showed GM volume loss.
Beyond these ROIs, changes in GM volume were also observed. The superior thalami, left
inferior temporal pole, right subcallosal cortex and parasagittal primary motor areas exhibited
increases in GM volume. By contrast, the left anterior insula, right posterior
cingulate/precuneus, left lateral occipital cortex, subcallosal cortex and focal areas in the
temporal cortex bilaterally showed GM volume loss (Figure 6.2), consistent with previous
neuroimaging studies in individuals with HD (Dominguez et al., 2013; Georgiou-Karistianis
et al., 2013a; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013).
6.5.3 Cognitive and executive function changes
Significant improvement was observed on the delayed recall (number of words recalled after
delay) component of the HVLT-R after nine months of multidisciplinary rehabilitation (see
Table 6.2). No significant changes were found for CWIT, TMT and SDMT outcomes after
nine months of multidisciplinary rehabilitation (see Table 6.2).
6.5.4 Correlation analyses
Increased GM volume in the DLPFC (bilaterally) was found to be significantly associated
with preserved performance on the RDI of the HVLT-R (see Figure 6.1).

141

Figure 6.1 Significant GM volume changes after multidisciplinary rehabilitation in individuals with manifest HD
a) Significantly increased GM volume in the DLPFC and right caudate nucleus tail after nine months of multidisciplinary rehabilitation in
individuals with HD (red-yellow), and a significant correlation between increased GM volume in DLPFC and preserved performance on the RDI
task (green). Results are displayed on the study specific template normalized to MNI space (p<0.05, uncorrected). b) Scatterplot illustrating the
correlation between increased DLPFC volume at the peak voxel and preserved performance on the RDI task
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Figure 6.2 Whole brain GM volume changes in individuals with manifest HD
Results of the VBM analysis beyond the ROIs after nine months of multidisciplinary rehabilitation. GM volume loss in blue; GM volume
increases in red-yellow. Results are displayed on the study specific template normalized to MNI space (p<0.01, uncorrected)
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Table 6.2 Changes in cognitive function after nine months of multidisciplinary rehabilitation
in individuals with manifest HD.
Outcome Measures

Baseline (n=15)

Post-trial (n=15)

p value

Colour naming

48.35 ± 18.86

52.35 ± 22.57

p=0.0999

Word reading

34.00 ± 10.97

35.35 ± 9.77

p=0.3249

Inhibition

91.00 ± 39.25

93.57 ± 41.39

p=0.4525

Visual scanning

38.76 ± 15.76

43.52 ± 15.98

p=0.1149

Number sequencing

55.73 ± 19.87

61.80 ± 23.49

p=0.0507

Letter sequencing

61.92 ± 34.05

66.21 ± 30.77

p=0.1262

Motor speed

58.75 ± 27.39

62.31 ± 25.90

p=0.2433

Free recall

17.66 ± 5.56

16.73 ± 6.21

p=0.2019

Delayed recall

4.92 ± 2.36

6.28 ± 3.14

p=0.0130*

Retention

76.16 ± 29.21

81.22 ± 27.32

p=0.1866

Recognition

8.06 ± 3.08

8.93 ± 2.34

p=0.0793

Correct written

27.00 ± 10.25

26.78 ± 9.96

p=0.4525

Correct oral

31.00 ± 14.17

28.46 ± 15.59

p=0.1374

CWIT

TMT

HVLT-R

SDMT

CWIT, Colour Word Interference Test; TMT, Trail Making Trials; HVLT-R, Hopkins Verbal
Learning Test-Revised; SDMT, Symbol Digits Modalities Test. Significance was set at
*p<0.05
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6.6 DISCUSSION
This exploratory investigation has shown that multidisciplinary rehabilitation is capable of
increasing GM volume and enhancing some aspects of cognitive function in HD.
Specifically, we found evidence of increased GM volume in the right caudate and bilaterally
in the DLPFC, as well as an improvement in verbal learning and memory after nine months
of multidisciplinary rehabilitation. We also found a significant association between increased
GM volume in the DLPFC and preserved performance in verbal learning and memory.
Similar to previous investigations in HD, we observed GM volume loss in most cortical and
subcortical brain regions (Dominguez et al., 2013; Georgiou-Karistianis et al., 2013a; Hobbs
et al., 2011; Kassubek et al., 2005; Kipps et al., 2005; Mühlau et al., 2007; Mühlau et al.,
2009; Peinemann et al., 2005; Tabrizi et al., 2012; Tabrizi et al., 2011b; Tabrizi et al., 2013).
In this study however, after multidisciplinary rehabilitation, we also observed increased GM
volume in the DLPFC and in the right caudate nucleus in individuals with manifest HD.
While this is the first study to report such a finding, recent work has shown that cognitive
reserve (computed as the composite of intelligence and educational status) influences the rate
of volume loss in caudate and putamen structures in individuals with pre-manifest HD
(Bonner-Jackson et al., 2013b). Moreover, environmental enrichment has been shown to
preserve peristriatal cerebral volume in the R6/1 HD mouse model (van Dellen et al., 2000).
Motor and cognitive interventions have additionally been shown to increase hippocampal
volume, white matter and grey matter volume as well as cortical thickness in the left middle
frontal gyrus, inferior frontal gyrus, superior temporal gyrus in the elderly and those with
other neurodegenerative disorders (Bonzano et al., 2014; Boyke et al., 2008; Burciu et al.,
2013; Engvig et al., 2010; Engvig et al., 2012; Erickson et al., 2010; Erickson et al., 2011;
Lövdén et al., 2012; Prosperini et al., 2014b; Sehm et al., 2014). These findings provide
evidence to suggest that lifestyle factors play an important role in modulating the pathology
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and clinical profile of HD.
The structural brain changes observed in the present study and others may reflect an increase
in neurogenesis and/or favourable changes to neuronal morphology (Lazic et al., 2006;
Nithianantharajah et al., 2009; Nithianantharajah and Hannan, 2013). This supposition stems
from compelling evidence showing that environmental enrichment can increase markers of
neurogenesis within the hippocampus (Lazic et al., 2006) as well as increase the diameter of
dendritic spines in the R6/1 HD mouse model (Nithianantharajah et al., 2009). Molecular and
cellular mechanisms that may have encouraged the surmised neurogenesis and/or alterations
in neuronal morphology in response to multidisciplinary rehabilitation include an increased
expression of neurotrophins like brain derived neurotrophic factor (BDNF), enhanced
cerebral angiogenesis, and a decrease in elevated circulating glucocorticoids (i.e. cortisol)
(Rothman and Mattson, 2013). BDNF enhances neurite outgrowth, synaptogenesis and cell
survival, encouraging neurogenesis and experience-dependent synaptic plasticity (Rothman
and Mattson, 2013). Recent preclinical data suggests that BDNF-dependent neurogenesis is
tightly coupled with cerebral angiogenesis (Chen et al., 2013), and that both are dynamically
modulated by changes in circulating glucocorticoid levels (Gray et al., 2013a; Shikatani et al.,
2012; Weinstein et al., 2010). In particular, elevated glucocorticoid levels dampen cerebral
angiogenesis and BDNF expression in healthy rodent’s facilitating a decrease in neurogenesis
(Gray et al., 2013a; Rothman and Mattson, 2013; Shikatani et al., 2012). It is possible that
multidisciplinary rehabilitation facilitates an adaptive stress response that decreases
circulating glucocorticoids, thereby enhancing cerebral angiogenesis and BDNF expression,
encouraging neurogenesis and structural brain changes in HD patients.
There are currently no therapies that arrest or attenuate the progressive loss of cognitive
function seen in individuals with HD. Here we found evidence of an improvement in verbal
learning and memory after nine months of multidisciplinary rehabilitation. These findings
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extend on our previous work, where task-specific improvements in processing speed
measures were found after a nine month controlled investigation of multidisciplinary
rehabilitation in individuals with manifest HD (Thompson et al., 2013). Moreover, these
findings support experimental studies documenting improvements in cognitive performance
in rodent models of HD after environmental enrichment (Wood et al., 2010; Wood et al.,
2011). While evidence is limited in HD, an increasing number of studies are showing that
motor and cognitive interventions positively impact on cognitive function in the elderly
(Bherer et al., 2013; Erickson et al., 2011; Liu-Ambrose et al., 2010) and those suffering with
MCI (Hampstead et al., 2011; Hampstead et al., 2012; Smith et al., 2013), MS (Flavia et al.,
2010; Mattioli et al., 2010; Shatil et al., 2010; Solari et al., 2004) and PD (Calleo et al., 2011;
París et al., 2011; Sammer et al., 2006). It is likely that the improvements in verbal learning
and memory observed in this study resulted from the positive impact of multidisciplinary
rehabilitation on caudate and DLPFC structures.
It is well known that degeneration of GM contributes to the development of cognitive deficits
and progressive loss of cognitive function (Harrington et al., 2014; Scahill et al., 2013). In
this study, we found a significant association between increases in GM volume in the DLPFC
and preserved performance in verbal learning and memory. This finding is not unexpected
given that memory retrieval and recognition is driven primarily by DLPFC connectivity in
healthy individuals and in those with HD (Georgiou-Karistianis et al., 2013b).
A number of limitations must be taken into account when considering our findings. First,
there was no control group, which limits our ability to derive definitive conclusions on the
efficacy of multidisciplinary rehabilitation on disease pathology and clinical features in HD.
Second, the small sample of HD participants in this study makes generalizability difficult.
Lastly, participants remained on medication throughout the study, which may have
influenced the therapeutic response to multidisciplinary rehabilitation.
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Despite these limitations, our findings provide the very first evidence that multidisciplinary
rehabilitation is effective in increasing regional GM volume in cortical and subcortical brain
regions in HD. Results also show that multidisciplinary rehabilitation is capable of improving
some aspects of cognition over a nine month period. Moreover, we found that increased GM
volume in the DLPFC was associated with preservation of verbal learning and memory.
These findings collectively indicate that neuroplasticity may still be present in HD and
amenable to multidisciplinary rehabilitation. Future randomised controlled trials with larger
sample sizes, longer duration interventions, more comprehensive imaging and cognitive
outcomes and appropriate detraining periods are nevertheless required to confirm and expand
on our preliminary findings.
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6.8 SUPPLEMENTARY DATA
Supplementary Table 6.3 Exercises used in the clinical exercise program throughout the
study
Exercise
Mode
Active Warm
Up

Aerobic
Exercise

Resistance
Exercise

Exercises
Utilised
Walking
(Treadmill)
Cycling
(Ergometer)
Step ups
Walking
(Treadmill)
Cycling
(Ergometer)

Multi/Single
Joint
Exercises
Not
Applicable

Duration

Intensity

3-5
minutes

40-60%

Not
Applicable

8-10
minutes

Leg Press

Multi-joint

40
minutes

Knee
Extension

Single-joint

Knee Flexion

Single-joint

Leg
Abduction/
Adduction

Single-Joint

Lat Pull
Down

Multi-joint

Supported
Row

Multi-joint

Chest Press

Multi-joint

Abdominal
Crunches

Single-Joint

Walking
(Treadmill)
Not
Cool Down
Cycling
Applicable
(Ergometer)
Reps, Repetitions, kg, kilograms
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3-5
minutes

60-80%

60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps
60-80%
2-4 Sets
8-12 Reps

Progression
Increase warm
up intensity
Decrease
recovery period
Increase intensity
% (cadence/
resistance)
Increase training
volume (kg)
Increase training
volume (kg)
Increase training
volume (kg)
Increase training
volume (kg)
Increase training
volume (kg)
Increase training
volume (kg)
Increase training
volume (kg)

60-80%
2-4 Sets
8-12 Reps

Increase training
volume
(additional
weight)

40-60%

Not Applicable

Supplementary Table 6.4 Exercises used in the home-based exercise program throughout
the study
Exercise
Mode

Fine Motor

Resistance
Exercise

Exercises Utilised

Multi/Single
Joint
Exercise

Duration

Laser tracing
Button tying
Speed/Accuracy
trade-off

Not
Applicable

15 minutes

Knee
Extension/Flexion

Single Joint

45 minutes

Wall Push

Multi-joint

Leg Abduction/
Adduction

Single-joint

Row

Multi-joint

Abdominal
Crunches

Single-joint

ROM, range of motion
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Progression
Increase the
difficulty of
objects traced
Increase the
number and vary
the size of the
buttons tied
Decrease shape
size in the
speed/accuracy
trade-off tasks
Increase
resistance
(Sanctbands)
Progress to pushups on knees and
then to full ROM
push-ups
Increase
resistance
(Sanctbands)
Increase
resistance
(Sanctbands)
Increase time in
eccentric and
concentric
contraction phases

Supplementary Table 6.5 Exercises used in occupational therapy sessions throughout the
study
Exercise Modality

Tasks Utilised

Progression
Increase difficulty of cooking

Cooking
Perform laundry without cues
Laundry
Daily Activities
Gardening

Eating

Planning/Organisation

Utilisation of a diary
(written or
electronic)
Planning social
activities

Memory

Facial Recognition

Increased gardening to an
independent state
Improve the use and
manipulation of eating
utensils
Increase the number and
difficulty of tasks throughout
the day

Increase the number of faces
to be recognised

Sudoku

Increase the difficulty of the
Sudoku game

Board Puzzles

Increased the difficulty and
size of puzzle

Boggle

Include time constraints

Mastermind

Include time constraints

Problem Solving
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CHAPTER 7 – GENERAL DISCUSSION & FUTURE DIRECTIONS
Despite intense scientific efforts, there is still no cure or disease modifying strategy for HD,
and available pharmaceutical agents only provide partial relief of psychiatric and involuntary
motor features (Dominguez and Munoz-Sanjuan, 2014; Mason and Barker, 2009; Pidgeon
and Rickards, 2013). Lifestyle factors are known to influence the structure of the brain as
well as the onset and progression of clinical features in people living with HD (BonnerJackson et al., 2013b; Georgiou et al., 1999; Lopez-Sendon et al., 2011; Trembath et al.,
2010; Wexler, 2004). Lifestyle enrichment strategies, particularly multidisciplinary
rehabilitation may therefore have desirable effects on clinical and neuropathological aspects
of HD. Currently, there is only a handful of exploratory studies that have evaluated the
effects of multidisciplinary rehabilitation on clinical aspects of HD (Piira et al., 2013;
Veenhuizen et al., 2011; Zinzi et al., 2007). Considering the potential benefits of
multidisciplinary rehabilitation for patients, as well as the lack of inherent side effects and the
necessity for a better multidisciplinary care model for HD, it is obvious that further
investigations are warranted.
The work presented in this thesis is therefore timely. The central aim of this thesis was to
determine the clinical utility of multidisciplinary rehabilitation on clinical and
neuropathological aspects of HD (Chapters 4, 5 and 6). In order to design a comprehensive
multidisciplinary rehabilitation intervention, and because balance and mobility are two of the
most debilitating aspects of HD, the factors contributing to impairments in mobility and
balance were investigated first of all (Chapter 2) (Cruickshank et al., 2014). Published
rehabilitation strategies, with favourable effects on mobility and balance in other
neurodegenerative disorders, were also investigated through a literature search (Chapter 3).
As a result of our investigations in study 1, lower extremity muscle weakness and the decline
in specific cognitive abilities (processing speed, attention, cognitive flexibility, response
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inhibition) were found to predict balance and mobility impairments in people with manifest
HD (Cruickshank et al., 2014). Our findings were in line with previous reports in PD and MS
(Broekmans et al., 2013b; D'Orio et al., 2012; Paul et al., 2013b; Sosnoff et al., 2013a). For
example, Paul et al (2013b) reported that lower extremity muscle power significantly predicts
balance and mobility performance in PD and more recent evidence has shown that cognitive
deficits also contribute to mobility impairments in PD (Gurevich et al., 2014). Moreover,
recent studies indicate that lower extremity strength is a significant predictor of mobility in
patients with MS (Broekmans et al., 2013a). Deficits in processing speed and innate
intelligence have also been documented to predict mobility outcomes in patients with MS
(D'Orio et al., 2012). These findings collectively infer that some commonality exists between
the outlined neurodegenerative disorders with respect to the clinical factors underpinning
balance and mobility impairments. It is therefore likely that rehabilitation interventions with
favourable effects on balance and mobility in neurodegenerative disorders like PD and MS
will be beneficial for HD patients.
An emerging body of evidence indicates that resistance exercise is beneficial for people with
neurodegenerative disorders (Corcos et al., 2013; Dalgas et al., 2013; Medina-Perez et al.,
2014; Shulman et al., 2013). Consensus regarding the efficacy of resistance exercise for
neurodegenerative populations nevertheless requires further elucidation. As part of this thesis,
a systematic investigation of the effects of resistance exercise as a therapy for people with
neurodegenerative disorders was performed. An intensive systematic literature search for
studies of resistance exercise in neurodegenerative disorders only identified studies in PD and
MS. A critical appraisal of the identified studies revealed that resistance exercise has
favourable disease dependent effects on muscle strength, mobility, balance, clinical disease
progression, fatigue, functional capacity, quality of life, disease biology, electromyography
activity, mood, skeletal muscle mass and architecture (Bloomer et al., 2008; Broekmans et
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al., 2011; Corcos et al., 2013; Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas et al., 2010b;
Dalgas et al., 2013; DeBolt and McCubbin, 2004; Dibble et al., 2006; Dibble et al., 2009;
Dodd et al., 2011; Fimland et al., 2010; Hass et al., 2012; Medina-Perez et al., 2014; Paul et
al., 2014; Sage et al., 2011; Schilling et al., 2010; Shulman et al., 2011). As expected, the
most robust effects were found for muscle strength outcomes. Interestingly, a meta-analysis
of changes in muscle strength revealed greater effects for people with PD. Different
pathological mechanisms underpinning each neurodegenerative disorder likely account for
the outlined discrepancy in the magnitude of muscle strength changes. Importantly,
improvements in mobility were reported in a number of the included PD studies. Individuals
suffering with HD display similar strength and mobility deficits. In line with our results in
HD from study 1 and the results of our systematic review (study 2), it can be surmised that
resistance exercise would have favourable effects on muscle strength and in turn mobility in
people with HD.
The outlined findings from study 1 and 2 informed our decision to incorporate resistance
exercise into our multidisciplinary rehabilitation intervention along with other rehabilitation
components including aerobic exercise, physical therapy and cognitive rehabilitation. The
latter rehabilitation components were selected given their favourable effects on brain
structure and function, functional capacity and cognitive abilities in the elderly and
individuals with neurodegenerative disorders (Colcombe et al., 2006; Erickson et al., 2010;
Erickson, 2013; Erickson and Kramer, 2009; Erickson et al., 2012; Erickson et al., 2011;
Filippi et al., 2012; Khalil et al., 2013; Nombela et al., 2011).
As previously outlined, the central aim of this thesis was to evaluate the clinical utility of
multidisciplinary rehabilitation on clinical and neuropathological aspects of HD. To the best
of our knowledge, this was the first controlled trial of multidisciplinary rehabilitation in
people with HD. Data from this trial showed that multidisciplinary rehabilitation is safe, well
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tolerated and well received by patients with HD. From a clinical standpoint, the data showed
that multidisciplinary rehabilitation can improve muscle strength, self-perceived balance and
body composition outcomes (Thompson et al., 2013). A preservation of mobility was also
observed.
The significant improvements observed in muscle strength were somewhat expected given
the large resistance exercise component of the multidisciplinary rehabilitation intervention.
This finding is nevertheless of clinical importance, especially considering the wealth of data
showing that muscle strength predicts functional capacity and falls in neurodegenerative
disorders, including HD (Aziz and Roos, 2013; Cruickshank et al., 2014; Padilla et al., 2006;
Paul et al., 2013a; Paul et al., 2013b). The improved muscle strength in the intervention
participants contrasted strongly with a static level of muscle strength in the no intervention
controls. Importantly, contrary to previous evidence declines in muscle strength were not
observed in the control group (Busse et al., 2008). This indicates that declines in muscle
strength may not be a universal feature of HD, but rather may reflect deconditioning that has
taken place over many years as individuals become progressively immobilised.
An improvement in balance confidence accompanied increases in muscle strength in the
intervention participants (Thompson et al., 2013). We did not however find favourable effects
on other balance measures (Berg Balance Scale and dynamic computerised posturography).
The Berg Balance Scale and dynamic computerised posturography have been shown to be
reliable and valid measures of static and dynamic balance in patients with HD (Kloos et al.,
2014; Quinn et al., 2013). These results indicate that patient perceived improvements in
balance do not reflect actual balance improvements. This may in part be due to a lack of
insight which has been previously documented in patients with HD. Our findings, at least in
part, contrast with previous work. For example, Piira et al (2013) reported significant
improvements in balance in patients with HD after intensive intermittent multidisciplinary
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rehabilitation using the Berg Balance Scale. Methodological differences likely account for the
outlined discrepancy in findings. In particular, Piira et al (2013) used a larger cohort of
patients with HD and incorporated formalised balance training exercises into their
intervention.
In contrast to previous work (Piira et al., 2013; Zinzi et al., 2007), we did not observe
improvement on mobility outcomes. Instead, we found that patients randomised to the
intervention group maintained their level of performance on mobility tasks, while those in the
control showed deterioration on several mobility outcomes. This suggests that mobility may
be preserved by multidisciplinary rehabilitation. In an earlier study, Zinzi et al (2007) found a
significant improvement in mobility in a small sample of HD patients after an intensive
intermittent multidisciplinary rehabilitation intervention. More recently, Piira et al (2013)
reported a significant improvement on mobility outcomes in a larger sample of HD patients,
using a similar intervention protocol. The outlined differences in findings may be attributed
to differences in the intervention intensity. Piira et al (2013) and Zinzi et al (2007) used an
intensive intermittent multidisciplinary rehabilitation intervention, whereas the current study
used a longer duration moderate intensity multidisciplinary rehabilitation approach. Emerging
evidence suggests that intensive rehabilitation interventions may produce more robust motor
benefits in those with neurodegenerative disorders (Frazzitta et al., 2012a; Frazzitta et al.,
2012b; Frazzitta et al., 2013).
Significant increases in body weight, lean tissue and fat mass were also important findings of
our study (Thompson et al., 2013). Weight loss, skeletal muscle atrophy (Farrer and Meaney,
1985; Farrer et al., 1985; Trejo et al., 2004; van der Burg et al., 2009) and adipose tissue
alterations (van der Burg et al., 2009) are well reported features of HD. Weight loss is
closely associated with a faster rate of disease progression (Aziz and Roos, 2013; Myers et
al., 1991; van der Burg et al., 2009). The favourable changes to weight observed in this study
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may therefore have a positive effect on disease progression, however this remains
speculative, and subject to future investigation. Alterations in metabolic, endocrine signalling
and immune pathways as well as a reduction in ghrelin-producing neurons in the stomach
have all been implicated as pathological mediators of changes in body composition (van der
Burg et al., 2008). Recent evidence indicates that elevated levels of stress may also mediate
abnormal changes in body composition (Du et al., 2014). Multidisciplinary rehabilitation may
positively impact on these mediators of weight loss, thereby improving or forestalling
pathological changes in body composition. In line with this, exercise has been shown to
upregulate ghrelin (Markofski et al., 2014), suppress leptin release (Ko and Choi, 2013;
Lichtenstein et al., 2014; Rämson et al., 2012), exert anti-inflammatory effects (Gleeson et
al., 2011) and reduce psychological stress (Greenwood and Fleshner, 2011; Puterman et al.,
2010) in healthy adults.
Exploratory data additionally showed, for the first time, that multidisciplinary rehabilitation
can increase GM volume in structures known to degenerate in people with HD. While
structural increases in brain volume have not been reported previously in HD patients,
preclinical studies have shown that environmental enrichment can preserve peristriatal
structures in transgenic HD mice (van Dellen et al., 2000). Motor and cognitive interventions
have additionally been shown to increase hippocampal volume as well as preserve white
matter and grey matter volume in elderly people (Boyke et al., 2008; Engvig et al., 2010;
Engvig et al., 2012; Erickson et al., 2010; Erickson et al., 2011). Exploratory findings from
this study also showed that multidisciplinary rehabilitation can increase GM volume in a
region dependent manner in patients with HD. Significant increases in GM volume were
observed in the caudate nucleus and DLPFC of patients after multidisciplinary rehabilitation
and were associated with verbal learning and memory. These findings are of clinical
relevance for several reasons. First, the increases in GM volume were observed in structures
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known to degenerate in people with HD (Dominguez et al., 2013; Georgiou-Karistianis et al.,
2013a; Hobbs et al., 2011; Kipps et al., 2005; Tabrizi et al., 2013). Second, a significant
improvement in verbal learning and memory has not been reported previously in patients
with HD after any therapy (Mason and Barker, 2009; Piira et al., 2013; Venuto et al., 2012).
Lastly, the significant association between increases in GM volume in the DLPFC and verbal
learning and memory performance indicates that structural brain changes can occur in
association with multidisciplinary rehabilitation with a clinically meaningful impact.
While multidisciplinary rehabilitation was found to improve some motor, body composition,
cognitive and neuropathological outcomes, we found no improvement in mood, quality of life
and bone mineral density. A number of cognitive outcomes also remained unchanged as did a
number of brain structures that displayed GM volume losses. While unfavourable, this latter
finding is in line with previous observational evidence reporting GM volume losses in
cortical and subcortical structures (Georgiou-Karistianis et al., 2013a; Georgiou-Karistianis et
al., 2013c; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013). Our inability to find
significant changes in mood was not surprising considering that BDI data showed no
evidence of a depressive syndrome in study participants at baseline (Thompson et al., 2013).
A lack of changes on the SF-36 was somewhat unexpected. Previous studies have reported
mixed findings with respect to the effects of rehabilitation on quality of life outcomes in
manifest HD. Piira et al (2013) reported a significant improvement on the physical
component, but not mental component of the SF-36 in a large cohort of HD patients after a
one year intensive intermittent multidisciplinary rehabilitation intervention. In another study,
Khalil et al (2013) reported no significant changes on the SF-36 in HD patients following a
short physical therapy intervention. The small sample size used in this study coupled with the
generic nature of the SF-36, likely accounts for our inability to find significant changes in
quality of life. Studies with larger samples using an HD specific quality of life assessment are
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required to appropriately assess the efficacy of multidisciplinary rehabilitation on quality of
life in individuals with manifest HD.
The inability to find significant changes in bone mineral density in this study was also
unexpected. However, it is important to note that no changes in bone mineral density were
observed in the control group at the completion of the study. This suggests that bone mineral
density is perhaps not an ideal biomarker, particularly given the duration of the current study.
Previous work has shown that individuals with pre-manifest HD display lower bone mineral
content relative to healthy age matched controls (Goodman and Barker, 2011). Moreover,
preclinical studies have documented a lower bone mineral density in the R6/2 mouse model
(Björkqvist et al., 2006). However, there is no data on longitudinal changes in bone mineral
density in people with HD. It is possible that changes in bone mineral density manifest over
many years as result of sedentary behaviour and taking medication (Bonelli et al., 2002) (or
may in some way just relate to gene status). With this in mind, it may be possible to find
favourable changes in bone mineral density using longer duration interventions. In support of
this, recent evidence showed that high intensity resistance exercise interventions over twelve
months increases bone mineral density in older adults (Kemmler et al., 2010) .
With the exception of verbal learning and memory, there was no evidence of performance
improvements on other cognitive domains. However, it is important to note that significant
deterioration on cognitive outcomes was not observed in the control group. These findings
were not unexpected, especially considering the slow temporal profile of cognitive
deterioration in people with HD, and the small sample of HD patients used in the current
study. A recent study by Stout et al (2012), reported that only the SDMT, Circling Tracing
Indirect and Stroop Word Reading assessments show robust evidence of cognitive
deterioration over 12 months in early HD. However, for these assessments sample size
estimates for a 50% effective treatment, 90% power and two tailed p<0.05 group
160

comparisons were estimated to be 150 (SDMT), 289 (Circling Tracing Indirect) and 337
(Stroop Word Reading). Evidence also indicates that these assessments are strongly
influenced by motor control (handedness, speech and ocular control) and psychiatric
symptom severity (Eddy and Rickards, 2014), limiting the validity of these measures for
assessing cognitive capacity in HD. Future rehabilitation studies aimed at improving
cognitive function require more careful methodological considerations, particularly with
respect to the sample size, selection of cognitive assessments (minimise time dependent
tasks) and duration of intervention utilised.
Beyond the caudate nucleus and DLPFC, GM volume loss was observed in the left anterior
insula, right posterior cingulate/precuneus, left lateral occipital cortex, subcallosal cortex and
focal areas in the temporal cortex. This is in line with findings from many prospective
observational trials (Georgiou-Karistianis et al., 2013a; Georgiou-Karistianis et al., 2013c;
Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013). These findings affirm the
usefulness of structural imaging as a biomarker for prospective treatment trials. In addition,
these results illuminate the possibility that multidisciplinary rehabilitation may exert regiondependent effects on the brain. Favourable region-dependent effects on hippocampal volume
have been documented previously after a one year aerobic exercise intervention in older
adults (Erickson et al., 2011). Combining rehabilitation strategies with different positive
region-dependent effects may therefore provide more robust benefits for brain structures
overall.
The work presented in this thesis is not without limitations. First, the sample size was small,
therefore the findings from this study cannot be generalised to the wider HD community.
Second, the work presented in this thesis only included individuals with mild to moderate
HD. Individuals with advanced HD were not included in the present work owing to their
inability to perform necessary outcome measures and many of the programmed
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multidisciplinary rehabilitation exercises. As such, our findings are not reflective of nor can
they generalised to the entire spectrum of manifest HD. Third, studies lacked a long term
follow up period, which precludes the possibility of examining the duration of benefits from
multidisciplinary rehabilitation. Fourth, study five did not include a control group limiting the
significance of the reported findings. However, given that there is a wealth of evidence
showing degeneration in the caudate nucleus and DLPFC, and no proven therapies with
neurorestorative effects, our findings are of clinical significance and warrant further
investigation.
7.1 Future Directions
Studies exploring the effects of multidisciplinary rehabilitation for people living with HD are
only in their infancy (Piira et al., 2013; Thompson et al., 2013; Veenhuizen et al., 2011; Zinzi
et al., 2007). The present research confirms and expands on previous reports documenting
significant improvement in clinical aspects of HD (Piira et al., 2013; Thompson et al., 2013;
Zinzi et al., 2007). This research also provides novel experimental evidence showing that
multidisciplinary rehabilitation can increase GM volume in the caudate nucleus and DLPFC.
Finally, this research shows that increases in GM volume are related to performance on
verbal learning and memory tasks. More work is nevertheless required to explore the clinical,
neurological and biological effects of multidisciplinary rehabilitation for people with HD.
Additional research is also required to identify the most therapeutically effective
rehabilitation components of multidisciplinary treatments for people living with HD. With
this is mind, the following section outlines future directions that should be undertaken to
improve the quality of evidence on multidisciplinary rehabilitation as a therapy for HD.
The work presented in this thesis and previous studies has shown that multidisciplinary
rehabilitation can improve clinical aspects of HD (Piira et al., 2013; Thompson et al., 2013;
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Veenhuizen and Tibben, 2009; Zinzi et al., 2007). In particular, significant improvements in
motor function, body composition, mood, anxiety, physical quality of life and verbal learning
and memory have been reported after multidisciplinary rehabilitation in patients with HD
(Piira et al., 2013; Thompson et al., 2013; Zinzi et al., 2007). Methodologically robust studies
with larger sample sizes, highly sensitive outcome measures, multiple assessment time points
at baseline, more effective cognitive training exercises, longer duration interventions, and
adequate follow up periods are nevertheless required to confirm and expand on this. Areas
that warrant expansion include assessing the effects of multidisciplinary rehabilitation on
sleep physiology, autonomic function, sexual behaviour, stress reactivity and cardiovascular
function. These latter physiological and psychological processes are known to be perturbed in
HD (Aziz et al., 2010a; Goodman et al., 2011; Jhanjee et al., 2011; Kobal et al., 2014; Mo et
al., 2014; Morton, 2013; Zielonka et al., 2014), and can severely impact on quality of life.
Observational evidence together with our exploratory findings indicates that lifestyle factors
influence structural brain changes in a region dependent manner in HD (Bonner-Jackson et
al., 2013b). Similar findings have been observed in other neurodegenerative disorders after
cognitive and motor training interventions (Bonzano et al., 2014; Prosperini et al., 2014a;
Sehm et al., 2014). These findings have significant clinical implications regarding the
selection and modulation of non-pharmacological treatments for individuals with
neurodegenerative disorders, particularly those with HD. Future studies should use targeted
multidisciplinary

rehabilitation

interventions,

encompassing

specific

rehabilitation

components, with known benefits on the clinical and/or biological outcomes of interest.
Significant volume loss can be observed in cortical and subcortical structures many years
before clinical signs can be detected (Georgiou-Karistianis et al., 2013b; GeorgiouKaristianis et al., 2013c; Georgiou-Karistianis et al., 2013d). This disconnect between
structural brain changes and clinical signs have led to the speculation that compensatory
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neural processes may be present during the early stages of disease (Georgiou-Karistianis et
al., 2013b). fMRI has the capacity to detect alterations in brain function and may enable
neural compensation mechanisms to be probed in HD (Gray et al., 2013b; Poudel et al., 2014;
Poudel et al., 2013). It would be interesting to explore the effects of multidisciplinary
rehabilitation on compensatory neural processes in individuals with pre-manifest and
manifest HD.
Longstanding evidence indicates that neuronal dysfunction precedes neuronal cell loss in HD
(Georgiou-Karistianis et al., 2013c). Recent advances in imaging methods have enabled the
quantification of neuronal dysfunction in pre-manifest and manifest HD, using fMRI
(Georgiou-Karistianis et al., 2013b; Gray et al., 2013b; Poudel et al., 2014; Poudel et al.,
2013). Emerging evidence in other neurodegenerative disorders has shown that cognitive and
motor training can have profound effects on neuronal function (Bonavita et al., 2014; Cerasa
et al., 2013; Chiaravalloti, 2012; Filippi et al., 2012; Nombela et al., 2011; Parisi et al., 2014;
Sastre-Garriga et al., 2011; van Paasschen et al., 2013). Future studies exploring the effects of
multidisciplinary rehabilitation on neuronal function in individuals at risk or with premanifest HD using fMRI methods would be of clinical interest.
Recent evidence by our group and others indicates that multidisciplinary rehabilitation exerts
favourable clinical and neurological benefits in people living with manifest HD (Piira et al.,
2013; Thompson et al., 2013; Veenhuizen et al., 2011; Zinzi et al., 2007). It is possible that
multidisciplinary rehabilitation exerts these benefits by positively impacting on disease
biology. Future studies investigating the effects of multidisciplinary rehabilitation on reliable
biological markers of disease progression, clinical status and brain health are warranted.
Candidate biological markers that could be utilised to assess the effects of multidisciplinary
rehabilitation on disease biology include mhtt (Baldo et al., 2012; Weiss et al., 2012), BDNF
(Zuccato et al., 2010), PGC-1α (Che et al., 2011; Taherzadeh-Fard et al., 2009), cortisol
164

(Shirbin et al., 2013a; Shirbin et al., 2013b; van Duijn et al., 2010), melatonin (Kalliolia et
al., 2014; van Wamelen et al., 2013) and cholesterol (Karasinska and Hayden, 2011; Leoni
and Caccia, 2014; Leoni et al., 2011).
Finally, it is important to identify which components of multidisciplinary rehabilitation
interventions produce favourable effects in people with HD. From a methodological
perspective this would involve examining the independent effects of each of the
multidisciplinary rehabilitation components (exercise [aerobic and resistance], dual task
training [cued motor training], cognitive training [computerised cognitive training, video
game playing, paper and pencil cognitive training, bilingual training and sign language
training], occupational therapy [cooking, planning and social organisation], speech and
language therapy, respiratory muscle training [inspiratory muscle training and expiratory
muscle training] and proprioceptive training) in people with HD. Data collected from such
studies would help optimise multidisciplinary rehabilitation programs for people living with
HD.

CHAPTER 8 – GENERAL CONCLUSION
The work presented in this thesis shows for the first time that multidisciplinary rehabilitation
can increase GM volume in structures known to degenerate in HD. Moreover, the present
work shows that multidisciplinary rehabilitation improves muscle strength as well as some
aspects of motor control, cognitive function and body composition. These findings, while
preliminary, have significant clinical implications with respect to the treatment of people with
manifest HD. Multidisciplinary treatment approaches may represent a viable therapeutic
avenue for people living with HD. Future studies are urgently required to confirm and expand
on our findings showing that multidisciplinary rehabilitation can have neurorestorative effects
and improve clinical aspects of HD.
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APPENDICES
Appendix 1 Huntington’s Disease Trangenic Mouse Models
Mouse
Model
(Strain)

Genetic
Characteristics

Repeat
Length

Behavioural Phenotype

Neurological Phenotype

Survival

Ref

10-13 weeks

(Mangiarini et al.,
1996)
(Carter et al., 1999)
(Davies et al., 1997)
(Turmaine et al., 2000)

32-40 weeks

(Mangiarini et al.,
1996)
(Carter et al., 1999)
(Davies et al., 1997)
(Turmaine et al., 2000)

Week 4.5 (wheel running
deficits)
Weeks 4-6 (hypoactivity;
open field testing)
R6/2

1kb sequence from exon 1
of the human HTT gene

~150

Week 5 (morris water maze
deficits)
Week 6 (rotarod deficits)

Decreased brain weight
Lateral ventricular enlargement
MSN dendrite diameter and
spine density decreases
NIIs appear by 4 weeks

11-13 weeks (visual learning
task deficits)

R6/1

1kb sequence from exon 1
of the human HTT gene

Week 13 (horizontal rod
deficits)
116

Week 18 (rotarod deficits)
Weeks 14-20 (clasping
phenotype)

N171-82Q

N-terminal fragments of
the first 171 AA of human
HTT (exons 1, 2 and part
of 3)

82

12 weeks (rotarod deficits)

HTT, Huntingtin gene, AA, amino acids, NIIs, neuronal intranuclear inclusion, MSN, medium spiny neuron
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NIIs appear by 20 weeks
32 weeks dendritic spine
atrophy

17 weeks striatal degeneration
ventricular enlargement

24-30 weeks

(Schilling et al., 1999)
(Luthi-Carter et al.,
2000)

Appendix 2 Participant Information Sheet
Project: The Effects of Environmental Enrichment on Clinical Measures of Disease
Progression and Quality of Life for Patients with Huntington’s Disease.
Senior Investigators: Prof Mel Ziman, Dr Jennifer Thompson, Mr Travis Cruickshank, Prof
Roger Barker, Dr Carmela Connor, Dr Joseph Lee, Prof Anthony Hannan, Dr Sonya Girdler,
Professor Rob Newton, Dr Stanley Lazic.
Please take time to read the following information carefully and discuss it with your friends,
family and clinician if you wish. Ask us any question if some part of the information is not
clear to you or if you would like more information. Please do this before you sign this consent
form.
Who is funding this study and where will it be conducted?
This study is a joint collaboration between Huntington’s WA (Inc.), Edith Cowan University,
the Neurosciences Unit, the Howard Florey Institute (Melbourne), the Centre for Brain
Repair at the University of Cambridge and the Brightwater Group, and it has been funded by
Lotterywest. It will be conducted at Edith Cowan University.
Contact persons:
Should you have any questions about the study you may contact:
Dr Jennifer Thompson: Phone 6304 5635 Email jennifer.thompson@ecu.edu.au or
Associate Professor Mel Ziman: Phone 6304 5171 Email m.ziman@ecu.edu.au
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All study participants will be provided with a copy of the Participant Information Sheet and
Participant Consent Form for their personal records.
You may decide to be in the study or not take part at all. If you do decide to take part in this
study, you may stop at any time or you may withdraw from any one procedure at any time.
However, before you decide, it is important that you understand why this research is being
done and what it will involve. Whatever your decision, this decision will not lead to any
penalty or affect your regular medical care or any benefit to which you are otherwise entitled.
The following Information Sheet will explain the study and will include details such as:
 What is the purpose of the study
 Why this trial might be suitable for you;
 The possible risks (side-effects) and benefits of the intervention;
 The nature of your participation;
 The type and frequency of any tests or procedures required by the trial;
 What are the costs to me;
 Your rights and responsibilities;
 What if something goes wrong;
 How will my safety be ensured;
 Will I find out the results of the study;
 Who is funding the study.
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What is the purpose of the study?
This study is a research project in which we are investigating the effects of mental and
physical stimulation (environmental enrichment) on the progression of Huntington’s disease.
This research project intends to implement a therapeutic intervention strategy for patients
with Huntington’s disease which is centred on mental and physical stimulation as a method
for reducing symptoms of the disease and improving quality of life for patients.
Why is this study suitable for me?
You have been invited to participate in this study because you have been diagnosed with
Huntington’s disease, and you currently display symptoms of the disease.
What are the possible benefits of taking part in this research study?
The results of this study may be of interest to you and your family, and you may decide on
whether or not the information may be disclosed to your family. You may experience an
improvement in the symptoms of your disease. Also, your participation in this research study
may assist researchers and health care providers to provide better treatment for people with
Huntington’s disease in the future.
How long will I be in this study and how will I participate?
If you agree to participate you will be randomly assigned to a research group with either a
therapeutic intervention strategy or no therapeutic intervention strategy, and you will
participate in a number of tests throughout the study to assess changes in the progression of
the disease. You will be asked to wear an Actiwatch throughout the study which measures
your physical activity, and provide blood/saliva samples at various stages of the research
study. Instigation of the study: Tests such as clinical assessment, questionnaires and
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MRI/DEXA (X-ray) scans will be performed at the beginning of the study as a baseline
measure of the status of the disease. You will be asked to provide a blood/saliva sample at
this stage.
6 months: You will be asked to undergo the same tests as above and provide a blood/saliva
sample.
6-18 months: Depending on the research group to which you are assigned, you may or may
not be treated for 12 months with an environmental enrichment intervention strategy which
will entail performing a number of physical and mental stimulation strategies each week. At
the end of a six month period, you will undergo clinical assessment and questionnaires. At
the end of the full intervention/no intervention period of 12 months, you will be asked to
undergo the final clinical assessment, questionnaires and MRI/DEXA (X-ray) scans, and
provide a blood/saliva sample.
Overall, participants will be involved for a period of 18 months. Participation will require
about 9 hours per week for the intervention strategy, and about 2 half days every six months
for the assessments. If you have a carer, they will also be asked to participate in this research
study.
What will happen if I decide to be in this study?
The study will be conducted over a 2 year period, with participants involved over 18 months.
Participants who are assigned to the intervention group will perform mental and physical
stimulation tasks over a 12 month period. These will be performed at Edith Cowan University
and at home. During this time, you will receive phone calls or visits from a trained scientist to
monitor your progress and participation in the research program.
As detailed above, you will take part in a variety of assessments throughout the study:170

 Clinical assessments will be performed by a neurologist to assess the status of the
disease. These assessments will be conducted at 0, 6, 12 and 18 months. These
assessments are mostly the same as the normal assessments you currently receive.
These assessments may be videorecorded for further analysis.
 You will complete questionnaires assisted by a trained scientist at 0, 6, 12 and 18
months. These questionnaires are mostly the same as the normal questionnaires you
currently participate in. If you have a carer, they will be asked to answer two
questionnaires at these times.
 MRI and DEXA (X-ray) scans will be performed at 0, 6 and 18 months.
 You will perform balance tests at 0, 6 and 18 months.
 Blood/saliva samples will be taken at 0, 6 and 18 months for physiological
assessment. The amount of blood taken will be small (20mls per visit). Blood will be
drawn into two tubes. You will be required to chew swabs a couple of times
throughout one day for saliva samples. Because your blood/saliva samples will only
be identifiable by a coded number, the researchers performing the tests will not know
which sample is yours. Samples will be analysed immediately and will not be stored
during the research study.
You may choose to attend voluntary workshops to be updated on the progress of the study
and to discuss with the research scientists any problems you or your family/carers may be
experiencing with the research study. You may contact the researchers at any time during the
study if you require any further general information.
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Are there any reasons I should not be in this study?
The clinical staff collaborating in this research study will discuss these with you in detail and
will ensure that this trial is both safe and appropriate for you.
What are the costs to me?
There will be no additional costs to you for participating in this research study. Blood
samples will be taken at Edith Cowan University when you visit for your assessments. All
transportation costs will be reimbursed by Edith Cowan University, or taxi vouchers will be
provided for travel to and from the University where necessary.
What are the possible benefits of taking part in this research project?
The results of this study may be of interest to you as the carer of a person with Huntington’s
disease. By participating in this research, you may be assisting patients to obtain an
improvement in the symptoms of their disease. Also, your participation in this research study
may assist researchers and health care providers to provide better treatment for people with
Huntington’s disease in the future.
How will my safety be ensured?
In this study, the sample that you provide is a blood or saliva sample and there is very little
risk to you in this procedure as only a small volume of blood or saliva is required for the test.
Exercise treatments will be supervised by an experienced exercise physiologist, and you will
be instructed on the correct warming up and cooling down procedures to minimise any
discomfort from the exercise regime. All occupational therapy tasks will be supervised by an
experienced occupational therapist. Scans will be performed by appropriately qualified health
care professionals. However, please do not hesitate to contact the study co-ordinator or your
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doctor in relation to any adverse effects you think you are experiencing. If the effects are
severe enough, your doctor may stop your participation in the study.
What alternatives do I have to going on this study?
Your participation in this research study is voluntary. This study will not affect your
treatment. Your treatment will continue in the same manner whether you decide to participate
in the study or not.
You may wish to discuss with your doctor or the researchers how the test will benefit patient
treatment in the future.
What are the possible side effects, risks and discomforts of taking part?
In this study, only a small volume of blood is taken (20 mls) at three different intervals
throughout the study. There is very little risk to you in this procedure as only a small volume
of blood is required. You may suffer a small amount of discomfort when you donate the
blood sample, like the feeling of a pinprick. The likelihood of side effects from donating
blood is small, around 1 in 100. However, should you suffer any side effects or experience
any new or unusual symptoms, please tell your doctor immediately.
There are minor risks associated with MRI and DEXA scans; the use of appropriately
qualified personnel reduces these risks. These risks will be discussed with you by a doctor.
You may experience minor discomfort during the performance of the physical exercises if
you participate in the intervention strategy. Should you experience excessive discomfort
during the performance of the physical exercises, or you do not feel comfortable, please
inform the exercise physiologist immediately.
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You may experience general body soreness if you participate in the exercise therapy. This is
normal after performing physical exercises that you are not used to. Should you suffer
excessive discomfort or experience any new or unusual symptoms, please tell your doctor
immediately.
The researchers acknowledge that should this intervention therapy prove to be unsuccessful,
or you do not experience as good a benefit as you anticipate you are going to achieve, that
you may feel depressed or unhappy. Throughout this project, levels of depression will be
assessed by a clinician and will be treated as the clinician deems necessary.
What if new information comes along during the study?
Sometimes, new information about an intervention or disease becomes available as a study
progresses. You will be told about any information that could be important to you and to your
decision to continue in the study. If you then want to continue in the trial, you may be asked
to sign a revised consent form.
Stopping the study early:
Sometimes a trial needs to be stopped early because of safety concerns, because the trial is
not effective enough, or for other reasons. If this occurs, the reasons will be explained to you
and your treatment will continue as it would have without the test. Your treatment will not be
influenced by participating in the research study in anyway.
What if something goes wrong?
You will receive the best medical care available during and after the intervention and/or tests.
However, unexpected results may be obtained. In the unlikely event of risks to your health
being identified, then you will be provided with the necessary care.
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Medical treatment will be provided at no cost to you for research-related harm. The term
“research-related harm” means both physical and mental injury caused by the product or
procedures that are required by this trial.
Your participation in this study does not prejudice any right to compensation which you may
have under statute or common law.
Will my taking part in this study be kept confidential?
The researchers will need to collect personal data about you, which may be sensitive, such as
your relevant health information. The researchers may also need to get some of your health
information from other health service providers, eg another hospital, pathology laboratory,
radiographer, GP or other medical specialist.
Any personal or health information will be kept private and confidential. It will be stored
securely and only authorised persons, who understand it must be kept confidential, will have
access to it. Your study details will be given a number so that your identity will not be
apparent. The trial records will be kept at the School of Exercise, Biomedical and Health
Science at Edith Cowan University during the study and in a locked archive for at least 5
years and for a maximum of 15 years from the time the study is closed, and may be destroyed
at any time thereafter.
Authorised representatives of the researchers, the investigating doctors, or University Human
Research Ethics Committees, and other regulatory bodies may require access to your study
records to verify study procedures and/or data. In all cases, when dealing with your
information these people are required to comply with privacy laws that protect you.
The results of the research will be made available to other doctors through medical journals
or meetings, but you will not be identifiable in these communications. By taking part in this
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study, you agree not to restrict the use of any data even if you withdraw. Your rights under
any applicable data protection laws are not affected.
Will I find out the results of the study?
The value of the research is not known at this time. You will be notified of the results of the
research in general terms at your request and the outcomes of the research as a whole may be
provided to you upon completion of the project.
What happens at the end of the study?
At the end of the study your visits to your doctor will continue and your treatment will not be
compromised in any way by participating in this research study. Your doctor may adjust your
medication as he/she feels appropriate depending on the outcome of the study.
Who has reviewed the study?
The Edith Cowan University Human Research Ethics Committee and the North Metropolitan
Area Mental Health Service Human Research Ethics Committee have reviewed this study and
have given approval for the conduct of this research trial. In doing so, this study conforms to
the principles set out by the National Statement on Ethical Conduct in Human Research and
according to the Good Clinical Practice Guidelines.
If you have any questions or require any further information about the research project,
please contact:
Dr Jennifer Thompson: Phone 6304 5635

Email jennifer.thompson@ecu.edu.au or

Associate Professor Mel Ziman: Phone 6304 5171 Email m.ziman@ecu.ed.au
If you have any concerns or complaints about the research project and wish to talk to an
independent person, you may contact:
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Research Ethics Officer,
Edith Cowan University,
270 Joondalup Drive,
JOONDALUP WA 6027
Phone (08) 6304 2170
Email: research.ethics@ecu.edu.au
OR

The Secretary,
North Metropolitan Area Mental Health Service Human Research Ethics
Committee,
Private Bag No 1,
CLAREMONT WA 6910
Phone (08) 9347 6618

All study participants will be provided with a copy of the Participant Information Sheet
and Participant Consent Form for their personal records.
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PLEASE TICK 

Appendix 3: Participant Consent Form

1. I have read and understood the ‘Participant Information Sheet’ for this

Y

N

Y

N

Y

N

Y

N

Y

N

study.
2. The nature and possible effects of the study have been explained to me.
3. I understand that the study involves the following procedures:
a. I will be required to obtain medical approval to undertake the study
before any measures or training can take place.
b. I will be randomly assigned to one of the following two groups:
(1) Therapeutic intervention group (including occupational therapy and
exercise tasks) or
(2) no therapeutic intervention group (no occupational therapy or
exercise tasks).
c. I will be required to have my cerebral volume (MRI scan), height,
weight, body composition (DEXA scan), and blood/saliva analysis
(insulin/c-peptide, glucose, cortisol) assessed before, during and after
the study period (at 0, 6 and 18 months).

Y

N

Y

N

d. I understand that as a measure of physical function, my balance ability
will be assessed before, during and after the study (at 0, 6 and 18
months).

e. I will be required to complete quality of life questionnaires and undergo
cognitive testing before, during and after the study period (at 0, 6, 12
and 18 months). I understand that most of these tests are performed as
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part of my normal medical care, and if I participate in this research
study without participating in the intervention, these tests will be
undertaken as per my normal care regime. I understand that some of the
cognitive tests may be videorecorded for analysis purposes.

Y

N

Y

N

Y

N

4. I understand that I will be required to wear an Actiwatch throughout the
timeframe of the research study.
5. I agree to my carer participating in this research project by completing

questionnaires about my health status, and give permission for them to do so.
This study has been approved by the Human Research Ethics Committees at
Edith Cowan University and the North Metropolitan Area Mental Health
Service. Should there be any concerns relating to the project, you can contact
the Edith Cowan University Ethics Officer at (08) 6304 2170 or Email:
research.ethics@ecu.edu.au or the Secretary, North Metropolitan Area Mental
Health Service Human Research Ethics Committee at (08) 9347 6618 or by
mail to Private Mail Bag No. 1, Clarement WA 6910.
Any questions concerning the project entitled “The effects of environmental
enrichment on clinical measures of disease progression and quality of life for
patients with Huntington’s disease” can be directed to Dr Jennifer Thompson
(Postdoctoral

Research

Fellow)

Phone

6304

5635

or

Email

jennifer.thompson@ecu.edu.au, or Associate Professor Mel Ziman (Principal
Investigator) Phone 6304 5171 or Email m.ziman@ecu.edu.au of the School of
Exercise, Biomedical and Health Sciences, Edith Cowan University,
Joondalup.
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Appendix 4: Statement of Informed Consent
I (the participant) have read the information above and any questions I have
asked have been answered to my satisfaction. I agree to participate in this
Y

N

Y

N

activity, realizing that I may withdraw at any time.
I agree the research data gathered for this study may be published provided my
name is not used.

I understand that the information I provide will be kept in the strictest
confidence by the researchers, unless obliged to release by law.

Y

N

Name (please print) _______________________________________________
Signed______________________________

Date_________________

Participant or Authorised Representative

Contact Phone Number________________________________________________________
Y

N

Are you currently participating in any other research project?
Investigator (Name, please print)________________________________________________
Signed _________________________________________ Date ____________________
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Appendix 5: Carer Information Sheet
Project: The Effects of Environmental Enrichment on Clinical Measures of Disease
Progression and Quality of Life for Patients with Huntington’s Disease.
Senior Investigators: Prof Mel Ziman, Dr Jennifer Thompson, Mr Travis Cruickshank, Prof
Roger Barker, Dr Carmela Connor, Dr Joseph Lee, Prof Anthony Hannan, Dr Sonya Girdler,
Professor Rob Newton, Dr Stanley Lazic.
Please take time to read the following information carefully and discuss it with your friends,
family and clinician if you wish. Ask us any question if some part of the information is not
clear to you or if you would like more information. Please do this before you sign this consent
form.
Who is funding this study and where will it be conducted?
This study is a joint collaboration between Huntington’s WA (Inc.), Edith Cowan University,
the Neurosciences Unit, the Howard Florey Institute (Melbourne), the Centre for Brain
Repair at the University of Cambridge and the Brightwater Group, and it has been funded by
Lotterywest. It will be conducted at Edith Cowan University.
Contact persons:
Should you have any questions about the study you may contact:
Dr Jennifer Thompson: Phone 6304 5635 Email jennifer.thompson@ecu.edu.au or
Associate Professor Mel Ziman: Phone 6304 5171 Email m.ziman@ecu.edu.au
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All study participants will be provided with a copy of the Participant Information Sheet and
Participant Consent Form for their personal records.
You may decide to be in the study or not take part at all. If you do decide to take part in this
study, you may stop at any time or you may withdraw from any one procedure at any time.
However, before you decide, it is important that you understand why this research is being
done and what it will involve. Whatever your decision, this decision will not lead to any
penalty or affect your regular medical care or any benefit to which you are otherwise entitled.
.The following Information Sheet will explain the study and will include details such as:
 Why this trial might be suitable for you;
 The possible benefits of taking part in this research study;
 The nature of your participation;
 The type and frequency of any assistance you may be required to give;
 What are the costs to me;
 Your rights and responsibilities;
 Will I find out the results of the study;
 Will my taking part in this study be kept confidential;
 Who is funding the study;
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What is the purpose of the study?
This study is a research project in which we are investigating the effects of mental and
physical stimulation (environmental enrichment) on the progression of Huntington’s disease.
This research project intends to implement a therapeutic intervention strategy for patients
with Huntington’s disease which is centred on mental and physical stimulation as a method
for reducing symptoms of the disease and improving quality of life for patients.
Why is this study suitable for me?
You have been invited to participate in this study because you are the carer of a patient that
has been diagnosed with Huntington’s disease that currently displays symptoms of the
disease.
How long will I be in this study and how will I participate?
If you agree to participate, you will be asked to assist the research participant to take part in
an intervention strategy (if they are assigned to the intervention group) by attending exercise
and occupational therapy classes and assisting the participant to perform these tasks at home
during the week. You may be asked to assist the research participant to attend a number of
tests and scans throughout the study to assess changes in the progression of the disease. You
will be asked to assist the participant to comply with wearing an Actiwatch throughout the
study which measures their physical activity, and you will be asked to complete two
questionnaires at each timeframe before, during and after the study. Instigation of the study:
Tests such as clinical assessment, questionnaires, MRI/DEXA (X-ray) scans and blood/saliva
tests will be performed at the beginning of the study as a baseline measure of the status of the
disease. You will be asked to complete the questionnaires and assist the participant to attend
appointments at this stage.
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6 months: You will be asked to participate in the same manner as above.
6-18 months: If the participant is assigned to the intervention group, they will perform a
number of physical and mental stimulation strategies each week for a 12 month period. At the
end of a six month period (at 12 months), whether they have participated in the intervention
strategy or not, the participant will undergo clinical assessment and questionnaires. At the
end of the full period of 12 months (at 18 months), they will be asked to undergo the final
clinical assessment, questionnaires, MRI/DEXA (X-ray) scans and blood/saliva tests. You
will assist the participant in their performance of these tasks at home, and you may attend
classes and appointments for tests and scans. You will also be required to complete two
questionnaires each at 12 months and 18 months.
Overall, participants will be involved for a period of 18 months. Participation will require
about 9 hours per week for the intervention strategy, and about 2 half days every six months
for the assessments.
What are the possible benefits of taking part in this research study?
The results of this study may be of interest to you as the carer of a person with Huntington’s
disease. By participating in this research, you may be assisting patients to obtain an
improvement in the symptoms of their disease. Also, your participation in this research study
may assist researchers and health care providers to provide better treatment for people with
Huntington’s disease in the future.
What will happen if I decide to be in this study?
The study will be conducted over a 2 year period, with participants involved over 18 months.
Participants who are assigned to the intervention group will perform mental and physical
stimulation tasks over a 12 month period. These will be performed at Edith Cowan University
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and at home. During this time, you will assist the participant to perform these tasks and attend
appointments and you will receive phone calls or visits from a trained scientist to monitor the
progress and participation in the research program.
As detailed above, you will assist in a variety of assessments throughout the study: Clinical assessments will be performed by a neurologist to assess the status of the
disease. These assessments will be conducted at 0, 6, 12 and 18 months. These
assessments are mostly the same as the normal assessments the participant currently
receives. You may be required to assist the participant to attend these assessments.
 You will complete two questionnaires assisted by a trained scientist at 0, 6, 12 and 18
months.
 MRI and DEXA (X-ray) scans will be performed at 0, 6 and 18 months. You may
assist the participant to attend these scans.
 The participant will perform balance tests and have blood/saliva samples taken at 0, 6
and 18 months. You may assist the participant to attend these tests.
You may choose to attend voluntary workshops to be updated on the progress of the study
and to discuss with the research scientists any problems the participant or you may be
experiencing with the research study. You may contact the researchers at any time during the
study if you require any further general information.
What are the costs to me?
There will be no additional costs to you for participating in this research study. All
transportation costs will be reimbursed by Edith Cowan University, or taxi vouchers will be
provided for travel to and from the University where necessary.
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What alternatives do I have to going on this study?
Your participation in this research study is voluntary. This study will not affect the
participant’s treatment, which will continue in the same manner whether you decide to
participate in the study or not.
You may wish to discuss with your doctor or the researchers how the test will benefit patient
treatment in the future.
What if new information comes along during the study?
Sometimes, new information about an intervention or disease becomes available as a study
progresses. You will be told about any information that could be important to you and the
participant, and to your decision to continue in the study. If you then want to continue in the
trial, you may be asked to sign a revised consent form.
Stopping the study early:
Sometimes a trial needs to be stopped early because of safety concerns, because the trial is
not effective enough, or for other reasons. If this occurs, the reasons will be explained to you
and the participant’s treatment will continue as it would have without the test. The treatment
will not be influenced by the research study in anyway.
Will my taking part in this study be kept confidential?
Any information that you provide will be kept private and confidential. It will be stored
securely and only authorised persons, who understand it must be kept confidential, will have
access to it. The participant’s details will be given a number so that their or your identity will
not be apparent. The trial records will be kept at the School of Exercise, Biomedical and
Health Science at Edith Cowan University during the study and in a locked archive for at
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least 5 years and for a maximum of 15 years from the time the study is closed, and may be
destroyed at any time thereafter.
Authorised representatives of the researchers, the investigating doctors, or University Human
Research Ethics Committees, and other regulatory bodies may require access to the study
records to verify study procedures and/or data. In all cases, when dealing with the
information you provide, these people are required to comply with privacy laws that protect
you.
The results of the research will be made available to other doctors through medical journals
or meetings, but you or the participant will not be identifiable in these communications. By
taking part in this study, you agree not to restrict the use of any data even if you withdraw.
Your rights under any applicable data protection laws are not affected.
Will I find out the results of the study?
The value of the research is not known at this time. You will be notified of the results of the
research in general terms at your request and the outcomes of the research as a whole may be
provided to you upon completion of the project.
Who has reviewed the study?
The Edith Cowan University Human Research Ethics Committee and the North Metropolitan
Area Mental Health Service Human Research Ethics Committee have reviewed this study and
have given approval for the conduct of this research trial. In doing so, this study conforms to
the principles set out by the National Statement on Ethical Conduct in Human Research and
according to the Good Clinical Practice Guidelines.
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If you have any questions or require any further information about the research project,
please contact:
Dr Jennifer Thompson: Phone 6304 5635

Email jennifer.thompson@ecu.edu.au or

Associate Professor Mel Ziman: Phone 6304 5171 Email m.ziman@ecu.ed.au
If you have any concerns or complaints about the research project and wish to talk to an
independent person, you may contact:
Research Ethics Officer,
Edith Cowan University,
270 Joondalup Drive,
JOONDALUP WA 6027
Phone (08) 6304 2170
Email: research.ethics@ecu.edu.au

OR

The Secretary,
North Metropolitan Area Mental Health Service Human Research Ethics
Committee,
Private Bag No 1,
CLAREMONT WA 6910
Phone (08) 9347 6618

All carer participants will be provided with a copy of the Carer Information Sheet and
Carer Consent Form for their personal records.
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Appendix 6: Carer Consent form

PLEASE TICK

1. I have read and understood the ‘Carer Information Sheet’ for this study.

Y

N

2. The nature and possible effects of the study have been explained to me.

Y

N

3. I understand that the study involves the following procedures:
a. I will be required to complete quality of life questionnaires before, during
and after the study period (at 0, 6, 12 and 18 months).

Y

N

Y

N

Y

N

to assist the participant in performing exercise and occupational therapy tasks Y

N

b.

I may be required to attend appointments for tests and scans with the

participant before, during and after the study period (at 0, 6 and 18 months).
c.

If the participant is assigned to the intervention group, I may be required
to attend the exercise and occupational therapy classes.

d.

If the participant is assigned to the intervention group, I will be required

at home. I understand that I will be instructed on how to assist the participant.
4. I understand that the participant will be required to wear an Actiwatch
throughout the timeframe of the research study, and I may be required to assist
Y

with compliance in this regard.

This study has been approved by the Human Research Ethics Committees at
Edith Cowan University and the North Metropolitan Area Mental Health
Service. Should there be any concerns relating to the project, you can contact
the Edith Cowan University Ethics Officer at (08) 6304 2170 or Email:
research.ethics@ecu.edu.au or the Secretary, North Metropolitan Area Mental
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N

Health Service Human Research Ethics Committee at (08) 9347 6618 or by
mail to Private Mail Bag No. 1, Clarement WA 6910.
Any questions concerning the project entitled “The effects of environmental
enrichment on clinical measures of disease progression and quality of life for
patients with Huntington’s disease” can be directed to Dr Jennifer Thompson
(Postdoctoral

Research

Fellow)

Phone

6304

5635

or

Email

jennifer.thompson@ecu.edu.au, or Associate Professor Mel Ziman (Principal
Investigator) Phone 6304 5171 or Email m.ziman@ecu.edu.au of the School of
Exercise, Biomedical and Health Sciences, Edith Cowan University,
Joondalup.
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Appendix 7: Statement of Informed Consent
I (the carer) have read the information above and any questions I have asked have been
answered to my satisfaction. I agree to participate in this activity with the participant’s
consent, realizing that I may withdraw at any time.

Y

N

I understand that the information I provide will be kept in the strictest confidence by the
researchers, unless obliged to release by law.

Y

N

I agree to participate in this research study by completing quality of life questionnaires and
assisting the study participant to take part in this research project.
Y

N

Name of Carer (please print) _________________________________________________
Signed _____________________________________________

Date _______________

Contact Phone Number ______________________________________________________

Investigator (Name, please print)_______________________________________________
Signed _____________________________________________
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Date _______________

Appendix 8 Example page of the exercise diary
Week
Date
Day

Comments

Exercises
Leg
Extension

Leg
Flexion

Calve
Raise

Leg
Abduction

Monday

Tuesday

Wednesday

Thursday

Friday

Saturday

Sunday
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Leg
Adduction

Theraband
Row

(e.g. experienced pain, fatiguing,
easy to perform, hard to
perform)

Appendix 9 Statement of Contribution by Others (Study 2)
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Appendix 10 Statement of Contribution by Others (Study 3)
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